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ABSTRACT 
 Over the past several years, the Peterson group has developed synthetic 
mimics of cholesterol that rapidly incorporate into the plasma membrane of 
mammalian cells. These N-alkyl-3β-cholesterylamines cycle between the plasma 
membrane and early/recycling endosomes similar to natural cell surface 
receptors. Because of this unique activity, cholesterylamines have been linked to 
protein-binding and other motifs to generate artificial cell surface receptors. More 
recently, they have been conjugated to membrane disruptive peptides to 
generate synthetic agents that selectively permeabilize early endosomes and 
deliver cell-impermeable small molecules to the cytosol. Although this pioneering 
work has significant potential as a system to deliver cell-impermeable small 
molecule drugs and/or therapeutic agents, additional research is needed to 
understand the mechanism of action and develop therapeutic applications. 
 To further evaluate this system, we first investigated the structure-activity 
relationships of cholesterylamines using fluorescent analogues designed to 
probe the mechanism of cellular uptake. This study produced probes with robust 
activity that suggests an unprecedented mechanism of cholesterol uptake on 
mammalian cell surfaces. Second, we investigated novel endosome disruptive 
peptides that provided insights into their mechanism of action. Additionally, we 
applied this knowledge to obtain proof-of-concept with antibody conjugates and 
endosome disruptive peptides as a new strategy to selectively deliver small 
molecules to tumor cells that overexpress specific cell surface receptors. 
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 Another project involves the development of a fluorescence-based method 
to detect protein-protein interactions in complex biological systems. This method 
utilizes a novel fluorinated fluorophore that undergoes proximity-driven exchange 
between lysine residues at the interface of a protein complex. Transfer of this 
fluorophore from donor to acceptor lysine residues produces a fluorescent 
protein partner that can be detected by gel electrophoresis or proteomics 
methods. Since lysine is prevalent at the interface of numerous protein 
complexes, this method may be useful to identify novel protein-protein 
interactions and/or factors that affect these interactions. 
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Chapter 1 
 
Synthetic Mimics of Cholesterol and their Application to the Delivery of 
Cell-Impermeable Molecules 
 
1.1 Receptor-Mediated Endocytosis 
 The plasma membrane of mammalian cells is a highly complex structure 
of lipids and proteins that serves as a barrier to protect intracellular processes 
against toxins and other forms of environmental stress. The lipid portion of the 
membrane consists of a phospholipid bilayer that is only permeable to water or 
hydrophobic small molecules. Small polar nutrients, such as ions, carbohydrates 
and amino acids, are impermeable to the plasma membrane and require active 
transport by protein pumps and channels. Other small or macromolecular 
nutrients enter cells by a process called endocytosis, a term that describes 
several mechanisms in which a dynamic portion of the plasma membrane 
invaginates and pinches off to form a membrane bound vesicle.1-3 These vesicles 
become part of an intricate network of intracellular compartments involved in 
sorting and metabolizing the encapsulated contents. 
Receptor-mediated endocytosis (RME) represents one form of this 
mechanism that involves the internalization of receptor-ligand complexes.4 Two 
examples of RME, low-density lipoprotein (LDL) and transferrin (TF), are shown 
in Figure 1.1. These macromolecules serve as carriers of cholesterol and iron, 
respectively.5-8  
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Figure 1.1.  Receptor-mediated endocytosis of low-density lipoprotein (LDL) via 
the LDL receptor (LDLR) and transferrin (TF) via the transferrin receptor (TFR). 
	  
The LDL receptor (LDLR) and the transferrin receptor (TFR) are 
distributed throughout the plasma membrane.  Upon binding their respective 
ligands, the receptor-ligand complexes are concentrated in dynamic regions of 
the plasma membrane that actively undergo endocytosis.  The endocytic vesicle 
trafficks through the cytosol and fuses with early endosomes that are acidified to 
pH 6.0 by proton pumps and chloride channels.  In the case of LDL, acidification 
causes the dissociation of the LDL particle from its receptor.  The LDL particle is 
further sorted to late endosomes and lysosomes where metabolic enzymes 
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liberate cholesterol and amino acids for use by the cell.  The LDLR is sorted 
through the endocytic recycling compartment and back to the plasma membrane 
to recapture LDL.6, 7 The TF-TFR complex undergoes a similar mechanism, 
however iron is released upon acidification of sorting endosomes without 
dissociation of the ligand receptor complex. Receptor-bound apo-TF is cycled 
back to the plasma membrane and released into the extracellular environment.8 
For these reasons, fluorescent LDL and transferrin conjugates have been used 
extensively in microscopy as markers of lysosomes and early/recycling 
endosomes, respectively.9, 10  
 
1.2 Synthetic Mimics of Cholesterol 
 Cholesterol is a critical constituent of membranes of animal cells. This 
sterol stabilizes lipid bilayers and decreases membrane permeability to small 
molecules.11, 12 Its concentration needs to be tightly regulated in the plasma 
membrane and, as a result, mammalian cells have evolved multiple mechanisms 
for acquiring and transporting this sterol. A more detailed discussion of these 
mechanisms is provided in Chapter 2 of this dissertation. The lipid composition of 
the plasma membrane comprises ~30% cholesterol, and the plasma membrane 
and endocytic recycling compartment (ERC) contain the vast majority of total 
cellular cholesterol.11 
 Over the last decade, our lab has investigated the use of N-alkyl-
cholesterylamines as synthetic cell surface receptors, and this work was recently 
reviewed.13-16 More recently, we have focused on investigating fluorophore-linked 
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cholesterylamines as functional mimics of cholesterol to study uptake and 
trafficking properties in living cells.  The localization and transport of cholesterol 
has been extensively studied by fluorescence microscopy using fluorescent 
analogues such as those shown in Figure 1.2.17-21 However, the integration of a 
fluorophore onto the core sterol structure often greatly alters the ability of these 
compounds to stably incorporate into the lipid bilayer.20 As a result, several of 
these compounds do not display cellular localization similar to cholesterol.  
	  
Figure 1.2.  Structures of cholesterol, cholesterylamine, and fluorescent 
analogues of cholesterol.  PG-Glu-β-Ala-cholesterylamine (1), synthesized in the 
Peterson group, comprises the Pennsylvania green fluorophore as a head group 
linked to cholesterylamine via a short peptide linker region. 
As an example, 22-NBD cholesterol, a commonly used fluorescent 
cholesterol analogue, was added to Jurkat lymphocytes and analyzed by 
confocal laser scanning microscopy (Figure 1.3, Panels D-E). This compound 
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exhibits rapid trafficking into the Golgi apparatus and nuclear membrane due to 
its inability to stably incorporate into the plasma membrane.  Structurally 
optimized N-alkyl-cholesterylamines, exemplified by compound 1 which includes 
the Pennsylvania Green fluorophore (Figure 1.2), are rapidly taken up by living 
mammalian cells, associate with the plasma membrane, and accumulate in 
transferrin-positive early/recycling endosomes (Figure 1.3, Panels A-C).22, 23 In 
this way, fluorescent cholesterylamines demonstrate localization and trafficking 
properties that more meaningfully mimic the known properties of cholesterol. 
Based on previous structural analogues of compound 1, it was found that 
changes in the linker region greatly affected the efficacy of cellular uptake and 
partitioning between the plasma membrane and early/recycling endosomes.14, 22 
Compounds that contained hydrophobic uncharged linkers were found to show 
lower efficacy. Compounds that included one or two negatively charged amino 
acid residues showed higher efficacy and accumulate to a greater extent in early 
endosomes. These finding proved advantageous in that modifications of the 
linker region can be used to improve delivery of conjugated cargo into 
endosomes. 
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Figure 1.3.  Confocal laser scanning microscopy and differential interference 
contrast (DIC) microscopy of Jurkat lymphocytes treated with fluorescent 
cholesterol analogues.  These micrographs demonstrate the rapid binding of 
compound 1 and its accumulation on the plasma membrane and early/recycling 
endosomes (Panels A-B).  Panel C illustrates the co-localization between green 
fluorescent 1 and red fluorescent transferrin-AlexaFluor 647, indicating 
accumulation of 1 in early/recycling endosomes.  Panels D-E shows the non-
specific binding activity of 22-NBD cholesterol, with fluorescence observed in the 
Golgi apparatus and nuclear membrane.  Scale bar = 10 µm. 
	  
1.3 Disruption of Early Endosomes by Cholesterylamine-linked Peptides 
 Receptor-mediated endocytosis (RME) is an efficient mechanism of 
uptake for cell-impermeable molecules. However the majority of ligands 
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internalized by this process remain encapsulated until they are degraded in the 
lysosome. As a result, impermeable therapeutics or probe molecules that utilize 
RME for cellular internalization may show little efficacy since they cannot reach 
the cytosol in significant concentrations. To address this, encapsulation and/or 
modification of impermeable molecules with liposomes,24, 25 polymers,26, 27 or 
cell-penetrating peptides (CPPs)28, 29 have been extensively studied, but these 
approaches have provided mixed success and are generally of limited 
applicability. 
In order to deliver cell-impermeable molecules into the cytosol, our group 
developed a molecule that selectively disrupts early/recycling endosomes based 
on a derivative of a membrane-lytic dodecapeptide called PC-4.30 This peptide 
was previously published by Weber et al. and demonstrated pH-dependent 
disruption of liposomes at acidic pH.31 As shown in Figure 1.4, cholesterylamine-
linked PC-4 (2) can be used to selectively disrupt early/recycling endosomes.  
This allows cleavage of a disulfide bond by reduced glutathione (GSH) and 
efficient release of the cholesterylamine-linked fluorophore into the cytosol and 
nucleus of living Jurkat lymphocytes.30, 32 Because this release could be blocked 
by the proton pump inhibitor Bafilomycin A1, the pH-dependent nature of this 
activity was proposed to provide selectivity for early endosomes at pH 6.0 while 
preventing disruption of the plasma membrane at pH 7.4. 
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Figure 1.4.  Structures of cholesterylamine-linked PC4 (2, Panel A), a 
fluorescent disulfide-linked cholesterylamine (3, Panel B), and products following 
cleavage of 3 by reduced glutathione (GSH).  Panel C is a schematic 
representation of cellular release of 4 via endosome disruption.  Panels D-E: 
Confocal fluorescence and DIC micrographs of Jurkat lymphocytes treated with 3 
(2.5 µM, 12 h) in the absence and presence of endosome disruptor 2.  Scale bars 
= 10 µm. 
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1.4 Current Limitations in the Delivery of Cell-Impermeable Molecules 
 The use of cholesterylamines and endosome disruptive peptides for 
delivery applications faces a number of challenges. Previously designed 
fluorescent cholesterylamines have demonstrated that design of the head group 
and linker regions can greatly affect the uptake and trafficking properties of these 
compounds.22 However, a thorough investigation into the structure-activity 
relationships that govern cellular binding has not been performed. Also, the 
mechanism by which these compounds associate with cells remains unclear. 
Addressing these questions could provide insight into the design of better 
delivery systems. More importantly, further investigating fluorescent 
cholesterylamines as functional analogues of cholesterol could provide new 
information regarding how mammalian cells acquire and transport cholesterol. 
 Another limitation of previous research on these agents is the toxicity of 
the cholesterylamine-PC4 derivative (2) to cultured cells. As shown in Figure 1.5, 
the potency of this compound can be measured by using flow cytometry to 
quantitate the increase in cellular fluorescence observed upon disruption of 
endosomes and release of the fluorophore. When compared to the toxicity 
observed at 48 hours, this compound exhibits a relatively narrow toxicity index.30 
New peptide compounds that show higher potency with reduced toxicity are 
needed. Also, the mechanism of membrane disruption by PC-4 has not been 
elucidated. Analogues designed to probe the structural requirements could 
provide insight into this mechanism and assist in improving the toxicity index. 
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Yet another obstacle to this research is its applicability to in vivo drug 
delivery applications. Conjugation to cholesterylamines provides highly efficient 
delivery of linked cargo to early/recycling endosomes, and endosome disruptive 
peptides provide a mechanism for releasing cargo to its desired target. However, 
cholesterylamines are rapidly taken up by nearly all mammalian cell types and 
would not provide adequate selectivity for drug delivery applications such as 
cancer chemotherapy. Examination of other early endosome targeting agents 
that provide selectivity for different cell types, such as tumor cells, could greatly 
expand the therapeutic potential of this approach. 
 
	  
Figure 1.5.  Panel A: Efficacy of compound 2 for the release of the fluorescent 
probe 3 in Jurkat lymphocytes.  Panel B: Toxicity of compound 2 in Jurkat 
lymphocytes after 48 hours.  Analyses performed by flow cytometry. 
	  
1.5 Outline of this Dissertation 
 Based on pioneering studies of synthetic mimics of cholesterol and 
endosome disruptive peptides by the Peterson group, my research has focused 
on addressing the limitations outlined in the previous section and investigating 
new methods to broaden the scope of this work. Chapter 2 describes the design, 
synthesis, and evaluation of fluorescent mimics of cholesterol to probe the 
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structure-activity relationships that dictate the cellular binding of 
cholesterylamines and related compounds. This chapter also reports the 
investigation into the mechanism of uptake of cholesterylamines and its 
relationship to cholesterol.  Chapter 3 describes the development of endosome 
disruptive peptides with improved toxicity index and examination of the 
mechanism of their membrane disruptive properties. Chapter 4 describes the 
application of these peptides to cell-specific delivery of disulfide-linked cargo 
using antibodies and antibody-drug conjugates. Finally, Chapter 5 describes a 
novel method for fluorescence-based detection of protein-protein interactions in 
complex biological matrices. This system utilizes a proximity-driven nucleophilic 
aromatic substitution reaction (SNAr) of lysine-linked fluorophores between two 
interacting proteins. 
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Chapter 2 
 
Structure-Activity Relationships and Mechamism of Action Studies of 
Synthetic Mimics of Free Cholesterol 
 
2.1 Introduction 
 Cholesterol plays a unique and critical role among the various lipids of 
mammalian cell membranes. It provides structural stability to a complex mixture 
of phospholipids containing both saturated and unsaturated fatty acids, while 
maintaining adequate fluidity to allow for biological processes such as 
endocytosis and mitosis to occur. As such, cells have evolved multiple 
mechanisms to acquire and transport cholesterol, as well as mechanisms to 
tightly regulate its concentration within membranes.  Mammalian cells acquire the 
majority of their cholesterol through hydrolysis of cholesteryl esters. These esters 
are incorporated into lipoprotein particles such as low-density lipoprotein (LDL) 
that circulate through the bloodstream. The LDL receptor (LDLR) at the cell 
surface internalizes these particles via receptor-mediated endocytosis (RME) and 
the lipoproteins are delivered to the lysosome, where hydrolytic enzymes cleave 
the cholesteryl esters to release free cholesterol. The mechanism of LDL uptake 
via LDLR has been extensively studied and reviewed.1 Free cholesterol is 
transported to and from the lysosomal membrane by the proteins Niemann-Pick 
C1 and C2 (NPC1/2).2-5 From there, various cytosolic proteins are involved in 
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shuttling cholesterol to the plasma membrane and to various organelles, however 
these cellular processes are less understood.6, 7 
 Another mechanism by which cells acquire cholesterol involves the direct 
binding of free cholesterol by cell surface receptors such as Niemann-Pick C1 
Like 1 protein (NPC1L1).8-10 This receptor is mainly expressed in the liver and 
intestines and was shown to be the target for ezetimibe (6, Figure 2.2), an FDA-
approved drug used to treat hypercholesterolemia.11, 12 Ezetimibe, as well as its 
glucuronide metabolite, directly block the binding and uptake of dietary 
cholesterol in the intestinal epithelium. Figure 2.1 illustrates mechanisms by 
which cells can acquire exogenous cholesterol. 
 
	  
Figure 2.1.  Schematic representation of two mechanisms of cellular cholesterol 
absorption.  Cholesteryl esters are packaged into LDL and acquired via receptor-
mediated endocytosis.  Free cholesterol can directly bind cell surface receptors 
such as NPC1L1.  This mechanism is inhibited in the intestine and liver by 
ezetimibe (6). 
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 Derivatives of cholesterol have been used extensively as probes of 
cholesterol biology or as membrane targeting lipids for the delivery of 
macromolecules. Several fluorescent cholesterol analogues have been used to 
study cholesterol localization and trafficking, however their use has proven 
difficult since the addition of a fluorogenic moiety can dramatically change their 
biological properties.13 The use of cholesterol conjugates, particularly cholesteryl 
carbamates, has shown success when applied to siRNA delivery14, DNA 
transfection15, and other cellular targeting applications.16, 17 It has been shown 
that cellular uptake of these types of cholesterol conjugates is similar to 
cholesterol esters in that they require incorporation into lipoprotein particles for 
efficient delivery.14 However, many of these conjugates fail to show appreciable 
activity under physiologically relevant conditions in vivo. 
 As mentioned in Chapter 1, previous research by the Peterson group on 
fluorescent N-alkyl-3β-cholesterylamines as synthetic mimics of cholesterol has 
shown that these compounds are avidly taken up by mammalian cells and 
engage in a trafficking pathway between the plasma membrane and 
early/recycling endosomes.18-20 Several studies found that the design of the 
linker region between the cholesterylamine and fluorophore is critical to maintain 
high efficacy and trafficking properties. From these studies, it was shown that 
compounds containing one or two negatively charged glutamic acid residues in 
the linker region possessed high efficacy. Interestingly, subsequent experiments 
found that ezetimibe (6) inhibits the binding of cholesterylamines, exemplified by 
compound 1 (Figure 2.2), in living Jurkat lymphocytes. This finding that a non-
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steroidal small molecule drug inhibits binding of these compounds provided 
strong evidence that the binding and uptake cholesterylamines is mediated by a 
cell-surface receptor.  
 
	  
Figure 2.2.  Cellular uptake of PG-Glu-βAla-cholesterylamine (1, Panel A) and 
inhibition by ezetimibe (6, Panel E).  Panels B-D: Confocal fluorescence and DIC 
micrographs of Jurkat lymphocytes treated with 1 (2 µM) for 5 min (Panel B), 1 h 
(Panel C), and 5 min in the presence of 6 (200 µM, Panel D).  Panel F: 
Saturation binding analysis of 1 in the presence and absence of 6 (200 µM). 
Scale bar = 10 µm. 
	  
	  
 I describe in this chapter the design and synthesis of novel fluorescent 
mimics of cholesterol to further probe the structure-activity relationships that 
dictate cellular binding. Furthermore, studies to further elucidate the mechanism 
of cellular uptake of fluorescent cholesterylamines, including efforts to identify the 
cell surface receptor responsible for the observed activity are reported. 
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2.2 Design and Synthesis of Fluorescent Mimics of Cholesterol 
 In order to probe the structure-activity relationships that govern the cellular 
uptake of fluorescent cholesterol mimics, we designed and synthesized a series 
of probes to systematically compare 1) the requirement of the negatively charged 
glutamic acid residue(s) in the linker region, 2) the requirement of the cationic N-
alkyl-3β-cholesterylamine linkage, and 3) the specificity of the observed activity 
to cholesterol versus a structurally related sterol. Given that previous 
experiments suggested these compounds are bound by a cell-surface receptor, 
we hypothesized that the cationic secondary amino group of cholesterylamines 
might functionally mimic the 3β-hydroxyl group of cholesterol. In this way, 
cholesterylamines may demonstrate a cellular uptake mechanism similar to that 
of free cholesterol, whereas cholesteryl esters, carbamates and other related 
compounds undergo lipoprotein-mediated uptake. Figure 2.3 shows a series of 
fluorescent cholesterol analogues designed to probe this mechanism. 
Since the majority of the compounds investigated contain a glutamic acid 
residue linked to the Pennsylvania green fluorophore, the syntheses of these 
compounds was simplified by precoupling amine-deprotected glutamic acid (16) 
to 4-carboxy Pennsylvania green NHS ester to produce compound 17 (Figure 
2.4). Compound 17 could then be coupled to the deprotected amine of each 
precursor using EDC/HOBt peptide coupling conditions. 
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Figure 2.3.  Structures of fluorescent N-alkyl-3β-cholesterylamines (1, 7 – 9), N-
alkyl-3β-sitosterylamine (10), cholesteryl ether (11), cholesteryl amide (12), 
cholesteryl ester (13), and cholesteryl carbamates (14 – 15). 
 
To synthesize the N-alkyl-3β-cholesterylamine linked compounds 1 and 7 
– 9, the cholesterylamine precursor 18 was synthesized according to a previously 
described method.21 Phthalimide deprotection with hydrazine afforded the 
primary amine in excellent yields. Standard Fmoc deprotection and EDC/HOBt 
peptide couplings with Fmoc protected glycine, β-alanine, or tert-butyl protected 
glutamic acid afforded the precursors 19 - 23.  Either the NHS ester of 4-carboxy-
Pennsylvania green or compound 17 were coupled to the Fmoc deprotected 
precursors. The molecules were fully deprotected using TFA in dichloromethane 
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and purified by preparative reverse-phase HPLC (RP-HPLC). Compounds 1 and 
7 – 9 were isolated as TFA salts. 
 
Figure 2.4.  Synthesis of fluorescent N-alkyl-3β-cholesterylamines 1 and 7 – 9.  
Reagents and conditions:  (a) 20% piperidine, DMF, 30 min; (b) EDC, HOBt, 4 °C 
to 22 °C, 12 h;  (c) H2NNH2, EtOH, 50°C, 4 h; (d) EDC, HOBt, Fmoc-Glu(Ot-Bu)-
OH, 4°C to 22°C, 12 h; (e) EDC, HOBt, 17, DMF, 12 h;  (f) 50% TFA, DCM, 2 h;  
(g) EDC, HOBt, Fmoc-β-Ala-OH, 4 °C to 22 °C, 12 h;  (h) EDC, HOBt, Fmoc-Gly-
OH, 4°C to 22°C, 12 h; (i) 4-carboxy Pennsylvania Green-NHS Ester, DIEA, 
DMF, 12 h;  (j)  15% TFA, DCM, 12 h. 
	  
 The N-alkyl-3β-sitosterylamine (10) was synthesized as shown in Figure 
2.5 starting from β-sitosterol (24) using chemistry described for the synthesis of 
3β-aminocholestene.22 The 3β-hydroxyl group of sitosterol was converted to the 
mesylate (25) using mesyl chloride.  Treatment with TMS-N3 in the presence of 
BF3!OEt2 afforded 3β-sitostene (26) with retention of stereochemistry. Reduction 
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using LAH afforded the secondary amine 27, followed by alkylation with 3-
bromopropylphthalimide and Boc protection to afford the precursor 28.  Peptide 
coupling conditions using EDC/HOBt with Fmoc protected β-alanine provided 
compound 29.  Coupling to compound 17, followed by deprotection with TFA and 
purification by preparative RP-HPLC afforded compound 10 as a TFA salt. 
The cholesteryl ether 11 was synthesized from cholesterol as shown in 
Figure 2.5. The 3β-hydroxyl group of cholesterol was alkylated with acrylonitrile 
in the presence of KOH and 18-crown-6 followed by reduction to the primary 
amine 30 using NaBH4 and NiCl2 according to a literature procedure.23 Peptide 
coupling conditions using EDC/HOBt with Fmoc-β-alanine gave compound 31, 
followed by coupling to compound 17 to give the protected precursor to 
compound 11. Deprotection of the tert-butyl ester protecting group with TFA and 
purification by preparative RP-HPLC provided compound 11. 
 The cholesteryl amide (12) and ester (13) compounds were synthesized 
starting from 3β-aminocholestene (32) and cholesterol (33), respectively (Figure 
2.5). In both cases, acylation was carried out using the acid chloride of Fmoc-β-
alanine (34) to give compounds 35 and 36.  Peptide coupling conditions using 
EDC/HOBt with Fmoc-β-alanine afforded 37 and 38, followed by coupling to 
compound 17 to provide the tert-butyl protected precursors. Deprotection with 
TFA and purification by preparative RP-HPLC afforded compounds 12 and 13. 
 The cholesteryl carbamates 14 and 15 were synthesized from cholesteryl 
chloroformate (39). Treatment with excess ethylene diamine followed 
immediately by EDC/HOBt and Fmoc-glycine provided compound 40. 
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Figure 2.5.  Synthesis of fluorescent cholesteryl conjugates 10 – 15.  Reagents 
and conditions:  (a)  MsCl, TEA, DCM, 4 °C to 22 °C, 16 h; (b) TMS-N3, 
BF3!OEt2, DCM, 16 h;  (c)  LiAlH4, Et2O, DCM, 4 °C to 22 °C, 2h;  (d) N-3-
bromopropyl phthalimide, K2CO3, DMF, 60 °C, 24 h; (e) (Boc)2O, DIEA, DCM, 4 
h;  (f) H2NNH2, EtOH, 50 °C, 4 h; (g) EDC, HOBt, Fmoc-β-Ala-OH, 4 °C to 22 °C, 
12 h; (h) 20% piperidine, DMF, 30 min;  (i) EDC, HOBt, 17, DMF, 12 h;  (j)  50% 
TFA, DCM, 2 h;  (k) DMAP, DCM, 30 min;  (l) Ethylene diamine, DCM, 2 h;  (m) 
EDC, HOBt, Fmoc-Gly-OH, 4°C to 22°C, 12 h; (n) EDC, HOBt, Fmoc-Glu(Ot-Bu)-
OH. 
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Further coupling with compound 17 followed by deprotection of the tert-butyl 
ester with TFA and purification by RP-HPLC afforded compound 14.  Coupling of 
compound 40 with Fmoc-Glu(Ot-Bu)-OH using EDC/HOBt gave compound 41. 
Further coupling with compound 17 followed by deprotection with TFA and 
purification by RP-HPLC provided compound 15. 
 
2.3  Biological Evaluation of Fluorescent Cholesterol Mimics 
 To test the cellular uptake of fluorescent cholesterol mimics, confocal 
laser-scanning microscopy was used to analyze fluorescence intensity and 
cellular localization. In these experiments, Jurkat lymphocytes were treated for 
both 5 minutes and 1 hour with compounds 1 and 7 – 15 at 2 µM and 37 °C 
(Figure 2.6). Compounds containing the N-alkyl-cholesterylamine linkage showed 
significantly increased cellular uptake versus other linkages after only 5 minutes. 
At 1 hour, most of the probes showed visible uptake and similar cellular 
localization. 
 In order to generate quantitative data and accurately determine the 
structure-activity relationships, flow cytometry analysis was used to generate 
saturation binding data. In these experiments, Jurkat lymphocytes were treated 
with compounds 1 and 7 – 15 for 5 minutes at 37 °C in the absence and 
presence of excess of ezetimibe (200 µM) to block specific binding to the cell 
surface. The fluorescence values obtained from flow cytometry were normalized 
to fluorescent bead standards provided by Spherotech Inc.  These beads provide 
a standard curve to convert raw fluorescence values to molecular equivalents of 
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fluorescein (MEFL).  Given the similarities in structure and fluorescence 
properties between fluorescein and Pennsylvania green, this allows for the 
accurate measurement of the number of fluorescent probe molecules bound to 
each individual cell.   
	  
Figure 2.6.  Confocal laser scanning and DIC micrographs of Jurkat lymphocytes 
treated with 1 and 7 – 15 (2 µM) for 5 min and 1 h at 37 °C. 
	  
Using both the total and non-specific binding data versus concentration 
(Figure 2.7), analysis for specific binding was performed using the ‘one-site – 
specific binding’ model in GraphPad Prism 5.  This allows for the quantification of 
binding affinity (as an apparent dissociation constant, Kd, app) and efficacy (as 
maximum binding, BMAX).   The results of this analysis are shown in Figure 2.8 
and Table 2.1. 
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Figure 2.7.  Saturation binding analysis of 1 and 7 – 15 in Jurkat lymphocytes.  
Cells were treated with each compound at 37 °C for 5 min in the absence and 
presence of ezetimibe (6, 200 µM) to determine non-specific binding, washed, 
and analyzed by flow cytometry.  Fluorescence values expressed as molecular 
equivalents of fluorescein (MEFL). 
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Figure 2.8.  Specific binding of 1 and 7 – 15 to Jurkat lymphocytes treated for 5 
min at 37 °C in the absence and presence of ezetimibe (6, 200 µM) and analyzed 
by flow cytometry.  The linear non-specific binding component was subtracted 
from the total binding data and analyzed using the ‘One site – specific binding’ 
model in GraphPad Prism 5. 
	  
	  
	  
Table 2.1.  Affinity and efficacy of cellular binding for compounds 1 and 7 – 15 
based on specific binding analysis in Jurkat lymphocytes with ezetimibe (6, 200 
µM) competition.  Affinity expressed as apparent Kd (µM) and efficacy expressed 
as maximum binding (BMAX, in MEFL).  a NC = Not calculated due to lack of 
efficacy and poor fit of the data to the one-site binding model. 
	  
Structure Kd, app (µM) BMAX (MEFL x 106)
1 PG-Glu-βAla-Cholesterylamine 1.38 ± 0.45 0.86 ± 0.13
7 PG-Glu-Glu-βAla-Cholesterylamine 1.22 ± 0.24 2.12 ± 0.18
8 PG-Gly-βAla-Cholesterylamine NC a NC a
9 PG-Glu-Glu-Cholesterylamine 7.68 ± 4.09 3.12 ± 1.29
10 PG-Glu-βAla-Sitosterylamine NC a NC a
11 PG-Glu-βAla-Cholesteryl ether NC a NC a
12 PG-Glu-βAla-Cholesteryl amide NC a NC a
13 PG-Glu-βAla-Cholesteryl ester NC a NC a
14 PG-Glu-Gly-Cholesteryl carbamate NC a NC a
15 PG-Glu-Glu-Gly-Cholesteryl carbamate 3.18 ± 0.61 2.34 ± 0.28
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Saturation binding analysis supported the original hypothesis that both the 
N-alkyl-3β-cholesterylamine linkage and one or two anionic glutamic acid 
residues in the linker region are critical for activity. Compounds 1 and 7 
containing one and two glutamic acid residues respectively showed the highest 
affinity and efficacy of the series. Comparison of compound 1 with compound 8, 
which substitutes glycine for glutamic acid, shows the dramatic loss of cellular 
binding that occurs when the anionic charge is removed from the linker region. 
Compounds 11 – 14, which replace the N-alkyl-3β-cholesterylamine with various 
neutral linkages, showed very low activity, supporting the hypothesis that the 
cationic amine moiety is a functional mimic of free cholesterol that allows for 
rapid binding and cellular uptake at the cell surface. Linkages such as the 
cholesteryl amide, ether, and carbamate likely engage in a much slower 
lipoprotein-mediated cellular uptake mechanism. Interestingly, the addition of a 
second glutamic acid residue to the cholesteryl carbamate compound 15 was 
able to rescue the activity, further elaborating on the importance of anionic 
residues in the linker. 
 Compound 10 was used to probe the specificity of cellular binding and 
uptake. This compound utilizes sitosterol, a phytosterol bearing an ethyl 
substituent at the C-24 position, as its sterol membrane anchor. Remarkably, this 
compound shows a dramatic decrease in activity when compared to compound 
1. This illustrates a high degree of specificity that mammalian cells possess for 
incorporating cholesterol into their membranes versus other closely related 
sterols. 
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2.4  Kinetic Analysis of Uptake of Fluorescent Cholesterol Analogues 
 In order to further investigate the mechanism by which fluorescent 
cholesterol analogues are incorporated into the plasma membrane, more 
detailed flow cytometry analysis was conducted on a subset of the compounds 
from the previous series. It was unclear based on the previous data whether the 
observed activity was due to saturable binding at a cell surface receptor or kinetic 
uptake occurring via an active transport mechanism at the plasma membrane. 
Given the high efficacy and rapid binding activity, with 0.5 – 1.5 x 106 molecules 
bound per cell after 5 minutes, we hypothesized that an unknown protein at the 
cell surface may be actively transporting these cholesterol mimics into the 
plasma membrane. To test this, we performed time-dependent flow cytometry 
experiments to compare compounds 1, 7, 10, and 15 (Figure 2.9).  Analysis of 
the results using the Michaelis-Menten model of kinetics provided evidence that a 
catalytic process was occurring to actively insert these fluorescent probes into 
the plasma membrane. 
 Michaelis-Menten kinetic analysis allows for an alternative determination 
of binding affinity (as KM) and also provides information about the rate of 
enzymatic turnover (as VMAX, Table 2.2). This analysis reveals a highly efficient 
mechanism of cellular uptake of the most active molecules, with 1.8 – 5.0 x 105 
molecules incorporated into the plasma membrane per minute per cell (Table 
2.2). Comparison of compounds 1 and 7 further illustrates the importance of the 
negative charge in the linker, with an approximate 3-fold increase in VMAX 
observed for compound 7, which contains two glutamic acid residues. 
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Figure 2.9.  Kinetic analysis of cellular uptake of compounds 1, 7, 10, and 15 in 
Jurkat lymphocytes by flow cytometry.  Panels A – D: Representative data for the 
time-dependent analysis of each compound. Experiments were performed in 
triplicate at 22 °C in the presence of media containing 10% serum.  Linear 
regression analysis provided the slope (MEFL/min) at each concentration.  Panel 
E: Michaelis-Menton analysis of cellular uptake.  MEFL/min at each 
concentration averaged from three independent experiments and plotted versus 
concentration.  Analysis by non-linear regression using the ‘Michaelis-Menten’ 
model in GraphPad Prism 5 provided KM and VMAX values. 
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Table 2.2.  Binding affinity (KM) and VMAX of compounds 1, 7, 10, and 15 based 
on Michaelis-Menten analysis of cellular uptake in Jurkat lymphocytes.  
Experiments were performed at 22 °C in the presence of media containing 10% 
serum.  Values represent the mean and SEM from three independent 
experiments. 
	  
Once again, the experimental data shows the remarkable selectivity of this 
mechanism to cholesterol, with a 10- to 30-fold loss in VMAX observed for the 
sitosterol analogue 10 versus 1 and 7, respectively. The cholesteryl carbamate 
15 illustrates the importance of the cationic amine linkage, with a >2-fold loss in 
both affinity and efficacy when compared to the cholesterylamine 10. However, it 
is worth noting that the additional negative charge in the linker allows for efficient 
uptake of 15 to occur, with a VMAX value similar to that of compound 1. This result 
proved rather useful in the application of these cholesterol mimics to other 
ongoing projects in the Peterson lab, since cholesteryl carbamates can be 
prepared more easily than cholesterylamines. 
 
2.5  Target Identification Studies 
2.5.1  Niemann-Pick C1-Like 1 Protein (NPC1L1) 
 In order to identify the putative protein target responsible for binding of 
fluorescent cholesterylamines to the cell surface, we characterized the inhibition 
of cholesterylamine 1 by small molecules. Based on the inhibition of cellular 
Structure KM (µM) VMAX (MEFL/min x 105)
1 PG-Glu-βAla-Cholesterylamine 1.53 ± 0.34 1.83 ± 0.20
7 PG-Glu-Glu-βAla-Cholesterylamine 2.62 ± 0.70 4.97 ± 0.80
10 PG-Glu-βAla-Sitosterylamine 1.65 ± 0.52 0.17 ± 0.03
15 PG-Glu-Glu-Cholesteryl carbamate 5.75 ± 2.23 1.87 ± 0.54
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uptake by ezetimibe (6), we turned our attention to Niemann-Pick C1-Like 1 
protein (NPC1L1) as a possible target. It is reported in the literature that the 
glucuronide metabolite of ezetimibe (42) shows greater potency compared with 
the parent drug toward blocking the intestinal uptake of free cholesterol by 
NPC1L1. Using a published route24, ezetimibe glucuronide (42) was synthesized 
and tested for inhibition of uptake of compound 1. 
 
	  
Figure 2.10.  Panel A: Structure of ezetimibe glucuronide (42).  Panel B:  
Competitive binding analysis of 1 in the absence and presence of 42 (200 µM).  
Jurkat lymphocytes were pre-incubated with 42 for 30 min at 37 °C, then treated 
with 1 for 5 min at 37 °C.  Analysis performed by flow cytometry in triplicate and 
fit to the ‘One site – total binding’ model in GraphPad Prism 5. 
 
 Based on the competitive binding analysis, ezetimibe glucuronide (42) 
showed no inhibition of cellular uptake of 1. This result was in agreement with a 
literature survey of NPC1L1, which suggested that expression of this protein was 
mainly restricted to the liver and intestines.9, 25 Since the uptake of 
cholesterylamines is observed in nearly all mammalian cell types regardless of 
the tissue of origin, these results indicated that NPC1L1, the primary target of 
ezetimibe, is not responsible for the observed activity. 
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2.5.2  Scavenger Receptor B1 (SR-B1) 
 Ezetimibe has been reported to bind and inhibit other proteins including 
scavenger receptor B1 (SR-B1).25-27 This protein is a cell surface receptor 
involved in transport of cholesteryl esters to and from high-density lipoprotein 
(HDL).28 Previous work in the Peterson group found that BLT-4 (43, Figure 2.13), 
a small molecule inhibitor of SR-B1, also inhibited uptake of cholesterylamines. 
This napthylurea-based compound was identified in a high-throughput screen to 
inhibit uptake of cholesterol from HDL by SR-B1.29 Several analogues of BLT-4 
were synthesized by a former group member (Paul Munson) and showed 
inhibitory potencies similar to Ezetimibe. With this in mind, we began to 
investigate SR-B1 as a possible target. This cell surface protein is constitutively 
expressed in nearly all mammalian cell types and is relatively well studied as a 
cholesterol transport protein. Two experiments were performed to test this 
hypothesis using flow cytometry to measure uptake of cholesterylamine 1. The 
first experiment involved transient overexpression of human SR-B1 (hSR-B1) in 
HEK-293 cells using expression vectors published by the Sahoo lab at the 
Medical College of Wisconsin.30 Cells transfected with the plasmid expressing 
hSR-B1 were compared to non- transfected and empty vector controls, as well as 
two plasmids that express non-functional mutant forms of hSR-B1 (hSR-
B1_S112F and hSR-B1_T175A).	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 The second experiment involved CHO-ldlA cells that have been modified 
to knockdown expression of the LDL receptor. This cell line has been stably 
transfected with mouse SR-B1 (mSR-B1) to produce CHO-ldlA_mSR-B1 cells 
that overexpress mSR-B1.28 The Krieger lab at MIT kindly provided these two cell 
lines for use in this experiment. Cellular uptake analysis with compound 1 was 
performed with CHO-ldlA_mSR-B1 cells and compared to non-transfected cells 
as a negative control.   
As shown in Figure 2.11, HEK-293 cells transfected with hSR-B1 showed 
no increase in uptake of cholesterylamine 1 compared to empty vector and non-
functional mutant controls. The CHO-ldlA_mSR-B1 cells showed a slight 
Figure 2.11.  Investigation of SR-B1 as the cell surface target of 
cholesterylamines.  Panel A:  Cellular uptake of 1 following transient 
overexpression of HEK-293 cells with plasmids coding for human SR-B1 and two 
non-functional mutants.  Transient expression was allowed to proceed for 48 h 
and cells were treated with 1 (100 nM) for 5 minutes at 37 °C.  Analysis 
performed by flow cytometry in duplicate.  Panel B:  Cellular uptake of 1 by CHO-
ldlA_mSR-B1 cells that stably overexpress mouse SR-B1.  Cells were treated 
with 1 for 5 minutes at 37 °C.  Analysis was performed by flow cytometry in 
duplicate and compared to the non-transfected control cell line.  Data was fit to 
the ‘One site – total binding’ model of GraphPad Prism 5. 
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increase in cellular uptake of ~30 – 40% compared to non-transfected CHO-ldlA 
cells. However this modest increase in activity does not correlate well with 
published results from the Krieger lab, in which cells overexpressing mSR-B1 
demonstrated a >5-fold increase in HDL binding and a >10-fold increase in 
uptake of cholesteryl esters (measured by radioligand binding assays). Based on 
our results using experimental methods that are validated to upregulate SR-B1 
activity, we concluded that SR-B1 was not likely to be responsible for the uptake 
of cholesterylamines. 
 
2.5.3  Proteomics-Based Target Identification 
 Since two known targets of two small molecule inhibitors did not appear to 
be responsible for the uptake of cholesterylamines, we shifted to a proteomics-
based screening approach to attempt to identify the target protein. In this 
approach, a small molecule photoaffinity probe containing a purification handle is 
used to bind the protein of interest. Irradiation with ultraviolet light generates a 
highly reactive intermediate, which forms a covalent bond with an active site 
residue of the target protein. Following cell lysis, the crosslinked protein is 
enriched using the purification handle and identified using MS/MS sequencing 
analysis of trypsin-digested peptides (Figure 2.12). Based on known structure-
activity relationships of the BLT-4 scaffold, we designed and synthesized 
compounds 47 and 49 as photoaffinity labels. These compounds contain a 
phenylazide moiety as a photocrosslinker. Compound 47 contains a terminal 
alkyne, allowing target enrichment using click chemistry with azide-functionalized 
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biotin and immobilized streptavidin, whereas 49, which lacks this purification 
handle, is used as a competitive binding control. The synthesis of these 
compounds is shown in Figure 2.13. 
	  
Figure 2.12.  Schematic representation of a protein pull-down assay using a 
photoaffinity label for target identification. 
	  
	  
Figure 2.13.  Synthesis of the BLT-4 analogue photoaffinity probe 47 and binding 
competitor 49.  Reagents and Conditions:  (a) TMS-N3, CuBr, TBHP, MeCN, 3 h; 
(b) TMS-Acetylene, PdCl2(PPh3)2, CuI, TEA, 80 °C, 16 h; (c) 0.1 M aq. KOH, 
MeOH, 3 h;  (d) 44, Triphosgene, DCM, 3 h. 
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 Compounds 47 and 49 were tested using flow cytometry with competitive 
binding analysis and found to be inhibitors of uptake of cholesterylamine 1 
(Figure 2.14, Panel C). Interestingly, compound 47 (at 25 µM) showed better 
inhibition than Ezetimibe (at 200 µM), indicating that it is a relatively good 
inhibitor of the target protein. Based on this result, target identification 
experiments were performed using the protein pull-down assay described in 
Figure 2.12. 
As a preliminary experiment, Jurkat lymphocytes were treated with 
photoaffinity probe 47 (10 µM, 1 h) in the presence and absence of compound 49 
(100 µM) as a competitive inhibitor, then irradiated with 365 nm light for 5 
minutes.  The cells were washed and lysed using brief ultra-sonication and the 
membrane protein fraction was separated from the cytosolic fraction using 
centrifugation.  The crosslinked membrane proteins were enriched from the 
resulting cell lysates and analyzed by SDS-PAGE with silver staining.  As shown 
in Figure 2.14 (Panel D), a protein band was observed at ~80 kDa that did not 
appear in either the untreated or competitive knockdown conditions, indicating a 
specific interaction and possible protein target. 
 The experiment was repeated and the resulting enriched protein samples 
were subjected to on-bead trypsin digestion and submitted to the KU Analytical 
Proteomics Laboratory (APL) for sequencing analysis.  Unfortunately, despite 
several attempts, the experimental procedure did not provide a strong enough 
signal-to-noise ratio to observe any specific proteins compared to untreated and 
competitive-binding controls. Furthermore, the protein band at ~80 kDa observed 
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in the SDS-PAGE analysis is consistent with the molecular weight of glycosylated 
human SR-B1 (~82 kDa).30 Since human SR-B1 is a known target of the 
naphthylurea-based BLT analogues, we would expect to observe this protein in a 
pulldown experiment using a BLT-based photoaffinity probe. However, since SR-
B1 was previously determined to be an unlikely target and no other proteins were 
observed by SDS-PAGE or MS/MS analyses, we are currently focused on new 
approaches to identify the protein responsible for uptake of cholesterylamines. 
	  
Figure 2.14. Panels A – B: Confocal laser scanning and DIC micrographs of 
Jurkat lymphocytes treated with 1 (2 µM) in the absence and presence of 47 (25 
µM).  Scale bar = 10 µm.  Panel C:  Competitive binding analysis of 1 in Jurkat 
lymphocytes in the absence and presence of ezetimibe (6, 200 µM), 47 (25 µM), 
or 49 (100 µM).  Analysis by flow cytometry and fit to a non-linear regression. 
Panel D: Protein pulldown assay using Jurkat lymphocytes and SDS-PAGE 
analysis with silver staining. Lane 1: untreated control; Lane 2: 47 (10 µM); Lane 
3: co-treatment of 47 (10 µM) with 49 (100 µM) as a binding competitor. 
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2.6  Conclusions 
  We designed and synthesized a series of fluorescent cholesterol mimics 
to probe structure-activity relationships that govern uptake by mammalian cells.  
Compounds possessing an N-alkyl-3β-cholesterylamine and a cholesteryl 
carbamate bearing a negatively charged linker showed highly efficient cellular 
uptake.  Evidence from competitive binding and kinetic experiments suggests 
that uptake occurs via a receptor-mediated process at the plasma membrane. In 
this way, these compounds appear to function as mimics of free cholesterol since 
their uptake does not require lipoprotein or receptor-mediated endocytosis. 
Target identification studies were performed, but have not identified a cell surface 
protein responsible for the observed activity.  Other target identification 
approaches are still being actively pursued in the Peterson lab. Because of the 
structural and functional similarities between cholesterylamines and free 
cholesterol, this unknown cell surface receptor may play a key role in the cellular 
uptake of cholesterol and/or charged cholesterol metabolites. 
 
2.7  Experimental Section 
2.7.1 General 
Chemical reagents were purchased from Apptec, Acros, Aldrich, Alfa 
Aesar, EMD Biosciences, or TCI America, and were used without further 
purification. Solvents were from Aldrich or Fisher Scientific. Ezetimibe (Zetia®), 
obtained from a local pharmacy, was isolated in pure form by extraction of 
crushed tablets from ddH2O with DCM, drying the organic layer over anhydrous 
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Na2SO4, and removal of solvent under vacuum. Biotin-azide was commercially 
available from TCI America. 3β-Amino-5-cholestene (32)22, cholesteryl-
oxypropan-1-amine (30)23, 4-carboxy-Pennsylvania green NHS ester31, 32, 1821, 
1921, ezetimibe glucuronide (42)24, and 4433 were synthesized by previously 
reported methods. Anhydrous solvents were obtained after passage through a 
drying column of a solvent purification system from GlassContour/SG Waters 
(Nashua, NH). All reactions were performed under an atmosphere of dry argon or 
nitrogen. Reactions were monitored by analytical thin-layer chromatography on 
plates coated with 0.25 mm silica gel 60 F254 (EMD Biosciences). TLC plates 
were visualized by UV irradiation (254 nm) or stained with either 
phosphomolybdic acid (20%) in ethanol or ninhydrin in ethanol. Column 
chromatography employed Silica Gel (SiliCycle, 40-63 µm). Preparative HPLC 
employed an Agilent 1200 Series preparative pump / gradient extension with a 
Hamilton PRP-1 (polystyrene-divinylbenzene) reverse-phase preparative column 
(10-12 µm particle size, 21.5 mm x 25 cm) with a flow rate of 25.0 mL/min. 
Melting points were measured with a Thomas Hoover capillary melting point 
apparatus and are uncorrected. Infrared spectra were obtained with a Perkin 
Elmer Spectrum 100 FTIR. NMR spectra were obtained with a Bruker Avance-
400 or DRX-500 instrument with chemical shifts reported in parts per million 
(ppm, δ) referenced to either CDCl3 (1H, 7.26 ppm; 13C, 77.16 ppm), CD3OD (1H, 
3.34 ppm; 13C, 49.00 ppm), or (CD3)2SO (1H, 2.50 ppm; 13C, 128.06 ppm). High-
resolution mass spectra were obtained at the University of Kansas Mass 
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Spectrometry Facility (ESI and EI). Peaks are reported as m/z. Basic compounds 
purified by reverse-phase HPLC were isolated as trifluoroacetic acid salts. 
 
2.7.2  Synthetic Procedures and Compound Characterization Data 
 
9H-Fluoren-9-ylmethyl(3-((3-((tert-butoxycarbonyl)(3β-cholest-5-en-3-
yl)amino)propyl)amino)-3-oxopropyl) carbamate (20). To a solution of 18 
(1.41 g, 2.1 mmol) in absolute ethanol (50 mL) was added anhydrous hydrazine 
(350 µL, 11 mmol). The solution was heated to 50 °C and stirred for 4 h. The 
reaction was cooled to 22 °C, and a white precipitate was removed by filtration. 
The filtrate was concentrated under vacuum, and the residue was dissolved in 
chloroform (100 mL). After insoluble material was removed by filtration, 
concentration of the filtrate under vacuum afforded the phthalimide-deprotected 
primary amine (1.13 g, 99%), a white solid that was carried forward without 
further purification. To Fmoc-β-Ala-OH (715 mg, 2.3 mmol) in anhydrous DCM 
(50 mL) at 4 °C was added hydroxybenzotriazole (HOBt, 340 mg, 2.5 mmol) and 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, 480 mg, 2.5 mmol). This 
mixture was stirred at 4 °C for 30 min. The phthalimide-deprotected primary 
amine in anhydrous DCM (25 mL) was added dropwise, the reaction was allowed 
to warm to 22 °C and was further stirred for 12 h. The solution was diluted with 
DCM (100 mL) and washed with aqueous NaOH (0.1 M, 100 mL) followed by 
saturated aqueous NaCl (100 mL). The organic layer was dried over anhydrous 
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Na2SO4 and concentrated under vacuum. Flash column chromatography 
(hexanes/ethyl acetate, 2:1) afforded 20 (1.62 g, 93%) as a glassy solid, mp 84-
86 °C; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.3 Hz, 2H), 7.58 (d, J = 7.4 Hz, 
2H), 7.39 (m, 2H), 7.30 (m, 2H), 7.05 (br, 1H), 5.82 (br, 1H), 5.33 (s, 1H), 4.34 (d, 
J = 7.2 Hz, 2H), 4.22 (t, J = 6.8 Hz, 1H), 3.51-3.24 (m, 6H), 2.60-0.86 (m, 54H), 
0.67 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.0, 156.5, 144.0, 143.9, 141.2, 
127.6, 127.6, 127.0, 125.1, 125.0, 121.4, 119.9, 77.1, 66.7, 56.7, 56.1, 50.0, 
47.2, 42.3, 39.7, 39.5, 37.2, 36.8, 36.5, 36.1, 35.9, 35.7, 31.8, 28.5, 28.2, 27.9, 
26.8, 24.2, 23.8, 22.8, 22.5, 20.9, 19.4, 18.7, 11.8 ; IR (film) νmax 3323, 2949, 
1717, 1668, 1539, 1449, 1412, 1366, 1251, 1169, 1081, 908, 737 cm-1; HRMS 
(ESI+) m/z 836.5831 (M+Na+, C53H77N3O5Na requires 836.5755). 
 
 
tert-Butyl-(15S)-5-(3β-cholest-5-en-3-yl)-15-(((9H-fluoren-9-
ylmethoxy)carbonyl)amino)-2,2-dimethyl-4,10,14-trioxo-3-oxa-5,9,13-
triazaoctadecan-18-oate(22). Compound 20 (303 mg, 0.36 mmol) was added to 
DMF (2 mL) containing piperidine (20%) and stirred for 30 min at 22 °C. The 
solvent was removed under vacuum to afford the crude primary amine. To a 
solution of Fmoc-Glu(Ot-Bu)-OH (157 mg, 0.37 mmol) in anhydrous DCM (10 
mL) at 4 °C were added HOBt (55 mg, 0.41 mmol) and EDC (79 mg, 0.41 mmol) 
and the solution was stirred for 30 min. To this solution was added the crude 
primary amine derived from 20 dissolved in anhydrous DCM (5 mL). The reaction 
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was allowed to warm to 22 °C and stirred for 12 h. This solution was diluted with 
DCM (30 mL) and washed with aqueous NaOH (0.1 M, 30 mL) followed by 
saturated aqueous NaCl (30 mL). The organic layer was dried over anhydrous 
Na2SO4 and concentrated under vacuum. Flash column chromatography 
(DCM/MeOH, 50:1) afforded 22 (361 mg, 98%) as a white solid, mp 120-122 °C; 
1H NMR (400 MHz, CDCl3) δ7.76 (d, J = 7.5 Hz, 2H), 7.60 (d, J = 7.5 Hz, 2H), 
7.51 (br, 1H), 7.39 (t, J = 7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.09 (br, 1H), 5.88 
(d, J = 8.0 Hz, 1H), 5.31 (d, J = 4.0 Hz, 1H), 4.34 (t, J = 7.1 Hz, 2H), 4.21 (t, J = 
7.1 Hz, 2H), 3.57-3.16 (m, 6H), 2.60-0.85 (m, 67H), 0.66 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 172.7, 171.4, 171.4, 156.2, 143.9, 143.8, 141.3, 127.7, 127.9, 
125.2, 121.4, 119.9, 80.9, 79.9, 67.1, 56.7, 56.1, 54.6, 50.1, 47.2, 42.3, 39.7, 
39.8, 39.6, 38.4, 37.1, 36.7, 36.2, 36.0, 35.8, 31.9, 31.5, 28.6, 28.2, 28.1, 28.0, 
27.9, 27.0, 24.3, 23.8, 22.8, 22.6, 21.0, 19.5, 18.7, 11.8 ; IR (film) νmax 3295, 
3066, 3005, 2935, 2863, 1726, 1652, 1540, 1465, 1451, 1415, 1366, 12523, 
1163, 1046, 849, 757, 666 cm-1; HRMS (ESI+) m/z 1043.6853 (M+Na+, 
C62H92N4O8Na requires 1043.6813). 
 
 
(4S)-5-((3-((3-(3β-Cholest-5-en-3-ylamino)propyl)amino)-3-
oxopropyl)amino)-4-((4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-
methylbenzoyl)amino)-5-oxopentanoic acid (1). Compound 22 (75 mg, 0.074 
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mmol) was added to DMF (1 mL) containing piperidine (20%) and stirred for 30 
min at 22 °C. The solvent was removed under vacuum to afford the crude 
primary amine. The resulting residue was dissolved in anhydrous DMF (5 mL), 4-
carboxy-Pennsylvania Green succinimidyl ester (30 mg, 0.062 mmol) was added, 
followed by diisopropylethylamine (DIEA, 50 µL, 0.24 mmol). The reaction was 
stirred at 22 °C for 12 h and concentrated under vacuum. To the resulting orange 
residue was added DCM (5 mL) containing TFA (30%) and the solution was 
stirred at 22 °C for 12 h. The reaction was concentrated under vacuum, the crude 
product was dissolved in DMSO (2 mL), and the product was purified by 
preparative reverse-phase HPLC (gradient: 90/10 H2O/MeCN to 100% MeCN 
over 20 min with 0.1% TFA added; retention time = 15 min (495 nm)) to afford 1 
(23 mg, 36.4%) as an orange solid, mp 196-198 °C; 1H NMR (300 MHz, DMSO-
d6) δ 8.76-8.72 (m, 3H), 8.19 (s, 2H), 8.14 (s, 1H), 8.05 (d, J = 5.4 Hz, 1H), 7.49 
(d, J = 5.7 Hz, 1H), 6.98 (s, 2H), 6.72 (d, J = 8.2 Hz, 2H), 5.45 (s, 1H), 4.53 (d, J 
= 2.7 Hz, 1H), 3.23 (m, 2H), 3.14 (m, 2H), 3.01 (m, 3H), 2.46-0.92(m, 51H), 0.72 
(s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 174.0, 172.7, 171.2, 170.8, 165.9, 158.0, 
149.3, 138.6, 135.9, 135.2, 134.5, 129.8, 129.0, 125.5, 122.4, 105.2, 56.6, 56.1, 
55.5, 53.1, 49.3, 41.8, 41.6, 36.4, 36.2, 35.6, 35.3, 35.2, 34.3, 31.2, 30.5, 27.7, 
27.4, 26.9, 26.2, 24.3, 23.8, 23.2, 22.6, 22.4, 20.5, 19.2, 18.7, 18.5, 11.6 ; IR 
(film) νmax 3324, 3071, 2950, 2863, 1671, 1646, 1610, 1539, 1503, 1465, 1373, 
1310, 1193, 1136, 836, 759 cm-1; HRMS (ESI+) m/z 1007.5679 (M+H+, 
C59H77F2N4O8Na requires 1007.5704). 
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tert-Butyl (15S,18S)-15-(3-tert-butoxy-3-oxopropyl)-5-(3β-cholest-5-en-3-yl)-
18-(((9H-fluoren-9-ylmethoxy)carbonyl) amino)-2,2-dimethyl-4,10,14,17-
tetraoxo-3-oxa-5,9,13,16-tetraazahenicosan-21-oate (23). Compound 22 (150 
mg, 0.15 mmol) was added to DMF (2 mL) containing piperidine (20%) and 
stirred for 30 min at 22 °C. The solvent was removed under vacuum to afford the 
crude primary amine. To Fmoc-Glu(Ot-Bu)-OH (70 mg, 0.16 mmol) in anhydrous 
DCM (10 mL) at 4 °C was added HOBt (24 mg, 0.18 mmol) and EDC (35 mg, 
0.18 mmol) and the solution was stirred for 30 min. The crude primary amine 
derived from 22 in anhydrous DCM (5 mL) was added. The reaction was allowed 
to warm to 22 °C and stirred for 12 h. This solution was diluted with DCM (30 mL) 
and washed with aqueous NaOH (0.1 M, 30 mL) followed by saturated aqueous 
NaCl (30 mL). The organic layer was dried over anhydrous Na2SO4 and 
concentrated under vacuum. Flash column chromatography (DCM/MeOH, 30:1) 
afforded 23 (162 mg, 92%) as a white solid, mp 138-144 °C; 1H NMR (400 MHz, 
CDCl3) δ7.78 (d, J = 7.5 Hz, 2H), 7.63 (d, J = 7.2 Hz, 2H), 7.59 (br, 1H), 7.41 (t, J 
= 7.4 Hz, 2H), 7.36 (br, 1H), 7.33 (t, J = 7.4 Hz, 2H), 7.19 (br, 1H), 5.92 (br, 1H), 
5.32 (d, J = 6.4 Hz, 1H), 4.36 (d, J = 7.2 Hz, 3H), 4.24 (t, J = 7.0 Hz, 2H), 3.58-
3.20 (br, 7H), 2.60-0.86 (m, 79H), 0.67 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
172.9, 172.8, 171.4, 171.1, 156.3, 156.3, 143.9, 143.7, 141.2, 127.7, 127.1, 
125.2, 121.3, 120.0, 81.0, 80.9, 77.2, 67.2, 56.7, 56.2, 53.1, 50.1, 47.1, 42.3, 
39.8, 39.5, 38.4, 36.7, 36.2, 35.8, 31.9, 28.6, 28.2, 28.0, 27.9, 24.3, 23.8, 22.8, 
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22.6, 21.0, 19.5, 18.7, 11.8 ; IR (film) νmax 3289, 3066, 3005, 2934, 2868, 1729, 
1693, 1679, 1636, 1539, 1450, 1413, 1388, 1367, 1281, 1254, 1158, 1044, 757, 
667 cm-1; HRMS (ESI+) m/z 1206.8032 (M+H+, C71H108N5O11 requires 
1206.8040). 
 
 
(4S)-5-(((1S)-3-Carboxy-1-(((3-((3-(3β-cholest-5-en-3-ylamino)propyl)amino)-
3-oxopropyl)amino)carbonyl)propyl)amino)-4-((4-(2,7-difluoro-6-hydroxy-3-
oxo-3H-xanthen-9-yl)-3-methylbenzoyl)amino)-5-oxopentanoic acid (7). 
Compound 23 (30 mg, 0.025 mmol) was added to DMF (1 mL) containing 
piperidine (20%) and stirred for 30 min at 22°C. The solvent was removed under 
vacuum to afford the crude primary amine. To the resulting residue in dry DMF (2 
mL) was added 4-carboxy-Pennsylvania Green succinimidyl ester (13 mg, 0.027 
mmol) followed by DIEA (50 µL, 0.24 mmol). The reaction was stirred at 22 °C for 
12 h and concentrated under vacuum. The orange residue was treated with DCM 
(5 mL) containing TFA (30%) and stirred at 22 °C for 12 h. The reaction was 
concentrated under vacuum, and the crude product was dissolved in DMSO (2 
mL) and purified by preparative reverse-phase HPLC (gradient: 90/10 
H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; retention time = 
14 min (495 nm)) to afford 7 (6.2 mg, 22%) as an orange solid, mp 145-148 °C; 
1H NMR (400 MHz, DMSO-d6) δ 8.65 (d, J = 7.8 Hz, 1H), 8.37 (s, 2H), 8.07-7.92 
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(m, 4H), 7.39 (d, J = 8.0 Hz, 1H), 6.85 (s, 1H), 6.62 (d, J = 10.9 Hz, 1H), 5.37 (s, 
1H), 4.46 (m, 1H), 4.21 (m, 1H), 3.29-3.20 (m, 4H), 2.90 (m, 3H), 2.46-0.92 (m, 
55H), 0.63 (s, 3H); 13C NMR (100 MHz, DMSO-d6) δ 174.4, 172.6, 171.8, 171.7, 
129.8, 129.0, 125.5, 122.4, 105.2, 57.0, 56.5, 56.0, 49.8, 42.3, 42.1, 39.3, 39.2, 
39.1, 36.8, 36.6, 36.1, 36.0, 35.8, 35.6, 33.8, 31.7, 31.0, 30.6, 27.9, 25.8, 24.9, 
24.8, 24.3, 23.6, 23.1, 22.8, 19.5, 19.2, 19.0, 12.1 ; IR (film) νmax 3419, 2951, 
1682, 1643, 1540, 1438, 1375, 1310, 1205, 1142, 1015, 801, 721.6 cm-1; HRMS 
(ESI+) m/z 1136.6179 (M+H+, C64H84F2N5O11 requires 1136.6130). 
 
 
tert-Butyl-3β-cholest-5-en-3-yl(14-(9H-fluoren-9-yl)-5,9,12-trioxo-13-oxa- 
4,8,11-triazatetradec-1-yl)carbamate (21). Compound 20 (150 mg, 0.18 mmol) 
was added to DMF (2 mL) containing piperidine (20%) and stirred for 30 min at 
22 °C. The solvent was removed under vacuum to afford the crude primary 
amine. To a solution of Fmoc-Gly-OH (60 mg, 0.20 mmol) in anhydrous DCM (10 
mL) at 4 °C was added HOBt (30 mg, 0.22 mmol) and EDC (42 mg, 0.22 mmol) 
and the solution was stirred for 30 min. The primary amine derived from 20 in 
anhydrous DCM (5 mL) was added. The reaction was allowed to warm to 22 °C 
and stirred for 12 h. This solution was diluted with DCM (30 mL) and washed with 
aqueous NaOH (0.1 M, 30 mL) followed by saturated aqueous NaCl (30 mL). 
The organic layer was dried over anhydrous Na2SO4 and concentrated under 
vacuum. Flash column chromatography (DCM/MeOH, 20:1) afforded 21 (153 mg, 
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97%) as a white solid, mp 112-114 °C; 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 
7.4 Hz, 2H), 7.60 (d, J = 7.0 Hz, 2H), 7.39 (t, J = 7.3 Hz, 2H), 7.30 (t, J = 7.3 Hz, 
2H), 6.99 (br, 1H), 5.78 (br, 1H), 5.31 (s, 1H), 4.38 (d, J = 6.9 Hz, 2H), 4.22 (t, J = 
7.0 Hz, 1H), 3.86 (d, J = 4.5 Hz, 2H), 3.56 (d, J = 5.0 Hz, 2H), 3.22 (m, 2H), 2.52-
0.86 (m, 56H), 0.67 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.5, 169.0, 156.5, 
148.3, 143.8, 141.2, 127.7, 127.0, 125.1, 121.4, 119.9, 80.0, 67.1, 56.7, 56.1, 
50.0, 47.1, 44.3, 42.3, 41.5, 39.7, 39.5, 38.4, 37.1, 36.7, 36.1, 35.9, 35.7, 31.8, 
28.5, 28.2, 27.9, 26.8, 24.2, 23.8, 22.8, 22.5, 20.9, 19.4, 18.7, 11.8 ; IR (film) ν 
max 3311, 2936, 2868, 1717, 1667, 1543, 1465, 1450, 1413, 1365, 1249, 1168, 
1048, 758 cm-1; HRMS (ESI+) m/z 893.6122 (M+H+, C55H81N4O6 requires 
893.6151). 
 
 
N-(2-((3-((3-(3β-Cholest-5-en-3-ylamino)propyl)amino)-3-oxopropyl)amino)-
2-oxoethyl)-4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-
methylbenzamide (8). Compound 21 (25 mg, 0.028 mmol) was added to DMF 
(1 mL) containing piperidine (20%) and stirred for 30 min at 22 °C. The solvent 
was removed under vacuum to afford the crude primary amine. To the resulting 
residue in dry DMF (2 mL) was added 4-carboxy-Pennsylvania Green 
succinimidyl ester (11 mg, 0.023 mmol) followed by DIEA (50 µL, 0.24 mmol). 
The reaction was stirred at 22 °C for 12 h and concentrated under vacuum. The 
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orange residue was treated with DCM (5 mL) containing TFA (30%) and stirred at 
22 °C for 12 h. The reaction was concentrated under vacuum, and the crude 
product was dissolved in DMSO (2 mL) and purified by preparative reverse-
phase HPLC (gradient: 90/10 H2O/MeCN to 100% MeCN over 20 min with 0.1% 
TFA added; retention time = 13 min (495 nm)) to afford 8 (18 mg, 82%) as an 
orange solid, mp 200-203 °C; 1H NMR (300 MHz, DMSO-d6) δ 8.91 (s, 1H), 8.56 
(s, 2H), 8.0-7.91 (m, 4H), 7.40 (d, J = 7.6 Hz, 1H), 6.86 (s, 2H), 6.60 (d, J = 11.1 
Hz, 2H), 5.38 (s, 1H), 3.87 (m, 2H), 3.14 (m, 4H), 2.93 (m, 3H), 2.30-0.85 (m, 
47H), 0.61 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 170.9, 168.8, 166.0, 149.0, 
138.5, 136.0, 135.2, 134.8, 129.9, 129.0, 125.3, 122.6, 105.0, 56.5, 56.1, 55.5, 
49.3, 42.7, 41.7, 41.5, 36.1, 35.9, 35.6, 35.4, 35.2, 34.2, 31.2, 27.7, 27.4, 26.2, 
26.1, 24.4, 23.2, 22.7, 22.4, 20.5, 19.2, 18.7, 18.5, 11.6; IR (film) νmax 3419, 
2950, 2115, 1646, 1540, 1465, 1374, 1310, 1194, 1147, 1016, 875 cm-1; HRMS 
(ESI+) m/z 957.5350 (M+Na+, C56H72F2N4O6Na requires 957.5350). 
 
 
5-(tert-butoxy)-2-(4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-
methylbenzamido)-5-oxopentanoic acid (17) Fmoc-Glu(O-t-Bu)-OH (16, 
67mg, 0.156 mmol) was treated with piperidine (20%) in DMF (1 mL) for 30 min. 
The solvent was removed under vacuum to afford the crude primary amine. A 
solution of 4-carboxy-Pennsylvania Green succinimidyl ester (25 mg, 0.052 
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mmol) in DMF (1 mL) was added to the crude primary amine in DMF (1 mL) 
followed by DIEA (0.25 mL). The reaction was allowed to stir at 22 °C for 16 h, 
dried under vacuum, and purified by flash column chromatography (MeOH/DCM/ 
AcOH, 5:94.9:0.1) to afford 17 (27 mg, 90%) as an orange residue, mp 134-138 
°C; 1H NMR (400 MHz, CD3OD) δ 8.00 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.40 (d, 
J = 7.9 Hz, 1H), 6.98 – 6.89 (m, 2H), 6.81 – 6.77 (m, 2H), 4.70 (d, J = 9.6 Hz, 
1H), 2.47 (t, J = 7.0 Hz, 2H), 2.39 – 2.27 (m, 1H), 2.14 – 2.08 (m, 1H), 2.12 (s, 
3H), 1.46 (s, 9H); 13C NMR (101 MHz, CD3OD) δ 174.95, 173.97, 169.66, 
156.19, 138.02, 137.15, 136.55, 131.01, 130.47, 126.62, 112.98, 112.76, 106.32, 
81.94, 53.70, 32.95, 28.35, 27.66, 19.60 ; IR (film) νmax 2929, 1678, 1607, 1536, 
1371, 1302, 1190, 1139, 953, 842, 801, 750, 724 cm-1; HRMS (ESI+) m/z 
568.1779 (M+H+, C30H28F2NO8, requires 568.1777). 
 
 
(4S)-5-(((2S)-4-carboxy-1-((3-(3β-cholest-5-en-3-ylamino)propyl)amino)-1-
oxobutan-2-yl)amino)-4-(4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-
methylbenzamido)-5-oxopentanoic acid (9). Compound 19 (26.8 mg, 0.028 
mmol), synthesized by a previously reported method21, was added to DMF (0.5 
mL) containing piperidine (20%) and stirred for 30 min at 22 °C. The solvent was 
removed under vacuum to afford the crude primary amine. To a solution of 17 
(8.0 mg, 0.014 mmol) in anhydrous DMF (2 mL) at 4 °C was added HOBt (4.0 
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mg, 0.028 mmol) and EDC (5.4 mg, 0.028 mmol) and the solution was stirred at 
22 °C for 30 min. The primary amine derived from 19 in anhydrous DMF (1 mL) 
was added at 4 °C, then the reaction was allowed to warm to 22 °C and stirred 
for 12 h. The reaction was concentrated under vacuum and the resulting residue 
was re-dissolved in DCM containing TFA (30%) and stirred at 22 °C for 2 h. The 
solvent was removed under vacuum, the crude product was dissolved in DMSO 
(2 mL), and purified by preparative reverse-phase HPLC (gradient: 90/10 
H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; retention time = 
16 min (495 nm)) to afford 9 (13.1 mg, 87%) as a orange solid, mp 175-178 °C; 
1H NMR (500 MHz, CD3OD) δ 7.93 (s, 1H), 7.87 – 7.84 (m, 1H), 7.45 (t, J = 7.5 
Hz, 1H), 6.87 – 6.75 (m, 2H), 6.72 – 6.58 (m, 2H), 5.39 (d, J = 4.9 Hz, 1H), 4.45 
(m, 1H), 4.19 (m, 1H), 3.37 – 3.28 (m, 2H), 3.28 – 3.23 (m, 2H), 3.03 – 2.94 (m, 
2H), 2.88 (m, 1H), 2.54 – 0.69 (m, 52H), 0.59 (s, 3H); 13C NMR (126 MHz, 
CD3OD) δ 176.85, 176.47, 174.94, 174.34, 169.92, 156.15, 146.38, 140.74, 
139.53, 138.09, 136.70, 131.60, 131.47, 131.15, 130.50, 130.09, 127.07, 125.93, 
125.15, 124.55, 122.22, 115.64, 113.74, 106.42, 59.41, 58.03, 57.51, 55.76, 
55.01, 51.42, 44.75, 41.95, 40.99, 40.69, 38.22, 37.82, 37.35, 37.10, 36.92, 
36.38, 33.77, 32.11, 31.55, 31.23, 30.01, 28.44, 27.82, 27.67, 27.58, 26.27, 
25.98, 25.24, 24.96, 24.09, 22.10, 22.06, 19.64 19.43, 19.22, 12.27; IR (film) νmax 
3387, 2323, 1675, 1541, 1439, 1202, 1135, 842, 802, 724 cm-1; HRMS (ESI-) 
m/z 1063.5757 (M-H+, C61H77F2N4O10 requires 1063.5613). 
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Sitost-5-en-3β-ol methanesulfonate (25). To a solution of β-sitosterol (24, 5.0 
g, 12.0 mmol) in anhydrous DCM (100 mL) at 4 °C was added freshly distilled 
triethylamine (2.7 mL, 18.1 mmol) followed by a dropwise solution of 
methanesulfonyl chloride (1.03 mL, 13.25 mmol) in anhydrous DCM (10 mL). The 
reaction was maintained at 4 °C for 30 min, warmed to 22 °C, and stirred for 16 
h. The reaction was concentrated under vacuum and the resulting residue was 
purified by flash chromatography (ethyl acetate/hexane, 1:4) to give 25 (4.1 g, 
69%) as a white solid, mp 97-100 °C; 1H NMR (400 MHz, CDCl3) δ 5.45 – 5.38 
(m, 1H), 4.52 (dt, J = 11.9, 3.7 Hz, 1H), 2.99 (s, 3H), 2.51 (d, J = 7.2 Hz, 2H), 
2.09 – 0.75 (m, 42H), 0.68 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 138.57, 123.61, 
81.82, 56.52, 55.96, 49.86, 45.76, 42.19, 39.55, 39.04, 38.62, 36.79, 36.25, 
35.97, 33.84, 31.71, 31.52, 29.12, 28.85, 28.04, 26.09, 24.11, 22.98, 20.89, 
19.62, 19.12, 18.96, 18.63, 11.75, 11.43; IR (film) νmax 2958, 2931, 2867, 1465, 
1350, 1326, 1168, 946, 865, 802 cm-1; HRMS (EI+) m/z 492.3637 (M+, 
C30H52O3S requires 492.3632). 
 
 
3β-Azido-5-sitostene (26). To a solution of 25 (1.7 g, 3.45 mmol) in anhydrous 
DCM (30 mL) was added TMS-N3 (0.68 mL, 5.20 mmol), followed by BF3·Et2O 
(0.86 mL, 6.90 mmol). The reaction was stirred at 22 °C for 16 h. The reaction 
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was slowly poured into aqueous NaOH (1.0 M, 30 mL) and stirred for 5 min. The 
organic phase was separated and the aqueous layer was extracted with DCM 
(30 mL). The combined organic extracts were washed with saturated NaCl 
solution (500 mL), dried over anhydrous Na2SO4, and concentrated under 
vacuum to give the crude product as light yellow oil. The crude product was 
purified by flash column chromatography (ethyl acetate/hexane, 2:98) to afford 
26 (800 mg, 53%) as a white solid, mp 74-78 °C; 1H NMR (400 MHz, CDCl3) δ 
5.42 – 5.35 (m, 1H), 3.20 (t, J = 11.5 Hz, 1H), 2.29 (d, J = 7.9 Hz, 2H), 2.05 – 
0.75 (m, 42H), 0.68 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 139.84, 122.55, 61.17, 
56.73, 56.07, 50.11, 45.84, 42.32, 39.72, 38.17, 37.59, 36.62, 36.16, 33.95, 
31.85, 31.73, 29.16, 28.25, 27.96, 26.08, 24.29, 23.08, 21.01, 19.84, 19.29, 
19.05, 18.80, 11.93, 11.65; IR (film) νmax 2935, 2867, 2090, 1463, 1377, 1259, 
750 cm-1; HRMS (EI+) m/z 411.3872 (M-N2, C29H49N requires 411.3865). 
 
 
3β-Amino-5-sitostene (27). To a solution of 26 (180 mg, 0.44 mmol) in 
anhydrous diethyl ether (5 mL) at 4 °C was added LiAlH4 powder (25 mg, 0.66 
mol) in two equal portions. The reaction was maintained at 4 °C for 30 min, 
warmed to 22 °C, and stirred for 2 h. The reaction was cooled to 4 °C and 
carefully quenched by slow dropwise addition of ice-cold water. When evolution 
of H2 gas ceased, the solution was poured into water (10 mL). The organic phase 
was separated, and the aqueous phase was extracted with ethyl acetate (10 mL 
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× 2). The combined organic extracts were washed with saturated NaCl solution 
(10 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The 
resulting solid was dissolved in chloroform (10 mL) and residual inorganic salts 
were removed by filtration. Concentration of the filtrate afforded 27 (140 mg, 
77%) as a white solid, mp 122-125 °C; 1H NMR (400 MHz, CDCl3) δ 5.39 – 5.27 
(m, 1H), 2.78 – 2.72 (m, 1H), 2.49 (d, J = 13.0 Hz, 2H), 2.21 – 0.74 (m, 42H), 
0.67 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 141.54, 120.89, 56.80, 56.06, 51.90, 
50.23, 45.74, 45.56, 42.74, 42.32, 39.80, 38.11, 36.56, 36.16, 33.95, 32.14, 
31.90, 29.15, 28.26, 26.07, 24.31, 23.07, 21.02, 19.83, 19.45, 19.04, 18.79, 
11.93, 11.68; IR (film) νmax 3360, 3280, 3160, 2926, 2852, 1587, 1462, 1381, 
1022, 957, 836, 799, 738 cm-1; HRMS (ESI+) m/z 414.4074 (M+H+, C29H52N 
requires 414.4094). 
 
 
tert-Butyl-3β-sitost-5-en-3-yl(3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) 
propyl)carbamate (28). Compound 27 (130 mg, 0.31 mmol), N-(3-
bromopropyl)phthalimide (103 mg, 0.38 mmol), and K2CO3 (108 mg, 0.78 mmol) 
were added to DMF (8 mL) and the solution was heated to 60 °C and stirred for 
24 h. The reaction was cooled to 22 °C, and the solvent removed under vacuum. 
To the resulting residue was added DCM (10 mL). The insoluble material was 
removed by filtration and washed with DCM (2 × 5 mL). To the combined filtrate 
and wash solutions containing the crude secondary amine product was added 
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(Boc)2O (135 mg, 0.62 mmol) and DIEA (0.17 mL, 1.24 mmol). The reaction was 
stirred for 4 h at 22 °C, then concentrated under vacuum. Flash column 
chromatography (hexane/ethyl acetate, 85:15) afforded 28 (90 mg, 42% over 2 
steps) as a white solid, mp 122-124 °C; 1H NMR (400 MHz, CDCl3) δ 7.88 – 7.79 
(m, 2H), 7.72 (m, 2H), 5.37 – 5.25 (m, 1H), 3.85 (t, J = 6.9 Hz, 1H), 3.70 (t, J = 
7.1 Hz, 2H), 3.15 (br, 2H), 2.06 – 0.73 (m, 56H), 0.66 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 168.34, 134.07, 133.94, 132.11, 123.35, 123.21, 79.42, 56.71, 
56.04, 50.12, 45.83, 42.31, 39.75, 36.17, 35.96, 33.94, 31.88, 29.14, 28.47, 
28.26, 26.07, 24.29, 23.06, 20.99, 19.83, 19.41, 19.04, 18.78, 11.93, 11.64; IR 
(film) νmax 3340, 2935, 2869, 1713, 1676, 1466, 1365, 1249, 1169, 1143, 907, 
730 cm-1; HRMS (ESI+) m/z 723.4980 (M+Na+, C45H68N2O4Na, requires 
723.5071). 
 
 
9H-Fluoren-9-ylmethyl (3-((3-((tert-butoxycarbonyl)(3β-sitost-5-en-3-yl) 
amino)propyl)amino)-3-oxopropyl) carbamate (29). To a solution of 28 (80 
mg, 0.11 mmol) in absolute ethanol (3 mL) was added anhydrous hydrazine (17 
µL, 0.55 mmol). The solution was heated to 50 °C and stirred for 4 h. The 
reaction was cooled to 22 °C, and a white precipitate was removed by filtration. 
The filtrate was concentrated under vacuum, and the residue was dissolved in 
chloroform (6 mL). After insoluble material was removed by filtration, 
concentration of the filtrate under vacuum afforded the phthalimide-deprotected 
 57 
primary amine, a white solid that was carried forward without further purification. 
To Fmoc-β-Ala-OH (69 mg, 0.22 mmol) in anhydrous DCM (2 mL) at 4 °C were 
added HOBt (30 mg, 0.22 mmol) and EDC (42 mg, 0.22 mmol) followed by 
stirring at 4 °C for 30 min. The phthalimide-deprotected primary amine in 
anhydrous DCM (2 mL) was slowly added, and the reaction was allowed to warm 
to 22 °C and stirred for 12 h. The solution was concentrated under vacuum, and 
flash column chromatography (DCM/MeOH, 99:1) afforded 29 (56 mg, 60% over 
two steps) as a white solid, mp 86-90 °C; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J 
= 7.5 Hz, 2H), 7.60 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 
Hz, 2H), 6.99 (br, 1H), 5.79 (br, 1H), 5.33 (d, J = 4.6 Hz, 1H), 4.35 (d, J = 7.2 Hz, 
2H), 4.20 (t, J = 7.1 Hz, 1H), 3.56 – 3.46 (m, 2H), 3.25 (m, 4H), 2.44 (m, 2H), 
2.07 – 0.73 (m, 56H), 0.67 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 156.50, 144.04, 
141.29, 127.64, 127.03, 125.19, 121.47, 119.94, 66.71, 56.75, 56.06, 50.10, 
47.27, 45.84, 42.32, 39.75, 38.45, 36.74, 36.16, 35.98, 33.95, 31.88, 29.15, 
28.55, 28.26, 26.08, 24.30, 23.07, 21.01, 19.84, 19.47, 19.04, 18.79, 11.93, 
11.66; IR (film) νmax 3320, 2934, 2869, 1665, 1541, 1450, 1365, 1249, 1167, 
1141, 908, 732 cm-1; HRMS (ESI+) m/z 886.5963 (M+Na+, C55H81N3O5Na, 
requires 668.6068). 
 
(4S)-5-((3-((3-(3β-Sitost-5-en-3-ylamino)propyl)amino)-3-oxopropyl)amino)-
4-((4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-methylbenzoyl) 
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amino)-5-oxopentanoic acid (10). Compound 29 (24.4 mg, 0.028 mmol) was 
added to DMF (0.5 mL) containing piperidine (20%) and stirred for 30 min at 22 
°C. The solvent was removed under vacuum to afford the crude primary amine. 
To a solution of 17 (8.0 mg, 0.014 mmol) in anhydrous DMF (2 mL) at 4 °C was 
added HOBt (4.0 mg, 0.028 mmol) and EDC (5.4 mg, 0.028 mmol), and the 
solution was stirred for 30 min. The primary amine derived from 29 was added in 
anhydrous DMF (1 mL). The reaction was allowed to warm to 22 °C and stirred 
for 12 h. The reaction was concentrated under vacuum, DCM (2 mL) containing 
TFA (30%) was added, and the mixture was stirred for 2 h. The solvent was 
removed under vacuum and the crude product was dissolved in DMSO (2 mL). 
Purification by preparative reverse-phase HPLC (gradient: 90/10 H2O/MeCN to 
100% MeCN over 20 min with 0.1% TFA added; retention time = 18 min (495 
nm)) afforded 10 (11.4 mg, 79%) as an orange solid, mp 192-195 °C; 1H NMR 
(500 MHz, CD3OD) δ 7.93 (s, 1H), 7.85 (d, J = 7.4 Hz, 1H), 7.30 (d, J = 7.9 Hz, 
1H), 6.86 – 6.75 (m, 2H), 6.73 – 6.57 (m, 2H), 5.37 (d, J = 4.5 Hz, 1H), 4.44 (d, J 
= 9.1, 1H), 3.43 (t, J = 6.3 Hz, 2H), 2.98 (t, J = 7.2 Hz, 2H), 2.89 (d, J = 12.1 Hz, 
1H), 2.48 – 0.66 (m, 57H), 0.60 (s, 3H); 13C NMR (126 MHz, CD3OD) δ 176.70, 
175.01, 174.05, 169.61, 156.14, 139.52, 138.29, 138.09, 137.87, 136.96, 136.67, 
131.10, 130.51, 126.76, 124.79, 112.74, 111.92, 106.43, 59.30, 58.05, 57.41, 
55.45, 51.45, 49.52, 49.35, 49.18, 49.07, 48.88, 48.84, 48.58, 48.42, 47.26, 
43.40, 43.24, 40.99, 38.24, 37.81, 37.41, 37.19, 36.91 36.60, 36.34, 35.07, 
32.98, 31.77, 31.52, 30.37, 29.32, 27.97, 27.88, 27.15, 26.33, 25.24, 24.14, 
22.05, 20.21, 19.69, 19.62, 19.17, 12.32, 11.94; IR (film) ν max 3306, 2956, 
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2869, 1671, 1541, 1302, 1201, 1135, 841, 801, 724 cm-1; HRMS (ESI-) m/z 
1033.5874 (M-H+, C61H79F2N4O8 requires 1033.5871). 
 
 
9H-fluoren-9-ylmethyl (3-((3-((3β-cholest-5-en-3-yl)oxy)propyl)amino)-3-
oxopropyl)carbamate (31). To Fmoc-β-Ala-OH (380 mg, 1.22 mmol) in 
anhydrous DCM (5 mL) at 4 °C was added HOBt (165 mg, 1.22 mmol) and EDC 
(234 mg, 1.22 mmol), and the mixture was stirred at 4 °C for 30 min. Compound 
30, synthesized as previously reported, (350 mg, 0.81 mmol) was added in 
anhydrous DCM (5 mL). The reaction was allowed to warm to 22 °C and was 
stirred for 12 h. The solution was diluted with DCM (10 mL) and washed with 
saturated aqueous NaHCO3 (10 mL) and saturated aqueous NaCl (10 mL). The 
organic layer was dried over anhydrous Na2SO4 and concentrated under 
vacuum. Flash column chromatography (DCM/MeOH, 99:1) afforded 31 (515 mg, 
87%) as a glassy solid, mp 148-150 °C; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 
7.5 Hz, 2H), 7.59 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 Hz, 
2H), 6.34 (br, 1H), 5.58 (br, 1H), 5.34 – 5.26 (m, 1H), 4.35 (d, J = 7.2 Hz, 2H), 
4.20 (t, J = 7.1 Hz, 1H), 3.61 – 3.44 (m, 4H), 3.38 (d, J = 11.4 Hz, 2H), 3.16 – 
3.04 (m, 1H), 2.46 – 0.79 (m, 44H), 0.69 – 0.63 (m, 3H); 13C NMR (101 MHz, 
CDCl3) δ 171.19, 156.62, 144.12, 141.42, 140.64, 127.79, 127.17, 125.29, 
122.02, 120.09, 79.46, 67.37, 66.90, 56.87, 56.29, 50.27, 47.35, 42.44, 39.89, 
39.65, 39.23, 38.86, 37.24, 36.96, 36.33, 35.99, 35.86, 32.00, 31.64, 29.24, 
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28.61, 28.36, 28.15, 24.40, 23.96, 22.96, 22.70, 21.17, 19.49, 18.86, 11.99 ; IR 
(film) νmax 3306, 2934, 2867, 1682, 1639, 1537, 1448, 1376, 1342, 1268, 1240, 
1103, 1018, 908, 735 cm-1; HRMS (ESI+) m/z 775.4972 (M+K+, C48H68N2O4K 
requires 775.4811). 
 
 
(4S)- 5-((3-((3-(3β-Cholest-5-en-3-yloxy)propyl)amino)-3-oxopropyl)amino)-
4-((4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-methylbenzoyl) 
amino)-5-oxopentanoic acid (11). Compound 31 (15.0 mg, 0.020 mmol) was 
added to DMF (0.5 mL) containing piperidine (20%) and stirred for 30 min at 22 
°C. The solvent was removed under vacuum to afford the crude primary amine. 
To a solution of 17 (11.3 mg, 0.020 mmol) in anhydrous DMF (2 mL) at 4 °C was 
added HOBt (5.5 mg, 0.040 mmol) and EDC (8.0 mg, 0.040 mmol) and the 
solution was stirred for 30 min. The primary amine derived from 31 was added in 
anhydrous DMF (1 mL), and the reaction was allowed to warm to 22 °C and 
stirred for 12 h. The reaction was concentrated under vacuum, DCM (2 mL) 
containing TFA (30%) was added, and the solution was stirred at 22 °C for 2 h. 
The solvent was removed under vacuum and the crude product was dissolved in 
DMSO (2 mL). Purification by preparative reverse-phase HPLC (gradient: 90/10 
H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; retention time = 
17 min (495 nm)) afforded 11 (13.1 mg, 87%) as an orange solid, mp 192-194 
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°C; 1H NMR (400 MHz, CD3OD) δ 8.01 (s, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.28 – 
7.36 (m, 1H), 7.04 – 6.85 (m, 2H), 6.82 – 6.70 (m, 2H), 5.32 – 5.26 (m, 1H), 4.60 
– 4.54 (m, 1H), 3.56 – 3.45 (m, 4H), 3.45 – 3.36 (m, 2H), 3.28 – 3.22 (m, 4H), 
3.17 – 3.04 (m, 2H), 2.62 – 0.81 (m, 46H), 0.67 (s, 3H); 13C NMR (101 MHz, 
CD3OD) δ 190.52, 183.25, 180.16, 173.46, 171.19, 161.26, 155.36, 150.34, 
141.55, 136.58, 133.73, 130.91, 126.48, 122.52, 106.27, 80.31, 67.05, 66.56, 
57.81, 57.19, 51.31, 43.21, 40.79, 40.41, 39.93, 38.54, 38.11, 37.76, 37.62, 
37.08, 36.94, 36.78, 36.34, 32.82, 32.77, 31.33, 30.49, 29.14, 28.87, 27.88, 
25.06, 24.68, 23.15, 22.89, 21.91, 19.81, 19.17, 12.28. IR (film) νmax 3369, 2925, 
2853, 2076, 1646, 1543, 1464, 1375, 1314, 1193, 1117, 971, 735 cm-1; HRMS 
(ESI-) m/z 1006.5441 (M-H+, C59H74F2N3O9 requires 1006.5399). 
 
 
(9H-fluoren-9-yl)methyl (3-((3β-cholest-5-en-3-yl)amino)-3-oxopropyl) 
carbamate (35). Fmoc-β-Ala-Cl (34, 170 mg, 0.54 mmol, prepared by treatment 
of Fmoc-β-Ala-OH with excess SOCl2 for 1 h followed by removal of SOCl2 under 
vacuum) was dissolved in anhydrous DCM (5 mL). A solution of 3β-amino-5-
cholestene (32, 250 mg, 0.65 mmol) and 4-dimethylaminopyridine (DMAP, 15 
mg, 0.10 mmol) in anhydrous DCM was slowly added and the solution was 
stirred at 22 °C for 30 min. The reaction was diluted with DCM (25 mL) and 
filtered to remove precipitated solids. The resulting filtrate was concentrated 
under vacuum and purified via flash column chromatography (DCM, MeOH, 99:1) 
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to afford 35 (128 mg, 35%) as a white solid, mp 124-128 °C; 1H NMR (400 MHz, 
CDCl3) δ 7.75 (d, J = 7.5 Hz, 2H), 7.58 (d, J = 7.5 Hz, 2H), 7.39 (t, J = 7.4 Hz, 
2H), 7.30 (t, J = 7.3 Hz, 2H), 5.54 (br, 1H), 5.41 – 5.32 (m, 2H), 4.36 (m, 2H), 
4.20 (t, J = 6.9 Hz, 1H), 3.69 (m, 1H), 3.48 (m, 2H), 2.39 (m, 2H), 2.29 (d, J = 
13.2 Hz, 1H), 2.14 – 0.82 (m, 39H), 0.69 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
170.28, 156.57, 144.00, 141.33, 140.12, 127.65, 127.04, 125.07, 122.07, 119.93, 
77.32, 77.00, 76.68, 66.78, 56.74, 56.23, 50.16, 49.86, 47.30, 42.34, 39.78, 
39.54, 39.31, 37.86, 37.22, 36.57, 36.22, 35.79, 31.87, 31.66, 29.18, 28.20, 
27.99, 24.27, 23.86, 22.77, 22.53, 20.99, 19.31, 18.73, 11.86; IR (film) νmax 3313, 
2933, 2867, 1686, 1636, 1534, 1449, 1267, 1148, 1023, 992, 735 cm-1; HRMS 
(ESI+) m/z 701.4615 (M+Na+, C45H62N2O3Na, requires 701.4658). 
 
 
(9H-fluoren-9-yl)methyl (3-((3-((3β-cholest-5-en-3-yl)amino)-3-
oxopropyl)amino)-3-oxopropyl) carbamate (37). Compound 35 (30.0 mg, 
0.045 mmol) was added to DMF (0.5 mL) containing piperidine (20%) and stirred 
for 30 min at 22 °C. The solvent was removed under vacuum to afford the crude 
primary amine. To a solution of Fmoc-β-Ala-OH (27.5 mg, 0.090 mmol) in 
anhydrous DMF (2 mL) at 4 °C were added HOBt (12.0 mg, 0.090 mmol) and 
EDC (17.0 mg, 0.090 mmol) and the solution was stirred for 30 min. The primary 
amine derived from 35 was added in anhydrous DMF (1 mL), and the reaction 
was warmed to 22 °C and stirred for 12 h. The reaction was concentrated under 
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vacuum, and flash column chromatography (DCM/MeOH, 98/2) afforded 37 (23.8 
mg, 71%) as a white solid, mp 178-180 °C; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, 
J = 7.5 Hz, 2H), 7.59 (d, J = 7.4 Hz, 2H), 7.39 (t, J = 7.4 Hz, 2H), 7.30 (t, J = 7.4 
Hz, 2H), 6.52 (br, 1H), 5.66 – 5.49 (m, 2H), 5.31 (d, J = 11.0 Hz, 1H), 4.35 (d, J = 
7.0 Hz, 2H), 4.20 (t, J = 7.1 Hz, 1H), 3.65 (m, 1H), 3.58 – 3.42 (m, 4H), 2.39 (m, 
4H), 2.24 (m, 1H), 2.12 – 0.78 (m, 39H), 0.66 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 170.64, 156.46, 143.99, 141.30, 139.96, 127.68, 127.05, 125.17, 
122.18, 119.97, 66.76, 56.67, 56.13, 49.97, 49.89, 47.25, 42.29, 39.62, 39.21, 
37.77, 36.51, 36.19, 35.98, 35.80, 35.54, 35.44, 31.80, 29.08, 28.13, 28.01, 
27.92, 24.27, 23.84, 22.83, 22.57, 20.94, 19.30, 18.72, 11.86; IR (film) νmax 3310, 
2932, 2867, 1687, 1637, 1536, 1450, 1367, 1273, 1148, 1105, 1025, 739 cm-1; 
HRMS (ESI+) m/z 772.4980 (M+Na+, C48H67N3O4Na, requires 772.5024). 
 
 
 
(4S)-4-(4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-
methylbenzamido)-5-((3-((3-((3β-cholest-5-en-3-yl)amino)-3-
oxopropyl)amino)-3-oxopropyl)amino)-5-oxopentanoic acid (12). Compound 
37 (21.0 mg, 0.028 mmol) was added to DMF (0.5 mL) containing piperidine 
(20%) and stirred for 30 min at 22 °C. The solvent was removed under vacuum to 
afford the crude primary amine. To a solution of 17 (8.0 mg, 0.014 mmol) in 
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anhydrous DMF (2 mL) at 4 °C was added HOBt (4.0 mg, 0.028 mmol) and EDC 
(5.4 mg, 0.028 mmol) and the solution was stirred for 30 min. The primary amine 
derived from 37 was added in anhydrous DMF (1 mL), and the reaction was 
warmed to 22 °C and stirred for 12 h. The reaction was concentrated under 
vacuum. DCM (2 mL) containing TFA (30%) was added and the solution was 
stirred for 2 h at 22 °C. The solvent was removed under vacuum, and the crude 
product was dissolved in DMSO (2 mL). Purification by preparative reverse-
phase HPLC (gradient: 90/10 H2O/MeCN to 100% MeCN over 20 min with 0.1% 
TFA added; retention time = 19 min (495 nm)) afforded 12 (10.2 mg, 71%) as a 
orange solid, mp 192-194 °C; 1H NMR (500 MHz, CD3OD) δ 8.01 (s, 1H), 7.96 
(d, J = 6.8 Hz, 1H), 7.33 (d, J = 7.7 Hz, 1H), 6.85 (m, 2H), 6.66 (m, 2H), 5.32 (m, 
1H), 3.64 – 3.52 (m, 2H), 3.52-3.44 (m, 2H), 2.58 – 0.81 (m, 53H), 0.69 (s, 3H); 
13C NMR (126 MHz, CD3OD) δ 175.61, 173.36, 168.58, 163.08, 155.99, 141.21, 
137.35, 136.58, 135.94, 130.61, 130.43, 129.83, 126.05, 122.33, 113.29, 111.80, 
106.20, 57.46, 56.87, 50.95, 50.55, 43.30, 42.94, 40.46, 40.17, 39.35, 38.62, 
37.24, 36.83, 36.51, 32.51, 29.19, 28.85, 28.63, 24.84, 24.45, 23.09, 22.83, 
21.59, 19.83, 19.64, 19.07, 12.21; IR (film) νmax 3305, 2932, 2871, 1646, 1541, 
1371, 1306, 1188, 952, 750 cm-1; HRMS (ESI-) m/z 1019.5361 (M-H+, 
C59H73F2N4O9 requires 1019.5351). 
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Cholesteryl 3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanoate (36). 
A solution of cholesterol (33, 681 mg, 1.76 mmol) and 4-dimethylaminopyridine 
(60 mg, 0.50 mmol) in anhydrous DCM (5 mL) was slowly added to Fmoc-β-Ala-
Cl (34, 500 mg, 1.60 mmol) in anhydrous DCM (5 mL) and the reaction was 
stirred at 22 °C for 12 h. The reaction was diluted with DCM (25 mL) and filtered 
to remove precipitated solids. The resulting filtrate was concentrated under 
vacuum and purified via flash column chromatography (hexane/ethyl acetate, 
7:3) to provide 36 (590 mg, 55%) as a white foam, mp 102-104 °C; 1H NMR (400 
MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.59 (d, J = 6.9 Hz, 2H), 7.40 (t, J = 7.4 
Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 5.39 (d, J = 3.8 Hz, 1H), 5.39-5.33 (m, 1H), 4.66 
(d, J = 8.4 Hz, 1H), 4.38 (d, J = 7.1 Hz, 2H), 4.21 (t, J = 7.0 Hz, 1H), 3.50 – 3.45 
(m, 2H), 2.54 (t, J = 5.7 Hz, 2H), 2.33 (d, J = 7.8 Hz, 2H), 2.07 – 0.80 (m, 38H), 
0.69 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.86, 156.32, 143.95, 141.32, 
139.48, 127.70, 127.05, 125.09, 122.87, 119.99, 74.52, 66.76, 56.70, 56.15, 
50.03, 47.25, 42.33, 39.64, 39.22, 38.14, 36.97, 36.60, 36.20, 35.81, 34.72, 
31.89, 28.25, 28.04, 27.82, 24.30, 23.85, 22.85, 22.59, 21.05, 19.33, 18.74, 
11.88 ; IR (film) νmax 3356, 2946, 2868, 1721, 1512, 1450, 1376, 1263, 1189, 
1006, 735 cm-1; HRMS (ESI+) m/z 702.4473 (M+Na+, C45H61NO4Na, requires 
702.4493). 
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Cholesteryl 3-(3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)propanamido) 
propanoate (38). Compound 36 (200 mg, 0.30 mmol) was added to DMF (1.0 
mL) containing piperidine (20%) and stirred for 30 min at 22 °C. The solvent was 
removed under vacuum to afford the crude primary amine. To a solution of 
Fmoc-β-Ala-OH (102 mg, 0.33 mmol) in anhydrous DMF (3 mL) at 4 °C was 
added HOBt (45 mg, 0.33 mmol) and EDC (64 mg, 0.33 mmol) and the solution 
was stirred for 30 min. The primary amine derived from 36 was added in 
anhydrous DMF (3 mL), and the reaction was warmed to 22 °C and stirred for 12 
h. The reaction was concentrated under vacuum, and flash column 
chromatography (DCM/MeOH, 98/2) afforded 38 (150 mg, 52%) as a white foam, 
mp 158-160 °C; 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.3 Hz, 2H), 7.59 (d, J 
= 7.3 Hz, 2H), 7.39 (t, J = 7.2 Hz, 2H), 7.30 (t, J = 7.1 Hz, 2H), 6.24 (br, 1H), 5.60 
(br, 1H), 5.35 (m, 1H), 4.62 (m, 1H), 4.35 (d, J = 6.5 Hz, 2H), 4.20 (t, J = 6.6 Hz, 
1H), 3.61 – 3.45 (m, 4H), 2.50 (t, J = 6.1 Hz, 2H), 2.45 – 2.35 (m, 1H), 2.29 (d, J 
= 7.3 Hz, 2H), 2.04 – 0.78 (m, 39H), 0.67 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
172.09, 171.42, 156.61, 144.07, 141.39, 139.49, 127.77, 127.15, 125.25, 122.98, 
120.05, 74.71, 66.83, 56.76, 56.23, 50.07, 47.34, 42.39, 39.71, 38.19, 37.19, 
37.00, 36.64, 36.29, 35.97, 35.86, 35.03, 34.37, 31.93, 31.81, 28.33, 28.12, 
27.87, 24.37, 23.94, 22.94, 22.68, 21.11, 19.38, 18.82, 11.95 ; IR (film) νmax 
3314, 2937, 1729, 1687, 1640, 1544, 1449, 1377, 1269, 1186, 1027, 739 cm-1; 
HRMS (ESI+) m/z 773.4793 (M+Na+, C48H66N3O4Na, requires 773.4864). 
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(4S)-4-(4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-
methylbenzamido)-5-((3-((3-((3-cholester -3-yl)oxy) 3-oxopropyl)amino)-3-
oxopropyl)amino)-5-oxopentanoic acid (13). Compound 38 (21.0 mg, 0.028 
mmol) was added to DMF (0.5 mL) containing piperidine (20%) and stirred for 30 
min at 22 °C. The solvent was removed under vacuum to afford the crude 
primary amine. To a solution of 17 (8.0 mg, 0.014 mmol) in anhydrous DMF (2 
mL) at 4 °C was added HOBt (4.0 mg, 0.028 mmol) and EDC (5.4 mg, 0.028 
mmol) and the solution was stirred for 30 min. The primary amine derived from 
38 was added in anhydrous DMF (1 mL), and the reaction was warmed to 22 °C 
and stirred for 12 h. The reaction was concentrated under vacuum. DCM (2 mL) 
containing TFA (30%) was added and the solution stirred at 22 °C for 2 h. The 
solvent was removed under vacuum and the crude product was dissolved in 
DMSO (2 mL). Purification by preparative reverse-phase HPLC (gradient: 90/10 
H2O/MeCN to 100% MeCN over 20 min with 0.1% TFA added; retention time = 
17 min (495 nm)) afforded 13 (10.5 mg, 73%) as an orange solid, mp 180-184 
°C; 1H NMR (500 MHz, CD3OD) δ 8.03 (s, 1H), 7.97 (d, J = 7.7 Hz, 1H), 7.36 (d, 
J = 7.9 Hz, 1H), 6.84 (m, 2H), 6.76 (m, 2H), 5.32 (d, J = 4.2 Hz, 1H), 4.59 (m, 
2H), 3.59 – 3.39 (m, 4H), 2.58 – 2.48 (m, 4H), 2.43 (d, J = 10.6 Hz, 2H), 2.29 (d, 
J = 7.7 Hz, 2H), 2.16 (s, 3H), 2.06 – 0.78 (m, 40H), 0.69 (s, 3H); 13C NMR (126 
MHz, CD3OD) δ 174.83, 171.84, 171.03, 167.27, 148.36, 141.22, 139.66, 138.91 
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(d, J = 9.8 Hz), 135.96, 134.86, 134.59, 131.93, 129.58 – 129.33, 129.20, 
128.73, 128.43, 126.53, 125.57, 124.73, 123.97, 122.66, 121.83, 119.23, 118.47, 
113.50, 112.21, 104.60, 73.79, 56.06, 55.49, 53.34, 49.49, 46.96, 43.56, 41.51, 
39.05, 38.74, 37.21, 36.23, 35.77, 35.40, 35.11, 34.63, 33.33, 31.09, 29.65, 
29.06, 27.39, 27.20, 26.85, 26.11, 23.37, 23.00, 21.47, 21.21, 20.19, 18.07, 
17.48, 10.58 ; IR (film) νmax 3298, 2930, 2868, 1725, 1643, 1610, 1534, 1456, 
1374, 1295, 1188, 1024, 952, 838, 732 cm-1; HRMS (ESI-) m/z 1020.5208 (M-H+, 
C59H73F2N3O10 requires 1020.5191). 
 
 
9H-fluoren-9-ylmethyl (3-((3-(((((cholester-3-yl)oxy) carbonyl)amino)ethyl) 
amino)-2-oxoethyl)amino)carbamate (40). A solution of cholesteryl 
chloroformate (39, 500 mg, 1.11 mmol) in DCM (5 mL) was very slowly added to 
a solution of ethylene diamine (1.50 mL, 22.26 mmol) in DCM (10 mL). The 
reaction was allowed to stir at 22 °C for 2 h. The excess diamine was removed 
under vacuum, the resulting solid was dissolved in DCM (10 mL), and the organic 
layer was washed with aqueous NaOH (1 M, 10 mL). The organic phase was 
dried over anhydrous Na2SO4, and concentrated under vacuum to provide the 
primary amine product, which was used without further purification. To a solution 
of Fmoc-Gly-OH (104 mg, 0.35 mmol) in anhydrous DCM (5 mL) at 4 °C was 
added HOBt (47 mg, 0.35 mmol) and EDC (67 mg, 0.35 mmol) and the solution 
was stirred for 30 min. The primary amine derived from 39 (150 mg, 0.32 mmol) 
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was added in anhydrous DCM (3 mL), and the reaction was warmed to 22 °C 
and stirred for 12 h. The reaction was concentrated under vacuum, and purified 
by flash column chromatography (DCM/MeOH, 98/2) to afford 40 (130 mg, 56%) 
as a white foam, mp 82-84 °C; 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 
2H), 7.60 (d, J = 7.2 Hz, 2H), 7.40 (t, J = 7.3 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 
6.74 (br, 1H), 5.46 (br, 1H), 5.35 – 5.26 (m, 1H), 5.04 (br, 1H), 4.43 (d, J = 7.2 
Hz, 2H), 4.22 (t, J = 6.9 Hz, 1H), 3.87 (s, 2H), 3.42 – 3.38 (m, 2H), 3.38 – 3.28 
(m, 2H), 2.92 (d, J = 32.0 Hz, 2H), 2.38 – 0.73 (m, 40H), 0.65 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 170.08, 162.84, 156.80, 143.88, 141.40, 139.71, 127.87, 
127.22, 125.23, 122.75, 120.12, 74.93, 67.38, 56.72, 56.27, 49.99, 47.24, 44.59, 
42.39, 39.72, 38.59, 36.98, 36.66, 36.31, 35.91, 31.78, 28.53, 28.02, 24.35, 
23.97, 22.94, 22.68, 21.11, 19.39, 18.83, 11.95 ; IR (film) νmax 3319, 2937, 2867, 
1665, 1527, 1450, 1382, 1252, 1153, 1031, 1009, 737 cm-1; HRMS (ESI-) m/z 
786.4638 (M+Cl-, C47H65N3O5Cl requires 786.4618). 
 
 
 
(4S)-4-(4-(2,7-difluoro-6-hydroxy-3-oxo-3H-xanthen-9-yl)-3-
methylbenzamido)-5-(3-((3-(((((3-cholester-3-
y)oxy)carbonyl)amino)ethyl)amino)-2-oxoethyl)amino)-5-oxopentanoic acid 
(14). Compound 40 (21.0 mg, 0.028 mmol) was added to DMF (0.5 mL) 
 70 
containing piperidine (20%) and stirred for 30 min at 22 °C. The solvent was 
removed under vacuum to afford the crude primary amine. To a solution of 17 
(8.0 mg, 0.014 mmol) in anhydrous DMF (2 mL) at 4 °C was added HOBt (4.0 
mg, 0.028 mmol) and EDC (5.4 mg, 0.028 mmol) and the solution was stirred for 
30 min. The primary amine derived from 40 in anhydrous DMF (1 mL) was 
added. The reaction was allowed to warm to 22 °C and stirred for 12 h. The 
reaction was concentrated under vacuum. DCM (2 mL) containing TFA (30%) 
was added and the solution was stirred at 22 °C for 2 h. The solvent was 
removed under vacuum and the crude product was dissolved in DMSO (2 mL). 
Purification by preparative reverse-phase HPLC (gradient: 90/10 H2O/MeCN to 
100% MeCN over 20 min with 0.1% TFA added; retention time = 19 min (495 
nm)) afforded 14 (9.0 mg, 63%) as an orange solid, mp 186-190 °C; 1H NMR 
(500 MHz, CD3OD) δ 8.06 (s, 1H), 8.01 (d, J = 7.0 Hz, 1H), 7.35 (d, J = 7.8 Hz, 
1H), 7.05 – 6.90 (m, 2H), 6.90 – 6.69 (m, 2H), 5.30 – 5.24 (m, 1H), 4.57 – 4.48 
(m, 1H), 4.42 – 4.32 (m, 2H), 4.18 (s, 1H), 3.95 – 3.87 (m, 2H), 3.41 – 3.33 (m, 
2H), 3.31 – 3.25 (m, 2H), 2.62 – 2.51 (m, 2H), 2.40 – 0.78 (m, 43H), 0.68 (s, 3H); 
13C NMR (126 MHz, CD3OD) δ 176.93, 174.60, 171.87, 169.77, 158.73, 150.37, 
141.11, 130.75, 128.54, 127.59, 125.98, 124.67, 123.60, 121.25, 120.48, 114.22, 
106.58, 75.79, 58.06, 57.50, 51.48, 43.90, 43.52, 41.54, 41.39, 41.54, 41.34, 
40.98, 39.75, 38.26, 37.75, 37.42, 37.13, 33.10, 31.59, 29.56, 29.12, 27.36, 
25.38, 25.01, 23.47, 23.22, 22.20, 20.09, 19.48, 12.59; IR (film) νmax 3312, 2931, 
2867, 1644, 1610, 1526, 1463, 1373, 1266, 1188, 1026, 952, 874, 733 cm-1; 
HRMS (ESI-) m/z 1021.5169 (M-H+, C58H71F2N3O10 requires 1021.5144). 
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tert-butyl (S)-4-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-((2-((2-
((((Cholester-3-yl)oxy)carbonyl)amino)ethyl)amino)-2-oxoethyl)amino)-5-
oxopentanoate (41).  Compound 40 (100 mg, 0.136 mmol) was added to DMF 
(2 mL) containing piperidine (20%) and stirred for 30 min at 22 °C. The solvent 
was removed under vacuum to afford the crude primary amine. To a solution of 
Fmoc-Glu(Ot-Bu)-OH (115 mg, 0.272 mmol) in anhydrous DCM (10 mL) at 4 °C 
was added HOBt (37 mg, 0.272 mmol) and EDC (52 mg, 0.272 mmol) and the 
solution was stirred for 30 min. The crude primary amine derived from 40 was 
added in anhydrous DCM (5 mL), and the reaction was warmed to 22 °C and 
stirred for 12 h. This solution was diluted with DCM (30 mL) and washed with 
aqueous NaOH (0.1 M, 30 mL) followed by saturated aqueous NaCl (30 mL). 
The organic layer was dried over anhydrous Na2SO4 and concentrated under 
vacuum. Flash column chromatography (DCM/MeOH, 50:1) afforded 41 (87 mg, 
70%) as a white solid, mp 88-92 °C; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.5 
Hz, 2H), 7.58 (d, J = 7.0 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.28 (t, J = 7.5 Hz, 2H), 
7.09 (br, 2H), 6.26 (br, 1H), 5.49 (br, 1H), 5.35 – 5.28 (m, 1H), 4.39 (d, J = 6.6 
Hz, 2H), 4.20 (t, J = 7.0 Hz, 1H), 4.19 – 4.11 (m, 1H), 3.93 (s, 2H), 3.70 – 3.64 
(m, 1H), 3.37 – 3.30 (m, 2H), 3.28 – 3.21 (m, 2H), 2.60 – 0.77 (m, 53H), 0.65 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 172.96, 172.01, 169.39, 156.84, 143.70, 
141.29, 139.74, 127.77, 127.13, 125.08, 122.48, 120.00, 81.29, 74.57, 67.24, 
 72 
56.66, 56.15, 55.35, 49.98, 47.12, 43.16, 42.30, 39.72, 39.52, 38.51, 36.94, 
36.50, 36.20, 35.79, 31.83, 28.22, 28.08, 28.01, 24.26, 23.85, 22.82, 22.57, 
21.02, 19.30, 18.72, 11.85;  IR (film) νmax 3319, 2942, 1681, 1525, 1450, 1367, 
1250, 1152, 1032, 843, 735, 702 cm-1; HRMS (ESI+) m/z 959.5876 (M+Na+, 
C56H80N4O8Na+ requires 959.5868). 
 
 
(10S,13S)-10-(2-carboxylatoethyl)-13-(4-(2,7-difluoro-6-oxido-3-oxo-3H-
xanthen-9-yl)-3-methylbenzamido)-1-((Cholester-3-yl)oxy)-1,6,9,12-tetraoxo-
2,5,8,11-tetraazahexadecan-16-oate (15).  Compound 41 (30 mg, 0.027 mmol) 
was added to DMF (0.5 mL) containing piperidine (20%) and stirred for 30 min at 
22 °C. The solvent was removed under vacuum to afford the crude primary 
amine. To a solution of 17 (23 mg, 0.040 mmol) in anhydrous DMF (2 mL) at 4 °C 
was added HOBt (5 mg, 0.040 mmol) and EDC (8 mg, 0.040 mmol) and the 
solution was stirred for 30 min. The primary amine derived from 41 was added in 
anhydrous DMF (1 mL), and the reaction was warmed to 22 °C and stirred for 12 
h. The reaction was concentrated under vacuum, DCM (2 mL) containing TFA 
(30%) was added, and the solution was stirred at 22 °C for 2 h. The solvent was 
removed under vacuum and the crude product was dissolved in DMSO (2 mL). 
Purification by preparative reverse-phase HPLC (gradient: 90/10 H2O/MeCN to 
100% MeCN over 20 min with 0.1% TFA added; retention time = 19 min (495 
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nm)) afforded 15 (10 mg, 33%) as an orange solid, mp 182-186 °C; 1H NMR (500 
MHz, CD3OD) δ 8.02 (s, 1H), 7.99 (d, J = 8.1 Hz, 1H), 7.40 (d, J = 7.9 Hz, 1H), 
6.97 – 6.91 (m, 2H), 6.81 – 6.63 (m, 2H), 5.35 – 5.29 (m, 1H), 4.65 – 4.57 (m, 
1H), 4.40 - 4.34 (m, 1H), 4.31 – 4.24 (m, 1H), 4.10 – 3.73 (m, 2H), 3.33 – 3.18 
(m, 4H), 2.58 (t, J = 8.1 Hz, 4H), 2.53 – 0.80 (m, 48H), 0.68 (s, 3H); 13C NMR 
(126 MHz, CD3OD) δ 176.76, 176.34, 174.80, 174.43, 171.80, 169.87, 158.62, 
156.09, 153.56, 141.21, 138.02, 136.81, 136.61, 131.33, 130.56, 126.75, 123.53, 
115.90, 112.90, 112.74, 106.49, 75.58, 58.05, 57.53, 55.42, 55.23, 51.66, 43.70, 
43.43, 41.04, 40.70, 40.50, 39.70, 38.19, 37.64, 37.37, 37.13, 33.06, 32.92, 
31.49, 31.13, 30.77, 29.29, 29.18, 28.02, 27.13, 25.24, 24.99, 23.21, 22.96, 
22.07, 19.75, 19.69, 19.25, 12.26;  IR (film) νmax 3317, 2941,  1644, 1611, 1536, 
1465, 1372, 1336, 1307, 1191, 1032, 952, 875, 833 cm-1; HRMS (ESI+) m/z 
1174.5601 (M+Na+, C63H79F2N5O13Na+ requires 1174.5535). 
 
 
6-ethynylnaphthalen-2-amine (46).  6-Bromonaphthyl-2-amine 45 (100 mg, 
0.450 mmol) was added to dry, argon-flushed triethylamine (3 mL).  Ethynyl 
trimethylsilane (100 µL, 0.675 mmol), palladium dichloride bis-triphenylphosphine 
(15 mg, 0.025 mmol), and copper (I) iodide (7 mg, 0.037 mmol) were added, and 
the reaction was heated to 80 °C and stirred for 16 h.  The reaction mixture was 
dried under vacuum, re-dissolved in DCM (3 mL), loaded onto a short plug of 
silica, and eluted with DCM/MeOH (95/5).  The eluted product was dried under 
vacuum, re-dissolved in methanol (3 mL), and 1 M aqueous potassium hydroxide 
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(0.3 mL) was added and allowed to stir at 22 °C for 3 h.  The reaction mixture 
was diluted with chloroform (20 mL) and extracted with saturated NaHCO3 (2 x 
10 mL).  The organic layer was washed with brine, dried over Na2SO4, and 
concentrated under vacuum.  Flash chromatography (hexames/ethyl acetate, 
5:1) afforded compound 46 (41 mg, 54%) as a white solid, mp 82 – 86 °C; 1H 
NMR (500 MHz, CDCl3) δ 7.87 (s, 1H), 7.61 (d, J = 8.3 Hz, 1H), 7.52 (d, J = 8.5 
Hz, 1H), 7.41 (d, J = 8.5 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 6.94 (s, 1H), 3.94 (br, 
2H), 3.08 (s, 1H); 13C NMR (126 MHz, CDCl3) δ 145.30, 134.85, 132.39, 129.39, 
129.26, 127.29, 125.96, 118.88, 115.65, 108.39, 84.67, 76.37; IR (film) νmax 
3215, 2925, 2854, 1630, 1503, 1390, 1286, 1176, 905, 866, 811, 727 cm-1; 
HRMS (ESI+) m/z 168.0822 (M+H+, C12H10N+ requires 168.0808). 
 
 
1-(2-azidophenyl)-3-(6-ethynylnaphthalen-2-yl)urea (47).  Compound 44 (20 
mg, 0.150 mmol) was dissolved in DCM (4 mL).  Triphosgene (130 mg, 0.450 
mmol) was added and allowed to stir at 22 °C for 30 minutes.  The solution was 
then added directly to a short plug of silica and eluted using DCM/MeOH (95/5, 
30 mL).  The eluent was immediately dried under vacuum.  The crude 
chloroformate of 44 was dissolved in DCM (3 mL), and then N,N-
dimethylaminopyridine (DMAP, 12 mg, 0.100 mmol) and compound 46 (25 mg, 
0.150 mmol) were added.  The reaction was allowed to stir for 3 h at 22 °C. The 
reaction mixture was added directly to a column of silica and subjected to flash 
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chromatography (eluted with a gradient of DCM to 95/5 DCM/MeOH) to yield 24 
mg (0.074 mmol, 49%) as an off-white solid.  The final product was protected 
form light until use.  mp 204 – 208 °C;  1H NMR (500 MHz, (CD3)2SO) δ 9.61 (s, 
1H), 8.34 (s, 1H), 8.20 – 8.12 (m, 2H), 8.05 – 7.98 (m, 1H), 7.87 (d, J = 8.9 Hz, 
1H), 7.80 (d, J = 8.5 Hz, 1H), 7.50 (dd, J = 8.9, 2.2 Hz, 1H), 7.45 (dd, J = 8.5, 1.7 
Hz, 1H), 7.31 (dd, J = 7.9, 1.5 Hz, 1H), 7.16 (dd, J = 8.1, 1.5 Hz, 1H), 7.11 (dd, J 
= 7.7, 1.6 Hz, 1H), 4.21 (s, 1H);  13C NMR (126 MHz, DMSO) δ 152.14, 138.29, 
133.38, 131.39, 130.43, 128.61, 128.57, 128.44, 127.44, 127.40, 125.33, 122.98, 
120.12, 120.00, 118.77, 116.83, 112.94, 83.99, 80.49; IR (film) νmax 3287, 2137, 
1643, 1577, 1485, 1453, 1300, 1237, 890, 813, 741 cm-1; HRMS (ESI+) m/z 
328.1202 (M+H+, C19H14N5O+ requires 328.1193). 
 
 
 
1-(2-azidophenyl)-3-(naphthalen-2-yl)urea (49).  Compound 44 (40 mg, 0.30 
mmol) was dissolved in DCM (3 mL).  Triphosgene (130 mg, 0.450 mmol) was 
added and allowed to stir at 22 °C for 30 minutes.  The solution was then added 
directly to a short plug of silica and eluted using DCM/MeOH (95/5, 30 mL).  The 
eluent was immediately dried under vacuum.  The crude chloroformate of 44 was 
dissolved in DCM (3 mL), and then N,N-dimethylaminopyridine (DMAP, 24 mg, 
0.20 mmol) and naphthylamine (48, 40 mg, 0.28 mmol) were added.  The 
reaction was allowed to stir for 3 h at 22 °C. The reaction mixture was added 
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directly to a column of silica and subjected to flash chromatography (eluted with a 
gradient of DCM to 95/5 DCM/MeOH) to yield 64 mg (0.21 mmol, 74%) as an off-
white solid.  The final product was kept protected form light until use.  mp 180 – 
184 °C;  1H NMR (500 MHz, (CD3)2SO) δ 9.52 (s, 1H), 8.31 (s, 1H), 8.19 (d, J = 
8.2 Hz, 1H), 8.14 (s, 1H), 7.89 – 7.77 (m, 3H), 7.45 (t, J = 8.8 Hz, 2H), 7.36 (t, J = 
7.4 Hz, 1H), 7.31 (d, J = 6.5 Hz, 1H), 7.20 – 7.13 (m, 1H), 7.13 – 7.06 (m, 1H);  
13C NMR (126 MHz, (CD3)2SO) δ 152.30, 137.21, 133.73, 130.62, 129.14, 
128.54, 127.47, 127.36, 127.03, 126.41, 125.38, 124.03, 122.91, 120.02, 119.45, 
118.80, 113.30;  IR (film) νmax 3285, 2128, 1644, 1584, 1560, 1485, 1451, 1297, 
1232, 891, 856, 814, 740 cm-1; HRMS (ESI+) m/z 304.1191 (M+H+, C17H14N5O+ 
requires 304.1193). 
 
2.7.3 Biological Assays and Protocols 
 
General.  All cell culture reagents were purchased from Sigma, Fisher, USA 
Scientific, Santa Cruz Biotechnology, or ATCC.  The XTremeGene HP 
transfection reagent was purchased from Roche.  The human SR-B1 and mutant 
plasmids were kindly provided by Prof. Daisy Sahoo at the Medical College of 
Wisconsin.  The CHO-ldlA and CHO-ldlA_mSR-B1 cell lines were kindly provided 
by Prof. Monty Krieger at MIT.  NeutrAvidin resin (immobilized streptavidin) was 
purchased from Pierce Biotechnology.  SDS-PAGE analysis was performed on 
an Invitrogen XCell II module with Invitrogen pre-cast 4-20% polyacrylamide 
gradient, Bis-Tris gels.  Silver staining was done using a kit from Pierce 
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Biotechnology.  UV irradiation for photocrosslinking was performed with an 8-watt 
lamp from UltraViolet Products at 365 nm. 
 
Cell culture. Jurkat lymphocytes (human acute leukemia, ATCC #TIB-152) were 
cultivated in Roswell Park Memorial Institute (RPMI) 1640 medium. HEK-293 
(human embryonic kidney) cells were cultivated in DMEM.  CHO-ldlA cells were 
cultivated in Ham’s F12K media.  CHO-ldlA_mSR-B1 cells were cultivated under 
the same conditions with the addition of 0.25 mg/mL of G418 added to the media 
to maintain stable selection of mSR-B1 expressing cells.  All media types were 
supplemented with fetal bovine serum (FBS, 10%), penicillin (100 U/mL), and 
streptomycin (100 µg/mL). All cell lines were incubated in a humidified 5% CO2 
incubator at 37 °C. Media used for cell culture and all wash steps contained 
antibiotics and 10% FBS unless otherwise noted. 
 
Microscopy. An inverted Leica TCS SPE confocal laser-scanning microscope 
fitted with a Leica 63X oil-immersion objective was employed for imaging. 
Fluorescent probes were excited with a 488 nm solid-state laser and emitted 
photons were collected from 495-600 nm. Propidium iodide, used to counterstain 
dead cells red fluorescent, was excited with a 532 nm solid-state laser and 
emitted photons were collected from 650-800 nm. To image living Jurkat cells, 50 
µL of cells in media was pipetted to form a small droplet in the center of a 
coverslip fitted with a press-to-seal silicone isolator (Invitrogen). A microscope 
slide was added to the top of the coverslip to create a column of media 
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containing living cells. To allow accurate comparisons of differences in cellular 
fluorescence, laser power and PMT gain settings were identical for all samples 
shown in a given figure. 
 
Flow Cytometry. Populations of 10,000 Jurkat cells were analyzed for each 
sample using an Accuri C6 flow cytometer equipped with 488 nm and 640 nm 
solid-state lasers. Live cells were gated using both forward scattering (FSC) and 
side scattering (SSC) dot plots to identify physical cellular properties of size and 
granularity.  In some cases, propidium iodide (3 µM, excitation: 488 nm; 
emission: 670 nm LP) was used to identify cells with compromised membranes. 
When applicable, the average cellular fluorescence from excitation at 488 nm 
was converted to molecular equivalents of fluorescein (MEFL) using a 
normalization factor obtained from analysis of bead standards from Spherotech 
Inc.  These beads contained known fluorescein concentrations and provided a 
standard curve to convert raw fluorescence values into MEFL.  
 
Confocal microscopy of fluorescent probes.  Cells were suspended at 
300,000 cells/mL in RPMI-1640 media containing 10% FBS.  Fluorescent probes 
were added at 2 µM (diluted 1:1000 into media from DMSO stocks) and 
incubated at 37 °C for 5 minutes or 1 hour.  After this incubation, the samples 
were washed once with RPMI-1640 containing 0.5% FBS and immediately 
imaged by confocal microscopy as described above. 
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Saturation binding studies of fluorescent probes. Cells were suspended at 
300,000 cells/mL in RPMI-1640 media containing 10% FBS. Ezetimibe (200 µM; 
diluted 1:1000 from a 200 mM DMSO stock), Ezetimibe glucuronide (200 µM; 
diluted 1:1000 from a 200 mM DMSO stock), compound 47 (25 µM; diluted 
1:1000 from a DMSO stock), or vehicle control (DMSO) was added in competitive 
binding experiments.  Cell suspensions containing the competitor or vehicle 
control were prepared as 1 mL aliquots in 1.5 mL Eppendorf tubes.  Fluorescent 
probes were added at concentrations ranging from 0 nM to 2500 nM (diluted 
1:1000 into media from stocks in DMSO).  Once the probe was added and mixed 
well, the samples were split into three tubes each containing 330 µL.  Cells were 
incubated at 37 °C for 5 minutes. After this incubation, the samples were washed 
once with RPMI-1640 containing 0.5% FBS (to minimize efflux of the probe from 
the cell surface) and propidium iodide (3 µM). Samples were immediately 
analyzed by flow cytometry.  Fluorescence values in MEFL were analyzed as 
total binding (no competitor added) and a linear non-specific binding component 
(with added competitor) to calculate specific binding curves. Using GraphPad 
Prism 5.0 software, these curves were analyzed with a ‘One site with hill slope’ 
saturation binding model to determine the relative apparent Kd and Bmax values 
listed in Table 2.1. 
 
Kinetic analysis of cellular uptake of fluorescent probes.  Cells were 
suspended at 300,000 cells/mL in RPMI-1640 media containing 10% FBS.  
Fluorescent probes were added at concentrations ranging from 0 nM to 2500 nM 
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(diluted 1:1000 into media from DMSO stocks).  Cells were incubated at 22 °C for 
timepoints ranging from 1 – 12.5 minutes. After this incubation, the samples were 
washed once with RPMI-1640 containing 0.5% FBS (to minimize efflux of the 
probe from the cell surface).  Samples were immediately analyzed by flow 
cytometry.  Each probe was analyzed at 6 concentrations over 5 time points.  
Fluorescence values were converted to MEFL and plotted versus time for each of 
the 6 concentrations.  The data was fit to a linear regression and the slope of 
each line (MEFL/min) was plotted versus concentration. Each assay was 
performed three times to give average MEFL/min values and SEM for each 
concentration. These plots were analyzed by non-linear regression using the 
‘Michaelis-Menton’ kinetic model in GraphPad Prism 5 to generate the KM and 
VMAX data shown in Table 2.2. 
 
Transient expression of hSR-B1 plasmids in HEK-293 cells.  HEK-293 cells 
were plated on 24-well plates at 50,000 cells per well and allowed to attach 
overnight.  Transfection of plasmids encoding human SR-B1, non-functional 
mutant hSR-B1 (2), and empty vector control was done using the XTremeGene 
HP transfection reagent (Roche) according to the commercial protocol at ratio of 
2 µL of transfection reagent per microgram DNA.  Expression was allowed to 
proceed for 48 h.  Following this period, cells were treated with 100 nM of 
compound 1 at 37 °C for 5 minutes.  After treatment the cells were washed twice 
with DMEM, once with PBS 7.4, and trypsinized using 150 µL of 0.25% trypsin at 
37 °C for 5 minutes.  Once the cells were detached, the trypsin was neutralized 
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with 300 µL of DMEM and immediately analyzed by flow cytometry.  Each 
condition was performed in duplicate and reported as average fluorescence and 
SEM in MEFL. 
 
Saturation binding analysis in CHO-ldlA_mSR-B1 cells.  CHO-ldlA and CHO-
ldlA_mSR-B1 cells were plated on 24-well at 150,000 cells per well and allowed 
to attach overnight.  Compound 1 was added at concentrations ranging from 0 
nM to 1000 nM (diluted 1:1000 into media from DMSO stocks).  The cells were 
incubated at 37 °C for 5 minutes to allow uptake.  After incubation, the cells were 
washed twice with Ham’s F12K media, once with PBS 7.4, and trypsinized with 
150 µL of 0.25% trypsin at 37 °C for 5 miuntes.  After the cells were detached, 
the trypsin was neutralized with 300 µL of Ham’s F12K media and immediately 
analyzed by flow cytometry.  Each condition was performed in duplicate and 
plotted as averaged fluorescence and SEM in MEFL.  The data was analyzed by 
non-linear regression using the ‘One site – total binding’ model in GraphPad 
Prism 5. 
 
Photoaffinity labeling and protein pulldown protocol for target 
identification.   Approximately 6 x 107 Jurkat lymphocytes were suspended in 15 
mL of RPMI 1640 media and aliquoted into 5 mL samples (~2 x 107 each).  
Sample 1 remained untreated and was incubated at 37 °C in RPMI 1640 prior to 
washing and cell lysis.  Sample 2 was incubated in RPMI 1640 containing 
photoaffinity probe 47 at 10 µM for 1 hour at 37 °C.  Sample 3 was co-treated 
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with 47 at 10 µM and 49 at 200 µM for 1 hour at 37 °C.  After 1 hour, samples 2 
and 3 containing the photoaffinity label were irradiated with UV light (365 nm) for 
5 minutes in 10 cm culture dishes.  Following irradiation, all samples were 
washed once with RPMI-1640, once with PBS 7.4, re-suspended in 500 µL of 
PBS 7.4 containing 1 mM DTT and 1 mM PMSF, and placed on ice.  The cells 
were lysed using brief ultrasonication (one 3 second pulse) and the lysate was 
centrifuged at 10,000 x g and 4 °C for 10 minutes.  The supernatants containing 
the cytosolic fractions were removed, added to separate tubes, and placed on 
ice.  The pellets were re-suspended in 500 µL PBS 7.4 containing 1 mM DTT, 1 
mM PMSF, and 1% Triton X-100.  The samples were centrifuged 18,000 x g and 
4 °C for 10 minutes.  The supernatants containing the membrane fractions were 
removed and added to separate tubes.  Each of the 6 samples (3 cytosolic 
fractions and 3 membrane fractions) received 1 mM CuSO4, 2 mM Tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA), and 1 mM sodium ascorbate 
diluted from 100X stocks in ddH2O.  Each tube also received 50 µM biotin-azide 
diluted from a 100X stock in DMSO.  The click reaction was allowed to proceed 
overnight at 37 °C.  Following incubation, each tube received 50 µL of 
NeutrAvidin resin (provided as a 50% w/v suspension in PBS) and was incubated 
at 22 °C for 4 h with agitation.  The resin was washed three times by brief 
centrifugation and re-suspension in 1 mL PBS 7.4 containing 0.5% Triton X-100.  
The resin was then loaded into empty mini-spin columns (USA Scientific) and 
washed an additional five times with 500 µL of PBS 7.4.  Following washing, the 
resin was prepared for either SDS-PAGE or MS/MS sequencing analysis. 
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For SDS-PAGE Analysis. The resin was suspended in 40 µL 4X SDS-PAGE 
loading buffer containing 1 mM biotin and heated to 70 °C for 5 minutes.  The 
samples were briefly centrifuged to pellet the resin and 25 µL of the supernatant 
was loaded onto a pre-cast polyacrylamide gel and subjected to SDS-PAGE 
analysis.  The gel was visualized using silver staining following the commercial 
kit protocol (Pierce Biotechnology). 
For MS/MS Sequencing Analysis.  The resin was further washed with 0.2 M 
ammonium bicarbonate buffer.  On-resin trypsin digestion was performed 
following protocols provided by the KU Analytical Proteomics Laboratory (KU 
APL).  The resulting samples were submitted to the KU APL for sequencing 
analysis. 
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Chapter 3 
 
Biological Evaluation of Endosome Disruptive Peptides with Improved 
Biological Properties 
 
3.1  Introduction 
 As described in Chapter 2, cholesterylamines and other cholesterol-
mimetic membrane anchors provide a highly efficient mechanism to deliver 
conjugated cargo into early/recycling endosomes.  Previous work from the 
Peterson group has utilized these molecules as synthetic cell surface receptors 
capable of binding non-covalently and internalizing a variety of extracellular 
ligands via endocytosis.1, 2 Over the last several years we have focused on 
utilizing these membrane anchors as a delivery mechanism for covalently-linked 
cell-impermeable molecules.3 To accomplish this, one must employ a 
mechanism to allow entrapped endosomal cargo to be released into the cytosol 
to reach its molecular target.4, 5 
 There are numerous examples in nature of pathogens that disrupt 
endosomal membranes as a mechanism of virulence and/or protection.  Several 
enveloped viruses, such as the influenza virus, infect host cells using viral fusion 
peptides6 that induce mixing of host cell and viral membranes at acidic pH to 
release viral components.7, 8 Other non-enveloped viruses release membrane-
lytic peptides that enable escape of viral components into the cytosol. Several of 
these natural peptides have been characterized and often consist of a 
	   90 
hydrophobic or amphipathic helix that is kinked by internal proline or glycine 
residues.9-11 Bacteria also utilize membrane disruptive agents as a virulence 
factor.  For example, Listeria monocytogenes produces listerolysin O (LLO), a 
protein toxin that forms pores in cholesterol-containing membranes at acidic 
pH.12, 13 Other organisms produce membrane-active antimicrobial peptides that 
adopt kinked helical structures similar to viral peptides.14-17  
 A number of synthetic peptides have been generated to mimic the pore 
forming activity of natural endosome disruptive peptides.5, 18, 19 One example is 
the GALA peptide consisting of 30-amino acids with a repeating Glu-Ala-Leu-Ala 
sequence. This peptide forms hydrophobic alpha helices at acidic pH that insert 
into lipid bilayers. These membrane-spanning helices aggregate to form a pore 
structure capable of releasing endosomal contents.18, 20 
 In 2006, Weber and co-workers identified the PC-4 peptide using a phage 
display library.21 This 12-amino acid peptide demonstrated pH-dependent 
leakage of lipid vesicles with activity similar to known viral peptides. The 
Peterson group hypothesized that targeting this peptide to early endosomes 
using cholesterylamine might disrupt these endosomes and allow release of 
entrapped cargo. In 2008, our group reported the synthesis of cholesterylamine-
linked PC-4 and its ability to selectively disrupt early endosomes to release a 
disulfide-linked fluorophore into the cytosol of living mammalian cells (Figure 
1.4).3 Because early endosomes are oxidizing, the disulfide bond linking 
cholesterylamine to its fluorescent cargo remains stable and membrane bound.22 
However disruption of endosomes by cholesterylamine-PC-4 (2) exposes the 
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endosomal contents to reduced glutathione in the cytosol, cleaving the disulfide 
bond and enabling release of the free fluorophore. 
 As mentioned in Chapter 1, therapeutic applications of cholesterylamine-
PC-4 are limited by the toxicity index, a ratio of the observed toxicity and potency 
in cultured cells. Moreover, its mechanism of endosome disruption was unclear. 
This chapter describes the evaluation of novel endosome disruptors with 
improved biological properties and studies to elucidate their mechanism of 
action. Building on the work of Dr. Qi Sun and Sutang Cai, these new endosome 
disruptors, synthesized by Drs. Chamani Perera and Ze Li, may serve as useful 
agents for the delivery of cell-impermeable therapeutic molecules. 
 
3.2  Description of Biological Screening Assays 
 In order to accurately assess the potency and efficacy of new endosome 
disruptors, we used a biological screening assay similar to the assay used to 
quantify the activity of cholesterylamine-linked PC-4 (2).3 In this assay, 
carboxyfluorescein is conjugated to cholesterylamine through a disulfide-
containing linker and serves as the releasable cargo (3, Figure 3.1).  This probe 
contains two anionic glutamic acid residues that increase its propensity to 
accumulate in early endosomes versus the plasma membrane.  The pKa of 
carboxyfluorescein is 6.5.23 Therefore in early endosomes at pH 6.0, the 
fluorescence of the probe is approximately 60 – 70% quenched.  Upon 
endosome disruption, accumulation of the free fluorophore in the cytosol at pH 
7.4 produces a 4- to 5-fold increase in cellular fluorescence that can be 
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measured by flow cytometry (Figure 3.1).  Using Jurkat lymphocytes, the 
concentration of the fluorescent probe is held constant at 2.5 µM and the 
endosome disruptor is added at increasing concentrations.  The cells are allowed 
to incubate for 14 hours, then washed with complete media and incubated for 
another 30 minutes to allow the excess intact fluorescent probe to efflux from the 
cell surface. This step was found to significantly increase the signal-to-noise ratio 
of the assay. The cellular fluorescence with no endosome disruptor is taken as 
the background signal and subtracted from subsequent concentrations for each 
compound. Cellular fluorescence is plotted versus disruptor concentration and fit 
using non-linear regression to generate potency data as EC50 values. 
 
	  
Figure 3.1.  Schematic representation of the fluorescence assay used to obtain 
structure-activity relationships for endosome disruptors. 
	  
 The efficacy of each endosome disruptor is determined by the amount of 
cellular fluorescence observed at concentrations where the activity is saturated. 
In order to accurately compare efficacy values and decrease interassay 
variability, each round of testing included one previously tested compound as a 
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control to which the efficacy is normalized. All values were normalized as percent 
efficacy as compared to the published cholesterylamine-PC-4 (2) at 100%. 
 The toxicity of each endosome disruptor was measured after incubating 
Jurkat lymphocytes at concentrations up to 32 µM for 48 hours.  Analysis was 
performed by flow cytometry using forward and side light scattering to measure 
cell morphology.  The percent viability was represented by the percent of cells 
that fall within a live cell gate. 
 Given that the majority of the endosome disruptors in this project are 
relatively hydrophobic peptides, we included thermodynamic solubility testing into 
our biological screening to aid in compound design.  The vast majority of 
analogues contain a combination of tryptophan and tyrosine residues that allow 
for easy quantitation of concentration by UV absorbance at 280 nm.  Using the 
calculated extinction coefficient for each peptide sequence, thermodynamic 
solubility was measured in PBS at pH 7.4. 
 
3.3  Structure-Activity Relationships of Endosome Disruptor Analogues 
 Based on cholesterylamine-PC-4 (2), we designed several 
cholesterylamine-linked endosome disruptors to probe the structure-activity 
relationships (SAR) of the peptide sequence, linker, and membrane anchor 
regions of the molecule (Figure 3.2).  The first structural analogues probed the 
SAR of the membrane anchor and linker regions.  Inclusion of a β-alanine 
residue in the anchor and removal of aminohexanoic acid in the linker provided 
endosome disruptor 50 with similar activity to 2 (Figure 3.3, Table 3.1). The 
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membrane anchor of compounds 50 – 52, containing β-alanine, was chosen 
based on the SAR provided by the fluorescent probes described in Chapter 2. 
We then turned our attention to the PC-4 sequence.  An initial screen was 
performed using an alanine scan in which each analogue systematically 
substituted each amino acid with alanine along the complete sequence.  We 
found that substitution of each serine residue with alanine slightly enhanced 
potency (data not shown).  The combined substitution of all serine residues 
produced compound 51, which demonstrated an improved toxicity index.  	  
We hypothesized that these peptides were helical in nature, and that this 
conformation influenced the observed activity. We systematically substituted the 
N-terminal alanine residues of 51 with aminoisobutyric acid (Aib, U), a residue 
known to increase the propensity of peptides to form alpha- and 310-helices.24, 25 
Compound 52 showed a 4-fold increase in potency compared to the parent PC-4 
sequence with no increase in toxicity.  Moreover, it provided evidence for our 
hypothesis that helix formation could be responsible for the observed activity.	   
It was known from the literature that lipid-conjugated molecules often 
possess poor pharmacokinetic (PK) properties, mostly due to high serum binding 
and/or high clearance by the liver.26-28 In order to increase the therapeutic 
applicability of endosome disruptive compounds, we also studied compounds 53 
– 55 that do not contain the membrane anchor. It was observed that compound 
55 containing Aib residues demonstrated modest potency despite lacking the 
endosome targeting cholesterylamine moiety. This activity was beneficial for 
several reasons: 1) it increased the therapeutic potential of endosome disruptors 
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by eliminating the potential PK limitations of the lipid moiety, 2) it significantly 
decreased the time and cost of synthesis to produce analogues, and 3) it 
simplified the study by limiting the SAR to only the peptide sequence. We moved 
forward using the peptide sequence alone to study SAR of the peptide sequence 
and guide the design of new endosome disruptors. The optimal sequence from 
each round of analogues was also studied in conjugation with the membrane 
anchor to generate highly potent endosome disruptors for in vitro probe 
applications. 
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Figure 3.2. Structures of the previously published PC-4 peptide derivative (2) 
and endosome disruptor analogues 50 – 55. 
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Figure 3.3.  SAR of compounds 50 – 55 in Jurkat lymphocytes. A) Potency and 
efficacy based on the release of 3 after 14 h.  B) Toxicity of select analogues in 
Jurkat lymphocytes after 48 h. 
	  
Table 3.1.  SAR data for endosome disruptors 50 – 55 compared to the 
published PC-4 peptide (2).  Potency and efficacy (± standard deviation) were 
calculated based on non-linear regression of fluorescence (as a percentage of 2) 
plotted versus concentration. MA = Membrane anchor. ND = Not Determined. 
	  
Using the Aib containing peptide 55 as a lead compound, we designed 
and tested new analogues highlighted by compounds 56 – 62 (Figure 3.4). 
Peptides 56 and 57 contained four and five N-terminal Aib residues, respectively, 
to further induce a helical confirmation. Both peptides showed improved potency 
compared to 55, however it was found that addition of a fifth residue did not 
significantly improve activity versus four Aib residues. 
Potency Efficacy Toxicity Sol. 
(EC50, µM) (% of 2) (IC50, µM) (µM)
2 MA-SSAWWSYWPPVA-NH2 1.3 ± 0.3 99 ± 2 9 ± 0.3 112
50 MA-SSAWWSYWPPVA-NH2 3.5 ± 1.0 93 ± 2 ND ND
51 MA-AAAWWAYWPPVA-NH2 1.0 ± 0.3 101 ± 2 16 ± 0.6 ND
52 MA-UUUWWAYWPPVA-NH2 0.4 ± 0.1 86 ± 1 12 ± 1.3 ND
53 Ac-SSAWWSYWPPVA-NH2 ND ND ND 173
54 Ac-AAAWWAYWPPVA-NH2 >15 <10 ND 41
55 Ac-UUUWWAYWPPVA-NH2 5.9 ± 1.8 61 ± 2 >16 ND
Cpd. Sequence
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Figure 3.4.  Structures of endosome disruptor analogues 56 – 62. 
 
Substitution of the C-terminal alanine with valine in peptide 58 was also 
shown to improve potency compared to 56. To improve solubility, we evaluated 
peptides 59 and 60, which eliminated the N-terminal acetyl group to provide a 
cationic amine. Peptide 59 showed a slight loss in activity compared to its 
acetylated analogue 56.  Peptide 60 containing the alanine to valine substitution 
showed similar properties to peptide 58, indicating the cationic charge at the N-
terminus was tolerated. Compounds 61 and 62 utilized the peptide sequence of 
56 conjugated to cholesterylamine and cholesteryl carbamate containing 
membrane anchors, respectively. Both compounds included a miniature 
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polyethylene glycol amino acid (mPEG) linker to improve their solubility. These 
membrane anchored compounds showed 50- to 100-fold improvement in 
potency versus the parent peptide 56 and ~20-fold improvement versus the 
published cholesterylamine-PC-4 derivative (2). 
	  
	  
Figure 3.5.  SAR of compounds 56 – 62 in Jurkat lymphocytes. A) Potency and 
efficacy based on the release of 3 after 14 h.  B) Toxicity of select analogues in 
Jurkat lymphocytes after 48 h. 
	  
	  
Table 3.2.  SAR data for endosome disruptors 56 – 62.  Potency and efficacy (± 
standard deviation) were calculated based on non-linear regression of 
fluorescence (as a percentage of 2) plotted versus concentration. MA = 
Membrane anchor. ND = Not Determined. 
	  
Based on the sequence of peptide 60, we performed a second alanine 
scan to determine the importance of the aromatic and proline residues for 
Potency Efficacy Toxicity Sol. 
(EC50, µM) (% of 2) (IC50, µM) (µM)
56 Ac-UUUUWWAYWPPVA-NH2 4.9 ± 1.9 89 ± 13 >16 ND
57 Ac-UUUUUWWAYWPPVA-NH2 4.2 ± 1.3 86 ± 7 ND ND
58 Ac-UUUUWWAYWPPVV-NH2 3.8 ± 1.1 68 ± 3 ND ND
59 UUUUWWAYWPPVA-NH2 8.8 ± 2.6 57 ± 7 ND 40
60 UUUUWWAYWPPVV-NH2 5.1 ± 0.6 98 ± 2 >16 22
61 MA-UUUUWWAYWPPVA-NH2 0.08 ± 0.02 123 ± 6 8 ± 0.2 ND
62 MA-UUUUWWAYWPPVA-NH2 0.1 ± 0.03 106 ± 10 17 ± 0.4 ND
Cpd. Sequence
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endosome disruptive activity. Our previous alanine scan proved fruitful in 
providing more potent analogues, however the activity of these compounds may 
have been driven by the high endosomal accumulation provided by the 
membrane anchor. Compounds 63 – 69 systematically replaced each residue 
with alanine to provide SAR for each amino acid in the peptide sequence alone 
(Figure 3.6).  
	  
Figure 3.6.  Structures of the alanine scan endosome disruptor analogues 63 – 
69.  The alanine substitution for each compound is illustrated in red. 
	  
As shown in Table 3.3, compounds 63 – 66 containing substitutions of the 
aromatic residues showed a dramatic decrease in potency, with little to no 
observed activity at concentrations up to 16 µM. Compounds 67 and 68, which 
substituted each proline residue, showed significant decreases in efficacy, but 
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still demonstrated some activity at high concentration. Compound 69, substituting 
a valine in the C-terminal region, also showed some activity. 
 
	  
Figure 3.7.  SAR of alanine scan compounds 63 – 69 compared to the parent 
sequence 60 in Jurkat lymphocytes. Potency and efficacy based on the release 
of 3 after 14 h. 
	  
	  
Table 3.3.  SAR data for alanine scan analogues 63 – 69.  Potency and efficacy 
(± standard deviation) were calculated based on non-linear regression of 
fluorescence (as a percentage of 2) plotted versus concentration.  ND = Not 
Determined. 
	  
	  	  
Potency Efficacy Toxicity Sol. 
(EC50, µM) (% of 2) (IC50, µM) (µM)
60 UUUUWWAYWPPVV-NH2 5.1 ± 0.6 98 ± 2 >16 22
63 UUUUAWAYWPPVV-NH2 ND <5 ND 86
64 UUUUWAAYWPPVV-NH2 ND <10 ND 86
65 UUUUWWAAWPPVV-NH2 ND ND ND 63
66 UUUUWWAYAPPVV-NH2 ND <5 ND 86
67 UUUUWWAYWAPVV-NH2 ND ~35 ND 21
68 UUUUWWAYWPAVV-NH2 9.0 ± 2.7 54 ± 4 ND 22
69 UUUUWWAYWPPAV-NH2 ND ~35 ND 48
Cpd. Sequence
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 Based on the dramatic loss of activity for peptides 63 – 66, the alanine 
scan indicated that the aromatic residues were critical for activity. Thus, we 
tested several analogues to probe the sequence of the aromatic residues. 
Compounds 70 – 73 substituted each tryptophan residue with tyrosine, and 
compounds 74 and 75 substituted the central alanine residue to tryptophan and 
tyrosine, respectively, to increase the total aromatic content (Figure 3.8). 
	  
Figure 3.8.  Structures of the endosome disruptor analogues 70 – 78.  Tyrosine  
(blue) was substituted along the aromatic residues in 71 – 73.  The central 
alanine was also substituted for either tryptophan (74, purple) or tyrosine (75, 
green). 
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Substitution of tryptophan with tyrosine for compounds 70 – 73 did not 
significantly change either potency or efficacy. Interestingly, compounds 74 and 
75 showed a dramatic loss of efficacy, indicating that the addition of a larger 
amino acid at this position was not tolerated (Table 3.4). The sequence of 
peptide 73 was integrated into compounds 77 and 78 containing the cholesteryl 
carbamate membrane anchor.  Again, these compounds demonstrated 
approximately a 50-to 200-fold increase in potency versus the peptide sequence 
alone. 
 
	  
	  
Figure 3.9.  SAR of compounds 70 – 78 in Jurkat lymphocytes. A) Potency and 
efficacy based on the release of 3 after 14 h.  B) Toxicity of select analogues in 
Jurkat lymphocytes after 48 h. 
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Table 3.4.  SAR data for analogues 70 – 78.  Potency and efficacy (± standard 
deviation) were calculated based on non-linear regression of fluorescence (as a 
percentage of 2) plotted versus concentration. MA = Membrane anchored. ND = 
Not Determined. 
	  
 
3.4 Evaluation of Helicity by Circular Dichroism 
 To evaluate the hypothesis that helicity of these peptides is responsible for 
the observed activity, we obtained electronic circular dichroism (CD) spectra of 
selected analogues. These experiments were conducted in buffer at pH 7 to 
mimic the extracellular environment, at pH 5 to mimic the acidic lumen of 
endosomes, and in methanol to mimic the hydrophobic environment of 
membranes. CD spectra of α- and 310-helical peptides typically exhibit negative 
minima at ~208 and ~222 nm and a positive maximum at ~195 nm.29, 30 This type 
of spectroscopy cannot readily distinguish between these types of helices,31 and 
peptides containing helix-promoting residues are often comprised of mixtures of 
Potency Efficacy Toxicity Sol. 
(EC50, µM) (% of 2) (IC50, µM) (µM)
60 UUUUWWAYWPPVV-NH2 5.1 ± 0.6 98 ± 2 >16 22
70 UUUUWWAWWPPVV-NH2 3.4 ± 1.0 100 ± 5 ND ND
71 UUUUYWAWWPPVV-NH2 3.2 ± 1.4 105 ± 19 >16 21
72 UUUUWYAWWPPVV-NH2 6.7 ± 2.0 96 ±  12 >16 28
73 UUUUWWAWYPPVV-NH2 5.4 ± 1.6 101 ±  2 >16 13
74 UUUUWWWWYPPVV-NH2 3.1 ± 0.9 27 ±  1 ND ND
75 UUUUWWYWYPPVV-NH2 2.5 ± 1.2 18 ±  12 ND ND
76 Ac-UUUUWWAWYPPVV-NH2 2.3 ± 0.7 70 ± 1 >16 5
77 MA-UUUUWWAWYPPVV-NH2 0.06 ± 0.02 118 ± 7 10 ± 0.4 ND
78 MA-UUUUWWAWYPPVV-NH2 0.08 ± 0.02 111 ±  2 10 ± 0.1 ND
Cpd. Sequence
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α- and 310-helices in equilibrium, or these helices may co-exist in the same 
molecule.32 
 As shown in Figure 3.10, CD spectra of the inactive peptides 53 and 54 
showed negative minima near 200 nm in both aqueous buffer and methanol, 
consistent with a lack of secondary structure. In pH 7 buffer, the active peptides 
73 and 76 also showed a lack of secondary structure. However, in aqueous 
solution at pH 5, peptide 73 containing a protonated N-terminus, but not its 
acetylated analogue 76, showed increased negative ellipticity near 208 and 222 
nm, suggesting increased ordering. The intensities of these minima were 
increased in methanol for both 73 and 76. Moreover, 73 exhibited a prominent 
maximum at 195 nm, consistent with the adoption of a helical secondary 
structure. 
	  
Figure 3.10.  Circular dichroism spectra of 53, 54, 73, and 76. Spectra generated 
in aqueous buffer at pH 5 and pH 7 were obtained in phosphate buffer (10 mM) 
containing 5% MeOH. Markers (thin dashed lines) are shown at 195, 208, and 
222 nm, and molar ellipticity = 0 to illustrate bands commonly associated with 
helical secondary structure. 
 
3.5  Molecular Modeling of Endosome Disruptive Peptides 
 SAR and CD studies provided valuable information regarding the 
mechanism of endosome disruptive activity. Introduction of aminoisobutyric acid 
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(Aib) residues significantly increased potency, likely by inducing a helical 
conformation in the hydrophobic environment of the lipid bilayer. Alanine 
scanning illustrated that the aromatic residues were critical to activity. These 
aromatic positions could contain either tryptophan or tyrosine and maintain 
similar potency and efficacy. However the sequence of these residues was 
observed to be highly specific, requiring an “XXAXX” motif where X represents 
either tryptophan or tyrosine. Substitution of the alanine residue in this motif also 
resulted in a significant loss in efficacy. 
 Using this information, we modeled the sequence of compound 76 as 
idealized α- and 310-helices (Figure 3.10, Panels A and B). Literature precedent 
and CD spectroscopy suggested that the Aib residues increased the propensity 
for peptides to adopt either conformation.24, 25 When modeled as an α-helix, 76 is 
approximately 26 Å in length, which is much shorter than the thickness of a 
mammalian cell lipid bilayer (phosphate-phosphate distance of 35 – 43 Å when 
measured by X-ray scattering).33 This conformation also projects the crucial 
aromatic side chains at four different angles around the helical axis. However 
when modeled as a 310 helix, the peptide length increases to approximately 32 Å, 
which is only slightly shorter than the thickness of a lipid bilayer.  More 
importantly, this conformation orients the aromatic side chains at 120° angles 
from each other, with the alanine residue occupying a hydrophobic face of the 
helix.  Based on this modeling, we hypothesized that the 310-helical conformation 
of this peptide could self-assemble into a hexameric pore structure in the 
membranes of acidic compartments. In this model, an antiparallel assembly 
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would allow pi-stacking interactions between the aromatic side chains to define 
the walls of the pore, whereas the aliphatic residues would occupy a hydrophobic 
face projecting towards the lipid bilayer (Figure 3.11, Panel C). In support of this 
concept, related antiparallel peptide hexamers that form conductive channels in 
membranes have been identified in biological systems.34 Additionally, designed 
32-amino acid peptides that self-assemble as a hexamer of parallel alpha helices 
to form a 6 Å channel have been reported.35 
 
 
Figure 3.11.  Models of 76 as an idealized α- or 310-helix (Panel A, B). A model 
assembly of an antiparallel hexamer stabilized by intermolecular interactions of 
aromatic side chains. 
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3.5 Optimized Endosome Disruptive Peptides 
 To test the model shown in Figure 3.11, we designed new peptides based 
on the idealized 310 helix. We hypothesized that introducing three amino acids to 
the peptide sequence would extend the helix by one full turn, increasing the 
peptide length and possibly providing more stability to the hexameric assembly. 
The critical “XXAXX” sequence was extended to “XXAXXAXX” to produce 
compounds 79 – 82 with two more aromatic side chains in the correct orientation 
to provide additional pi-stacking interactions to the current model. 
 The extended peptide 79 bears an additional WWA sequence to add a 
tryptophan reside to each aromatic face. This peptide showed a 13-fold increase 
in potency compared to 73 with only a slight decrease in efficacy, however its 
solubility was quite low.  Peptides 80 and 81 replaced two or three of the 
tryptophan residues with tyrosine to improve solubility. These peptides 
demonstrated 20- and 10-fold improved potency, respectively, as well as 
improved efficacy and solubility. Additionally, CD spectra of 80 and its acetylated 
analogue 82 were similar to the shorter peptides 73 and 76, and provided 
evidence of a helical secondary structure in methanol (Figure 3.13, Panel C). As 
a control, compound 83 was designed to possess the same amino acids as 80, 
but as a scrambled sequence that does not contain the crucial “XXAXXAXX” 
motif.  As shown in Table 3.5, this compound showed a significant loss of activity 
(~25-fold), consistent with the proposed model. Conjugation of the extended 
peptide sequence of 81 to the cholesteryl carbamate membrane anchor provided 
compound 84. This compound produced nearly 100-fold greater potency than the 
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original PC-4 endosome disruptor (2), along with improved efficacy and no 
increase in cellular toxicity. 
 
	  
Figure 3.12.  Structures of endosome disruptor analogues 79 – 84. 
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Figure 3.13.  SAR of compounds 79 – 84 in Jurkat lymphocytes. A) Potency and 
efficacy based on the release of 3 after 14 h.  B) Toxicity in Jurkat lymphocytes 
after 48 h. C) Circular dichroism spectra for 80 and 82. 
	  
	  
Table 3.5.  SAR data for analogues 79 – 84.  Potency and efficacy (± standard 
deviation) were calculated based on non-linear regression of fluorescence (as a 
percentage of 2) plotted versus concentration. MA = Membrane anchor. ND = 
Not Determined. 
	  
Potency Efficacy Toxicity Sol. 
(EC50, µM) (% of 2) (IC50, µM) (µM)
73 UUUUWWAWYPPVV-NH2 5.4 ± 1.6 101 ±  2 >16 8
79 UUUUWWAWWAWYPPVV-NH2 0.22 ± 0.01 86 ± 54 >16 2
80 UUUUWYAWYAWYPPVV-NH2 0.28 ± 0.10 113 ± 4 >16 5
81 UUUUYYAWWAYYPPVV-NH2 0.33 ± 0.10 145 ± 5 >16 6
82 Ac-UUUUWYAWYAWYPPVV-NH2 0.77 ± 0.23 85 ± 7 >16 1
83 UUUUAWYAWYWYPPVV-NH2 8.9 ± 5.6 83 ± 12 >16 3
84 MA-UUUUYYAWWAYYPPVV-NH2 0.02 ± 0.01 128 ± 2 11 ± 0.2 66
Cpd. Sequence
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3.6 Cell-Based Assay for Functional Determination of Pore Size 
 To further validate the model shown in Figure 3.11, we synthesized the 
cholesterol-linked fluorescent probes 85 – 87. These probes were designed to 
release fluorescent cargo that systematically increased in molecular size. We 
hypothesized that the efficacy of endosome disruption would dramatically 
decrease as we increased the size of the releasable cargo beyond the diameter 
of the proposed pore structure. As shown in Figure 3.14, the size of the released 
cargo ranged from a minimal projection diameter (MPD) of 12.4 Å (3) to 17.9 Å 
(87), as calculated with ChemAxon software (MMFF94 force field). The 
cholesteryl carbamate membrane anchor in compounds 85 – 87 was chosen as 
a more easily synthesized alternative to the cholesterylamine of 3. 
	  
Figure 3.14.  Structures of the fluorescent disulfide probes 85 – 87 containing 
glutamic acid residues to increase molecular size of the released cargo. D-amino 
acids were used to synthesize the cargo to avoid potential proteolysis. Values for 
the minimal projection diameter of the thiol cleavage products were calculated 
using the geometry plugin of ChemAxon MarvinView v. 6.2.3 after conformational 
sampling with the MMFF94 force field (www.chemaxon.com). 
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These probes were used to measure the diameter of the pore induced in 
endosomes by the peptides 2 (cholesterylamine-PC-4), 73, and 80. The 
fluorescent probe 3 was included in the evaluation and used to normalize the 
efficacy of release (Figure 3.15). In these experiments, the smallest cargo of 
compounds 3 and 85 was released from endosomes to the greatest extent. The 
largest cargo of 87 was not released by any of the peptides tested. Linear 
regression analysis of efficacy versus MPD of the cargo for the related 
compounds 85 – 87 indicated that a calculated MPD of ≤ 15 Å is required for at 
least 50% release of these types of probes. This data provides experimental 
evidence that the maximum inner diameter of the pore induced by these 
endosome disruptive peptides is ~ 15 Å. 
	  
Figure 3.15.  Evaluation of pore size using fluorescent probes 85 – 87 (2.5 µM).  
Endosome disruptors 2 (cholesterylamine-PC-4, Panel A), 73 (Panel B), and 80 
(Panel C) were used to evaluate cellular release by flow cytometry.  Potency and 
efficacy based on release after 14 h. 
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Table 3.6.  Cellular release of fluorescent probes 85 – 87 containing glutamic 
acid residues as a measure of endosome disruptor pore size.  *Efficacy values 
for each endosome disruptor were normalized to release of 3 at 100%.  Potency 
and efficacy were calculated based on non-linear regression of efficacy plotted 
versus concentration. Measurements were determined in duplicate and standard 
deviation values were ~30% for potency and <5% for efficacy.  MA = Membrane 
anchored. ND = Not Determined due to lack of efficacy. 
 
3.7 Molecular Dynamics Simulations of the Proposed Model 
 Our collaborator, Dr. Gerry Lushington, performed molecular dynamics 
(MD) simulations to evaluate the structures of anti-parallel hexamers of peptides 
76 and 82 in a model membrane. Dynamic stability of the model pore complexes 
was evaluated via Nanoscale Molecular Dynamics (NAMD)36 simulations 
according to the CHARMM37 force field and electrostatics with recently described 
parameters for peptides containing Aib.38 As shown in Figure 3.16, these studies 
revealed that peptides 76 and 82 could form relatively stable pores comprising 
anti-parallel hexamers. Analysis of phi and psi angles indicates that contributions 
from both α- and 310-helices play major roles in the stability of these assemblies. 
Based on measurements of pore geometry during the MD simulations, these 
studies calculated pore diameters of 12.8 ± 7.6 Å for 76 and 12.2 ± 5.6 Å for 82 
with mean bottleneck diameter of 7.0 Å for 76 and 7.6 Å for 82. These calculated 
values are consistent with the experimental data shown in Figure 3.15 and Table 
3.6, where anionic cargo with a calculated MPD of ≤ 15 Å could escape through 
Pot. Eff. Pot. Eff. Pot. Eff. Pot. Eff.
(EC50, 
µM)
(%) (EC50, 
µM)
(%) (EC50, 
µM)
(%) (EC50, 
µM)
(%)
2 MA-SSAWWSYWPPVA-NH2 0.7 100* 0.7 122 0.5 52 ND <5
73 UUUUWWAWYPPVV-NH2 3.6 100* 3.5 135 2.1 91 ND <10
84 UUUUWYAWYAWYPPVV-NH2 0.3 100* 0.2 139 0.2 65 ND <5
87
ED Sequence
3 85 86
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the pore into the cytosol whereas cargo of MPD ≥ 18 Å remained trapped in the 
lumen of endosomes. 
	  
Figure 3.16.  Output from molecular dynamics simulations of endosome 
disruptors 76 and 82 as anti-parallel hexamers of 310 helices. Structures were 
extracted after 20,000-step MD simulations surrounded by lipids of a model 
membrane with explicit solvation by water. Membrane lipids and water molecules 
included in the simulation were removed for clarity. Values for secondary 
structure calculations do not sum to 100% due to overlap (± 27.5 degree error 
threshold) in definitions of alpha and 310-helices for dynamic structures. 
 
3.8 Conclusions 
 The Peterson lab has previously demonstrated that a pH-dependent 
membrane disruptive peptide can be targeted to early/recycling endosomes to 
allow for efficient release of disulfide-linked cargo.3 However in order to expand 
this delivery system beyond proof-of-concept, several limitations needed to be 
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addressed including the narrow toxicity index, limited in vivo applicability, and a 
poor understanding of the mechanism of action. 
Through extensive SAR evaluation we have produced endosome targeted 
peptides containing cholesterol-based membrane anchors that are nearly 100-
fold more potent than the parent cholesterylamine-PC-4 compound.  More 
importantly, we have developed several active peptides with sub-micromolar 
potency that do not require the membrane targeting cholesterol moiety.  None of 
the compounds highlighted by this SAR study have shown any significant 
increase in toxicity compared to the parent cholesterylamine-PC-4 compound. 
Because of this work, we have greatly improved the toxicity index and begun to 
address the limitations of in vivo applicability by eliminating the potential 
pharmacokinetic problems associated with lipid-conjugated molecules. 
 We also made significant progress toward understanding the mechanism 
of endosome disruptive activity. Based on key structure-activity relationships and 
circular dichroism studies, we hypothesized that these peptides formed helices in 
lipid membranes and self-assembled into a hexameric pore structure with 
aromatic residues forming critical stabilizing interactions. This model guided the 
design of extended peptide sequences that significantly improved cellular activity. 
We began to validate this model by probing the diameter of the proposed pore 
structure using fluorescent cargo with increasing molecular size. These results 
provided experimental evidence that the proposed pore structure was ~ 15 Å in 
diameter. In collaboration with Dr. Gerry Lushington, we provided further 
evidence for this model using molecular dynamics simulations.  This analysis 
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illustrated that helical peptides could form a stable, hexameric pore structure in 
model lipid membranes with pore geometry consistent with the proposed model. 
Further structural validation is currently ongoing using NMR spectroscopy and 
crystallization trials to attempt to produce an X-ray crystal structure. 
 In summary, we have developed endosome disruptive peptides with 
significantly improved activity and toxicity index. These compounds allow for 
efficient release of small molecule cargo from early endosomes and possess 
numerous potential applications for the delivery of cell-impermeable therapeutic 
agents. Currently efforts are focused on utilizing these peptides for the selective 
delivery of cytotoxic agents to tumor cells and this work will be discussed in 
Chapter 4. 
 
3.9 Experimental Section 
3.9.1 General 
Chemical reagents were purchased from Apptec, Acros, Aldrich, Alfa 
Aesar, EMD Biosciences, or TCI America, and were used without further 
purification. Solvents were from Aldrich or Fisher Scientific. Fmoc-protected 3-
((2-aminoethyl)disulfanyl)propanoic acid3, 3β-cholesterylamino-N-valeric acid3, 3-
((((cholester-3-yl)oxy)carbonyl) amino)propanoic acid39, 5-carboxyfluorescein 
NHS ester40, and the fluorescent disulfide probe (3)3 were prepared as previously 
described. All endosome disruptor compounds were synthesized by Dr. Chamani 
Perera or Dr. Ze Li and provided with >95% purity based on analytical HPLC 
profiling.  Column chromatography employed Silica Gel (SiliCycle, 40-63 µm). 
	   117 
Preparative HPLC employed an Agilent 1200 Series preparative pump / gradient 
extension with a Hamilton PRP-1 (polystyrene-divinylbenzene) reverse-phase 
preparative column (10-12 µm particle size, 21.5 mm x 25 cm) with a flow rate of 
25.0 mL/min.  HPLC fractions containing water were dried using a Labconco 
FreeZone 4.5 lyophilizer. Compounds containing basic amines were isolated as 
TFA salts. Analytical HPLC traces were acquired using an Agilent 1100 Series 
quaternary pump and a Hamilton PRP-1 (polystyrene-divinylbenzene) reverse 
phase analytical column (7 µm particle size, 4 mm x 25 cm) with diode-array 
detection at either 215 or 254 nm.  Chromatograms were acquired at 45 °C to 
minimize rotational isomers, however in some cases small peak shoulders can 
be observed in the analytical HPLC trace. Coalescence of these shoulders was 
significantly improved by increasing the analysis temperature and also provided 
equivalent m/z by LR-MS consistent with rotational isomers. Analytical HPLC 
traces employed a gradient elution of H2O:CH3CN (90:10 to 0:100) with added 
TFA (0.1%) over 20 min and a 100% CH3CN wash for an additional 5 min.  Purity 
was determined by integration of the chromatogram. Low-resolution mass 
spectra (LRMS) were obtained using a Waters Micromass ZQ instrument with 
ESI+ or ESI-. Peaks are reported as m/z. 
 
3.9.2 Synthetic Procedures and Characterization 
General Procedure for Solid Phase Peptide Synthesis (SPPS).  SPPS for 
compounds 50 – 84 was performed on a Mettler Toledo MiniBlock reactor (Model 
No: Bohdan 2080; 12-well block with glass reaction vessels, 600 rpm) utilizing 
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standard Fmoc chemistry employing Rink amide MBHA resin (0.5 mmol/g, 100 
mg, 0.05 mmol). The following amino acids were used in the syntheses: Fmoc-
Ser(Ot-Bu)-OH, Fmoc-Ala-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(Ot-Bu)-OH, Fmoc-
Pro-OH, Fmoc-Val-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Ahx-OH, Fmoc-β-Ala-OH, 
and Fmoc-Aib-F.  The resin was swelled in DMF for 2 h and the Fmoc group 
removed by agitating with deblocking solution (20% piperidine in DMF (2 mL), 
two times, for 4 minutes each). The resin was washed four times with DMF (2 
mL) to remove any traces of piperidine, and treated with Fmoc-amino acids (4 
eq.), HATU coupling reagents (3.8 eq.), and DIEA (8 eq.) in 2 ml of DMF with 
agitation until coupling was completed by Kaiser Test (3h , 6h, or 12 h).  Once 
the coupling was complete, the reaction solution was removed and resin was 
washed four times with DMF (2 mL). This coupling protocol was repeated for 
each additional Fmoc-amino acid. The hindered 2-aminoisobutyric acid (Aib) was 
coupled via acid fluoride chemistry. Fmoc-Aib-F was synthesized using DAST 
chemistry.41 Fmoc-Aib-F (4 eq.) was dissolved in 0.5 mL of DMF, added to the 
resin, and agitated for 2 h. For acetylated peptides, the final amine was capped 
by agitating with acetic anhydride/DIEA/DMF (1:2:7) for 1 h. For cholesterol 
modified peptides, the peptide was capped with either 3β-cholesterylamino-N-
valeric acid3 or 3-((((cholester-3-yl)oxy)carbonyl) amino)propanoic acid39 using 
the general coupling protocol with HATU. Synthesis of compounds 85 – 87 and 
89 employed a 50 mL peptide synthesis vessel (Quark Glassware) with a wrist 
action shaker and standard Fmoc amino acid methodology described above. 
Cleavage from Rink amide MBHA resin (compounds 50 – 87) was done using a 
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mixture of TFA/H2O/TIPS (95/2.5/2.5) with agitation for 2 h.  Cleavage from 2-
chlorotrityl resin (compound 89) was done by treatment with a mixture of 
DCM/TFE/acetic acid (7/2/1) with shaking for 2 h. The resin was removed by 
filtration and washed with DCM (2 mL, 3x) or DMF (2 mL, 3x). The filtrates were 
combined and concentrated under vacuum to give crude products. Purification 
was done using preparative reverse-phase HPLC (gradient: 90/10 H2O/MeCN to 
100% MeCN over 20 min with 0.1% TFA added). 
 
N-(5-(3β-cholest-5-en-3-ylammonio)pentanoyl)-β-Alanyl-L-Glutamyl-L-
Glutamyl-Aminohexanoyl-L-Seryl-L-Seryl-L-Alanyl-L-Tryptophyl-L-
Tryptophyl-L-Seryl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Alaninamide (50). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 50 (42 mg, 0.017 mmol, 
36% yield overall) as a white solid.  LR-MS (ESI-) m/z 2344.2 (M-H+, 
C123H173N21O25 requires 2344.3). 
	  
Figure 3.17. Analytical HPLC profile of 50 after preparative HPLC. Retention 
time = 18 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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N-(5-(3β-cholest-5-en-3-ylammonio)pentanoyl)-β-Alanyl-L-Glutamyl-L-
Glutamyl-Aminohexanoyl-L-Alanyl-L-Alanyl-L-Alanyl-L-Tryptophyl-L-
Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Alaninamide (51). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 51 (28 mg, 0.012 mmol, 
24% yield overall) as a white solid.  LR-MS (ESI-) m/z 2297.0 (M-H+, 
C123H173N21O22 requires 2296.8). 
	  
Figure 3.18. Analytical HPLC profile of 51 after preparative HPLC. Retention 
time = 16 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
N-(5-(3β-cholest-5-en-3-ylammonio)pentanoyl)-β-Alanyl-L-Glutamyl-L-
Glutamyl-Aminohexanoyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-
Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-
L-Valyl-L-Alaninamide (52). Using the general SPPS procedure, Rink amide 
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MBHA resin (0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 52 (17 mg, 
0.007 mmol, 15% yield overall) as a white solid.  LR-MS (ESI-) m/z 2338.4 (M-
H+, C126H179N21O22 requires 2338.9). 
	  
Figure 3.19. Analytical HPLC profile of 52 after preparative HPLC. Retention 
time = 16 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
N-(Acetyl)-L-Seryl-L-Seryl-L-Alanyl-L-Tryptophyl-L-Tryptophyl-L-Seryl-L-
Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-Alaninamide (53). Using the 
general SPPS procedure, Rink amide MBHA resin (0.5 mmol/g, 100 mg, 0.05 
mmol) was used to produce 53 (47 mg, 0.032 mmol, 64% yield overall) as a 
white solid.  LR-MS (ESI-) m/z 1476.1 (M-H+, C74H92N16O17 requires 1476.6). 
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Figure 3.20. Analytical HPLC profile of 53 after preparative HPLC. Retention 
time = 14 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
N-(Acetyl)-L-Alanyl-L-Alanyl-L-Alanyl-L-Tryptophyl-L-Tryptophyl-L-Alanyl-
L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-Alaninamide (54). Using 
the general SPPS procedure, Rink amide MBHA resin (0.5 mmol/g, 100 mg, 0.05 
mmol) was used to produce 54 (20 mg, 0.014 mmol, 28% yield overall) as a 
white solid.  LR-MS (ESI-) m/z 1428.1 (M-H+, C74H92N16O14 requires 1427.7). 
	  
Figure 3.21. Analytical HPLC profile of 54 after preparative HPLC. Retention 
time = 11 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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N-(Acetyl)-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-L-
Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Alaninamide (55). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 55 (32 mg, 0.022 mmol, 
44% yield overall) as a white solid.  LR-MS (ESI-) m/z 1470.2 (M-H+, 
C77H98N16O14 requires 1469.7). 
	  
Figure 3.22. Analytical HPLC profile of 55 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
N-(Acetyl)-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-
Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-
L-Valyl-L-Alaninamide (56). Using the general SPPS procedure, Rink amide 
MBHA resin (0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 56 (33 mg, 
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0.021 mmol, 42% yield overall) as a white solid.  LR-MS (ESI-) m/z 1555.3 (M-
H+, C81H105N17O15 requires 1554.8). 
	  
Figure 3.23. Analytical HPLC profile of 56 after preparative HPLC. Retention 
time = 13 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
N-(Acetyl)-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-
Aminoisobutyl-L-Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-
L-Prolyl-L-Prolyl-L-Valyl-L-Alaninamide (57).  Using the general SPPS 
procedure, Rink amide MBHA resin (0.5 mmol/g, 100 mg, 0.05 mmol) was used 
to produce 57 (23 mg, 0.014 mmol, 28% yield overall) as a white solid.  LR-MS 
(ESI-) m/z 1640.2 (M-H+, C85H112N18O16 requires 1639.8). 
	  
Figure 3.24. Analytical HPLC profile of 57 after preparative HPLC. Retention 
time = 13 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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N-(Acetyl)-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-
Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-
L-Valyl-L-Valinamide (58). Using the general SPPS procedure, Rink amide 
MBHA resin (0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 58 (32 mg, 
0.020 mmol, 40% yield overall) as a white solid.  LR-MS (ESI+) m/z 1607.4 
(M+Na+, C83H109N17O15Na requires 1606.8). 
	  
Figure 3.25. Analytical HPLC profile of 58 after preparative HPLC. Retention 
time = 13 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Alaninamide (59). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 59 (30 mg, 0.019 mmol, 
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38% yield overall) as a white solid.  LR-MS (ESI-) m/z 1513.5 (M-H+, 
C81H105N17O15 requires 1512.8). 
	  
Figure 3.26. Analytical HPLC profile of 59 after preparative HPLC. Retention 
time = 14 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (60). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 60 (43 mg, 0.028 mmol, 
56% yield overall) as a white solid.  LR-MS (ESI+) m/z 1543.2 (M+H+, 
C81H107N17O14 requires 1542.8). 
	  
Figure 3.27. Analytical HPLC profile of 60 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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N-(5-(3β-cholest-5-en-3-ylammonio)pentanoyl)-β-Alanyl-L-Glutamyl-L-
Glutamyl-mPEG-mPEG-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-
Aminoisobutyl-L-Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-
L-Prolyl-L-Prolyl-L-Valyl-L-Alaninamide (61). Using the general SPPS 
procedure, Rink amide MBHA resin (0.5 mmol/g, 100 mg, 0.05 mmol) was used 
to produce 61 (47 mg, 0.017 mmol, 34% yield overall) as a white solid.  LR-MS 
(ESI-) m/z 2717.3 (M-H+, C142H209N23O30 requires 2716.6). 
	  
Figure 3.28. Analytical HPLC profile of 61 after preparative HPLC. Retention 
time = 17 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
((3β-cholest-5-en-3-yl)carbonyl)-β-Alanyl-β-Alanyl-L-Glutamyl-L-Glutamyl-
mPEG-mPEG-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-
L-Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-
Prolyl-L-Valyl-L-Alaninamide (62). Using the general SPPS procedure, Rink 
amide MBHA resin (0.5 mmol/g, 100 mg, 0.05 mmol) was used to produce 62 (19 
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mg, 0.007 mmol, 14% yield overall) as a white solid.  LR-MS (ESI-) m/z 2732.7 
(M-H+, C141H205N23O32 requires 2732.5). 
	  
Figure 3.29. Analytical HPLC profile of 62 after preparative HPLC. Retention 
time = 19 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Alanyl-L-
Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (63). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 70 mg, 0.035 mmol) was used to produce 63 (26 mg, 0.018 mmol, 
51% yield overall) as a white solid.  LR-MS (ESI-) m/z 1540.0 (M-H+!TFA, 
C73H102N16O14 !CF3CO2H requires 1539.7). 
	  
Figure 3.30. Analytical HPLC profile of 63 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	   129 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Alanyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (64). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 70 mg, 0.035 mmol) was used to produce 64 (18 mg, 0.013 mmol, 
37% yield overall) as a white solid.  LR-MS (ESI-) m/z 1426.0 (M-H+, 
C73H102N16O14 requires 1425.7). 
	  
Figure 3.31. Analytical HPLC profile of 64 after preparative HPLC. Retention 
time = 13 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Alanyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (65). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 70 mg, 0.035 mmol) was used to produce 65 (19 mg, 0.013 mmol, 
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37% yield overall) as a white solid.  LR-MS (ESI-) m/z 1449.4 (M-H+, 
C75H103N17O13 requires 1448.8). 
	  
Figure 3.32. Analytical HPLC profile of 65 after preparative HPLC. Retention 
time = 13 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Alanyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (66). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 70 mg, 0.035 mmol) was used to produce 66 (30 mg, 0.021 mmol, 
60% yield overall) as a white solid.  LR-MS (ESI-) m/z 1426.2 (M-H+, 
C73H102N16O14 requires 1425.8). 
	  
Figure 3.33. Analytical HPLC profile of 66 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Alanyl-L-Prolyl-L-Valyl-L-
Valinamide (67). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 70 mg, 0.035 mmol) was used to produce 67 (15 mg, 0.010 mmol, 
28% yield overall) as a white solid.  LR-MS (ESI-) m/z 1515.6 (M-H+, 
C79H105N17O14 requires 1514.8). 
	  
Figure 3.34. Analytical HPLC profile of 67 after preparative HPLC. Retention 
time = 14 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Alanyl-L-Valyl-L-
Valinamide (68). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 70 mg, 0.035 mmol) was used to produce 68 (20 mg, 0.013 mmol, 
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37% yield overall) as a white solid.  LR-MS (ESI-) m/z 1515.2 (M-H+, 
C79H105N17O14 requires 1514.8). 
	  
Figure 3.35. Analytical HPLC profile of 68 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Alanyl-L-
Valinamide (69). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 70 mg, 0.035 mmol) was used to produce 69 (25 mg, 0.016 mmol, 
47% yield overall) as a white solid.  LR-MS (ESI-) m/z 1627.6 (M-H+!TFA, 
C79H103N17O14 !CF3CO2H requires 1626.8). 
	  
Figure 3.36. Analytical HPLC profile of 69 after preparative HPLC. Retention 
time = 11 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tryptophyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-
L-Valinamide (70). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 70 (14 mg, 0.009 mmol, 
30% yield overall) as a white solid.  LR-MS (ESI+) m/z 1566.2 (M+H+, 
C83H108N18O13 requires 1565.8). 
	  
Figure 3.37. Analytical HPLC profile of 70 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tyrosyl-L-
Tryptophyl-L-Alanyl-L-Tryptophyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (71). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 71 (23 mg, 0.015 mmol, 
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50% yield overall) as a white solid.  LR-MS (ESI-) m/z 1541.6 (M-H+, 
C81H107N17O14 requires 1540.8). 
	  
Figure 3.38. Analytical HPLC profile of 71 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tyrosyl-L-Alanyl-L-Tryptophyl-L-Tryptophyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (72). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 72 (21 mg, 0.014 mmol, 
45% yield overall) as a white solid.  LR-MS (ESI-) m/z 1541.2 (M-H+, 
C81H107N17O14 requires 1540.8). 
	  
Figure 3.39. Analytical HPLC profile of 72 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tryptophyl-L-Tyrosyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (73). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 73 (20 mg, 0.013 mmol, 
43% yield overall) as a white solid.  LR-MS (ESI-) m/z 1541.3 (M-H+, 
C81H107N17O14 requires 1540.8). 
	  
Figure 3.40. Analytical HPLC profile of 73 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Tryptophyl-L-Tryptophyl-L-Tyrosyl-L-Prolyl-L-Prolyl-L-Valyl-
L-Valinamide (74). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 74 (19 mg, 0.011 mmol, 
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38% yield overall) as a white solid.  LR-MS (ESI+) m/z 1657.7 (M+H+, 
C89H112N18O14 requires 1657.9). 
	  
Figure 3.41. Analytical HPLC profile of 74 after preparative HPLC. Retention 
time = 12 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Tyrosyl-L-Tryptophyl-L-Tyrosyl-L-Prolyl-L-Prolyl-L-Valyl-L-
Valinamide (75). Using the general SPPS procedure, Rink amide MBHA resin 
(0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 75 (19 mg, 0.011 mmol, 
39% yield overall) as a white solid.  LR-MS (ESI+) m/z 1635.4 (M+H+, 
C87H111N17O15 requires 1634.9). 
	  
Figure 3.42. Analytical HPLC profile of 75 after preparative HPLC. Retention 
time = 11 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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N-(Acetyl)-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-
Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tryptophyl-L-Tyrosyl-L-Prolyl-L-Prolyl-
L-Valyl-L-Valinamide (76). Using the general SPPS procedure, Rink amide 
MBHA resin (0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 76 (14 mg, 
0.009 mmol, 29% yield overall) as a white solid.  LR-MS (ESI-) m/z 1696.7 (M-
H+!TFA, C83H109N17O15 !CF3CO2H requires 1696.8). 
	  
Figure 3.43. Analytical HPLC profile of 76 after preparative HPLC. Retention 
time = 14 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
((3β-cholest-5-en-3-yl)carbonyl)-β-Alanyl-β-Alanyl-L-Glutamyl-L-Glutamyl-
mPEG-mPEG-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-
L-Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tryptophyl-L-Tyrosyl-L-Prolyl-L-
Prolyl-L-Valyl-L-Valinamide (77). Using the general SPPS procedure, Rink 
amide MBHA resin (0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 77 (10 
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mg, 0.004 mmol, 12% yield overall) as a white solid.  LR-MS (ESI-) m/z 1380.4 
(M-2H+/2, C143H209N23O32 requires 1379.8). 
	  
Figure 3.44. Analytical HPLC profile of 77 after preparative HPLC. Retention 
time = 19 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
((3β-Cholest-5-en-3-yl)carbonyl)-β-Alanyl-β-Alanyl-L-Glutamyl-L-Glutamyl-
mPEG-(β-Alanyl)4-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-
Aminoisobutyl-L-Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tryptophyl-L-Tyrosyl-
L-Prolyl-L-Prolyl-L-Valyl-L-Valinamide (78). Using the general SPPS 
procedure, Rink amide MBHA resin (0.5 mmol/g, 60 mg, 0.03 mmol) was used to 
produce 78 (15 mg, 0.005 mmol, 18% yield overall) as a white solid.  LR-MS 
(ESI-) m/z 1420.7 (M-H+/2, C146H212N26O32 requires 1420.3). 
	  
Figure 3.45. Analytical HPLC profile of 78 after preparative HPLC. Retention 
time = 18 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tryptophyl-L-Alanyl-L-Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tryptophyl-L-
Tyrosyl-L-Prolyl-L-Prolyl-L-Valyl-L-Valinamide (79). Using the general SPPS 
procedure, Rink amide MBHA resin (0.5 mmol/g, 60 mg, 0.03 mmol) was used to 
produce 79 (20 mg, 0.010 mmol, 33% yield overall) as a white solid.  LR-MS 
(ESI-) m/z 1985.6 (M-H+, C106H132N22O17 requires 1985.0). 
	  
Figure 3.46. Analytical HPLC profile of 79 after preparative HPLC. Retention 
time = 13 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tryptophyl-
L-Tyrosyl-L-Alanyl-L-Tryptophyl-L-Tyrosyl-L-Alanyl-L-Tryptophyl-L-Tyrosyl-
L-Prolyl-L-Prolyl-L-Valyl-L-Valinamide (80). Using the general SPPS 
procedure, Rink amide MBHA resin (0.5 mmol/g, 60 mg, 0.03 mmol) was used to 
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produce 80 (25 mg, 0.013 mmol, 42% yield overall) as a white solid.  LR-MS 
(ESI+) m/z 1941.1 (M+H+, C102H130N20O19 requires 1941.0). 
	  
Figure 3.47. Analytical HPLC profile of 80 after preparative HPLC. Retention 
time = 11 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Tyrosyl-L-
Tyrosyl-L-Alanyl-L-Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-Tyrosyl-L-
Prolyl-L-Prolyl-L-Valyl-L-Valinamide (81). Using the general SPPS procedure, 
Rink amide MBHA resin (0.5 mmol/g, 60 mg, 0.03 mmol) was used to produce 81 
(30 mg, 0.016 mmol, 52% yield overall) as a white solid.  LR-MS (ESI+) m/z 
1917.5 (M+H+, C100H129N19O20 requires 1918.0). 
	  
Figure 3.48. Analytical HPLC profile of 81 after preparative HPLC. Retention 
time = 11 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
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N-(Acetyl)-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-
Tryptophyl-L-Tyrosyl-L-Alanyl-L-Tryptophyl-L-Tyrosyl-L-Alanyl-L-
Tryptophyl-L-Tyrosyl-L-Prolyl-L-Prolyl-L-Valyl-L-Valinamide (82). Using the 
general SPPS procedure, Rink amide MBHA resin (0.5 mmol/g, 60 mg, 0.03 
mmol) was used to produce 82 (15 mg, 0.008 mmol, 25% yield overall) as a 
white solid.  LR-MS (ESI+) m/z 2005.4 (M+Na+, C104H132N20O20Na requires 
2005.0). 
	  
Figure 3.49. Analytical HPLC profile of 82 after preparative HPLC. Retention 
time = 18 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-Alanyl-L-
Tryptophyl-L-Tyrosyl-L-Alanyl-L-Tryptophyl-L-Tyrosyl-L-Tryptophyl-L-
Tyrosyl-L-Prolyl-L-Prolyl-L-Valyl-L-Valinamide (83). Using the general SPPS 
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procedure, Rink amide MBHA resin (0.5 mmol/g, 60 mg, 0.03 mmol) was used to 
produce 79 (18 mg, 0.009 mmol, 31% yield overall) as a white solid.  LR-MS 
(ESI+) m/z 1941.2 (M+H+, C102H130N20O19 requires 1941.0). 
	  
Figure 3.50. Analytical HPLC profile of 83 after preparative HPLC. Retention 
time = 17 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
	  
 
((3β-cholest-5-en-3-yl)carbonyl)-β-Alanyl-β-Alanyl-L-Glutamyl-L-Glutamyl-
mPEG-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-Aminoisobutyl-L-
Tyrosyl-L-Tyrosyl-L-Alanyl-L-Tryptophyl-L-Tryptophyl-L-Alanyl-L-Tyrosyl-L-
Tyrosyl-L-Prolyl-L-Prolyl-L-Valyl-L-Valinamide (84). Using the general SPPS 
procedure, Rink amide MBHA resin (0.5 mmol/g, 60 mg, 0.03 mmol) was used to 
produce 84 (10 mg, 0.004 mmol, 11% yield overall) as a white solid.  LR-MS 
(ESI-) m/z 1465.8 (M-H+/2, C153H214N24O34 requires 1465.3). 
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Figure 3.51. Analytical HPLC profile of 84 after preparative HPLC. Retention 
time = 18 min monitored by UV absorbance at 254 nm. Purity >95% by HPLC. 
Peak shoulder consistent with rotational isomer. 
 
 
Figure 3.52. Reagents and Conditions: a) 5-carboxyfluorescein NHS-ester, 
DIEA, DMF, 22 °C, 16 h. 
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(11S,14S)-11,14-bis(2-carboxyethyl)-1-((cholester3-yl)oxy)-1,5,9,12,15-
pentaoxo-19,20-dithia-2,6,10,13,16-pentaazatricosan-23-oic acid (89).  
Compound 89 was constructed using SPPS with 2-Chlorotrityl resin (1.3 mmol/g, 
385 mg, 0.5 mmol) using Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic 
acid3, 3-((((Cholester-3-yl)oxy)carbonyl) amino)propanoic acid39, and the 
following Fmoc-protected amino acids: Fmoc-β-Ala-OH, Fmoc-L-Glu(Ot-Bu)-OH.  
The crude product was purified using flash chromatography (gradient elution of 
DCM to DCM/MeOH 95/5) to yield compound 89 (425 mg, 0.38 mmol, 77% 
overall yield) as an off-white solid.  LR-MS (ESI-) m/z 1105.0 (M-H+, 
C57H95N5O12S2 requires 1104.6). 
 
Figure 3.53. Analytical HPLC profile of 89 after column chromatography.  
Retention time = 24.0 min.  Monitored by UV absorbance at 215 nm.  Purity 
>90% by integration of chromatogram. 
 
General Procedure for Synthesis of D-Glu Fluorescent Probes.  Compounds 
85 – 87 were constructed using SPPS with Rink amide LL resin with Fmoc-D-
Lys(Boc)-OH, Fmoc-D-Glu(Ot-Bu)-OH, and purified compound 89.  The crude 
peptides were dried under vacuum and azeotroped using a mixture of 
toluene/MeOH (3/1, 3 mL, 3x) to ensure complete removal of TFA and H2O.  The 
crude peptides were dissolved in 2mL dry DMF, then DIEA (0.2 mL) and 5-
	   145 
carboxyfluorescein NHS-ester (2 eq.) were added and allow to stir at 22 °C for 16 
h.  The solvent was removed, and the residue was dissolved in DMSO (1.5 mL) 
and subjected to preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) 
with added TFA (0.1%) over 20 min; elution time =  16-18 min).  Pure fractions 
were collected, combined, and lyophilized to provide product as a yellow solid. 
 
(11S,14S)-11,14-bis(2-carboxyethyl)-1-((cholester-3-yl)oxy)-1,5,9,12,15-
pentaoxo-19,20-dithia-2,6,10,13,16-pentaazatricosan-23-yl-[D-Lysyl(ε-N-(6-
hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid)] (85).  Using the general 
procedure described above, Rink amide LL resin (0.36 mmol/g, 63 mg, 0.0225 
mmol) was used to produce compound 85 (8.4 mg, 0.0057 mmol, 25% yield 
overall) as a yellow solid.  LR-MS (ESI-) m/z 1478.1 (M-H+, C76H102N8O18S2 
requires 1477.7). 
 
Figure 3.54. Analytical HPLC profile of 85 after preparative HPLC.  Retention 
time = 19.1 min.  Monitored by UV absorbance at 254 nm.  Purity >90% by 
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integration of chromatogram.  Peak shoulders provided equivalent m/z consistent 
with rotational isomers. 
 
 
(11S,14S)-11,14-bis(2-carboxyethyl)-1-((cholester-3-yl)oxy)-1,5,9,12,15-
pentaoxo-19,20-dithia-2,6,10,13,16-pentaazatricosan-23-yl-[D-Glutamyl-D-
Glutamyl-D-Lysyl(ε-N-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid)] (86).  
Using the general procedure described above, Rink amide LL resin (0.36 
mmol/g, 104 mg, 0.0375 mmol) was used to produce compound 86 (5.6 mg, 
0.0032 mmol, 8% yield overall) as a yellow solid.  LR-MS (ESI-) m/z 868.1 (M-
2H+/2, C86H117N10O24S2 requires 867.4). 
 
 
Figure 3.55. Analytical HPLC profile of 86 after preparative HPLC.  Retention 
time = 18.0 min.  Monitored by UV absorbance at 254 nm.  Purity >90% by 
integration of chromatogram.  Peak shoulders provided equivalent m/z consistent 
with rotational isomers. 
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(11S,14S)-11,14-bis(2-carboxyethyl)-1-((cholester-3-yl)oxy)-1,5,9,12,15-
pentaoxo-19,20-dithia-2,6,10,13,16-pentaazatricosan-23-yl-[D-Glutamyl-D-
Glutamyl-D-Glutamyl-D-Glutamyl-D-Lysyl(ε-N-(6-hydroxy-3-oxo-3H-xanthen-
9-yl)benzoic acid)] (87).  Using the general procedure described above, Rink 
amide LL resin (0.36 mmol/g, 125 mg, 0.045 mmol) was used to produce 
compound 87 (6.2 mg, 0.0031 mmol, 7% yield overall) as a yellow solid.  LR-MS 
(ESI-) m/z 997.4 (M-2H+/2, C96H133N12O30S2 requires 996.9). 
 
Figure 3.56. Analytical HPLC profile of 87 after preparative HPLC.  Retention 
time = 17.5 min.  Monitored by UV absorbance at 254 nm.  Purity >90% by 
integration of chromatogram.  Peak shoulders provided equivalent m/z consistent 
with rotational isomers. 
 
3.9.3 Biological Assays and Protocols 
General. Reagents were purchased from Sigma-Aldrich, Fisher Scientific, and 
Acros Organics. Cell culture reagents were from Sigma-Aldrich.  UV/Vis 
measurements employed an Agilent 8452A diode array spectrophotometer.   
	   148 
 
Cell culture. Jurkat lymphocytes (human acute leukemia, ATCC #TIB-152) were 
cultivated in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented 
with Fetal Bovine Serum (FBS, 10%), penicillin (100 units/mL), and streptomycin 
(100 µg/mL) and incubated in a humidified 5% CO2 incubator at 37 °C. Media 
used for cell culture and all wash steps contained antibiotics and 10% FBS 
unless otherwise noted. 
 
Microscopy. An inverted Leica TCS SPE confocal laser-scanning microscope 
fitted with a Leica 63X oil-immersion objective was employed for imaging. 
Fluorescent probes were excited with either a 405 nm or 488 nm solid-state laser 
and emitted photons were collected from 410-470 nm or 495-600 nm, 
respectively.  To image living cells, 50 µL of cells in media was pipetted to form a 
small droplet in the center of a coverslip fitted with a press-to-seal silicone 
isolator (Invitrogen). A microscope slide was added to the top of the coverslip to 
create a column of media containing living cells. To allow accurate comparisons 
of differences in cellular fluorescence, laser power and PMT gain settings were 
identical for all samples shown in a given figure. 
 
Flow Cytometry. Populations of 10,000 Jurkat cells were analyzed for each 
sample using an Accuri C6 flow cytometer equipped with 488 nm and 640 nm 
solid-state lasers. Live cells were gated using forward scattering (FSC) and side 
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scattering (SSC) dot plots to identify cellular physical properties of size and 
granularity. 
 
Analysis of Endosome Disruption by Release of Fluorescent Probes.  Jurkat 
lymphocytes were suspended at 350,000 cells per mL in media.  The fluorescent 
probe (3, or 85 – 87) was added at 2.5 µM (diluted from a 10 mM DMSO stock).  
Endosome disruptor was added at various concentrations from 10 nM to 16 µM 
(diluted from a 1000x DMSO stock).  The samples were aliquoted into two 
eppendorf tubes at 500 µL each to provide replicates and incubated for 14 h in a 
37 °C incubator with gentle rotation to maintain cell suspension.  Following 
incubation, the cells were pelleted by centrifugation at 2,000 rpm for 2 minutes, 
re-suspended in 500 µL media, and allowed to incubate at 22 °C for 30 minutes 
to allow efflux of excess fluorescent probe from the plasma membrane.  The cells 
were washed once more in media and analyzed for cellular fluorescence by flow 
cytometry. 
Data analysis. Cells that were not treated with endosome disruptor (fluorescent 
probe alone) were analyzed to provide baseline fluorescence values.  Following 
baseline subtraction, replicates for each compound were plotted versus 
concentration and analyzed by non-linear regression in Prism 5 using the 
“log(agonist) vs response – four parameter” model. To normalize the efficacy of 
each replicate, the span of the resulting curve was normalized to the activity of 
cholesterylamine-PC-4 (2) at 100%. To ensure the accuracy of efficacy 
measurements, each round of testing included either cholesterylamine-PC-4 (2) 
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or another previously normalized compound to serve as a known efficacy value 
to which additional compounds were normalized. The calculated EC50 values 
from the resulting curves were averaged to provide the mean EC50 ± standard 
deviation (SD). The average standard deviation of EC50 values for a given 
peptide was ~30% of the mean, based on multiple independent experiments for a 
subset of peptides. Analysis of each peptide contained at least two replicates, 
however for peptides that contained only two replicates and a SD <30% of the 
mean, the SD was adjusted to 30% of the mean. Efficacy values for each peptide 
were averaged to provide mean efficacy (as % of 2) ± SD. 
 
Toxicity Analysis of Endosome Disruptors.  Jurkat lymphocytes were 
suspended at 350,000 cells per mL in media and aliquoted into a 48-well plate at 
500 µL per well.  Endosome disruptor was added at various concentrations from 
1 µM to 32 µM (diluted from a 500x DMSO stock) in duplicate.  The samples 
were incubated for 48 h at 37 °C.  Following incubation, the cells were analyzed 
by flow cytometry.  Live gating by FSC and SSC provided the cell viability for 
each condition.  Cell viability at 48 h was plotted versus concentration and 
analyzed by non-linear regression in GraphPad Prism 6 to provide IC50 values. 
 
Analysis of Endosome Disruptor Solubility.  Endosome disruptor peptides 
(0.5 – 1.5 mg) were added to eppendorf tubes in triplicate.  Each tube received 1 
mL of PBS 7.4 and was placed in a sonication bath for 30 minutes at 22 °C to 
disperse the solid material.  The tubes were incubated for 24 h at 22 °C with 
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agitation.  Following incubation, the samples were centrifuged at 16,000 x G for 1 
h to pellet any un-dissolved material.  The supernatant was analyzed by UV 
absorbance at 280 nm and the concentration was determined using the 
calculated extinction coefficient for each peptide sequence (Table 3.7, 
http://www.basic.northwestern.edu/biotools/proteincalc.html).  Concentration 
values for each compound were averaged from three independent replicates to 
provide thermodynamic solubility with error values typically <10%. 
	  
Table 3.7. Calculated extinction coefficients (ε) for endosome disruptors 50 – 84 
based on tryptophan and tyrosine content and absorbance at 280 nm. 
 
Molecular Dynamics Simulations. MD simulations were performed by Dr. 
Gerry Lushington. For these simulations, close analogues of each peptide (e.g. 
sequence: AAAAWWAWYPPVV) were constructed via the Avogadro42 polymer 
builder, specifying backbone torsion angles corresponding to the 310 amino acid 
2 MA-SSAWWSYWPPVA-NH2 18350 67 UUUUWWAYWAPVV-NH2 18350
50 MA-SSAWWSYWPPVA-NH2 18350 68 UUUUWWAYWPAVV-NH2 18350
51 MA-AAAWWAYWPPVA-NH2 18350 69 UUUUWWAYWPPAV-NH2 18350
52 MA-UUUWWAYWPPVA-NH2 18350 70 UUUUWWAWWPPVV-NH2 22760
53 Ac-SSAWWSYWPPVA-NH2 18350 71 UUUUYWAWWPPVV-NH2 18350
54 Ac-AAAWWAYWPPVA-NH2 18350 72 UUUUWYAWWPPVV-NH2 18350
55 Ac-UUUWWAYWPPVA-NH2 18350 73 UUUUWWAWYPPVV-NH2 18350
56 Ac-UUUUWWAYWPPVA-NH2 18350 74 UUUUWWWWYPPVV-NH2 24040
57 Ac-UUUUUWWAYWPPVA-NH2 18350 75 UUUUWWYWYPPVV-NH2 19630
58 Ac-UUUUWWAYWPPVV-NH2 18350 76 Ac-UUUUWWAWYPPVV-NH2 18350
59 UUUUWWAYWPPVA-NH2 18350 77 MA-UUUUWWAWYPPVV-NH2 18350
60 UUUUWWAYWPPVV-NH2 18350 78 MA-UUUUWWAWYPPVV-NH2 18350
61 MA-UUUUWWAYWPPVA-NH2 18350 79 UUUUWWAWWAWYPPVV-NH2 29730
62 MA-UUUUWWAYWPPVA-NH2 18350 80 UUUUWYAWYAWYPPVV-NH2 20910
63 UUUUAWAYWPPVV-NH2 12660 81 UUUUYYAWWAYYPPVV-NH2 16500
64 UUUUWAAYWPPVV-NH2 12660 82 Ac-UUUUWYAWYAWYPPVV-NH2 20910
65 UUUUWWAAWPPVV-NH2 17070 83 UUUUAWYAWYWYPPVV-NH2 20910
66 UUUUWWAYAPPVV-NH2 12660 84 MA-UUUUYYAWWAYYPPVV-NH2 16500
Ext. Coeff. 
(ε, M-1 cm-1) Cpd. Sequence
Ext. Coeff. 
(ε, M-1 cm-1)Cpd. Sequence
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helix. The first four N-terminal alanine residues were mutated to Aib in PyMol.43 
Pymol was further used to assemble the putative multi-peptide pore models and 
add flanking 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) lipids. The ratio of 
peptide to lipid molecules was 1:2, and the lipid molecules were positioned to 
surround the multi-peptide pore model and ensure that no two pores would 
directly border each other under periodic boundary conditions. Aromatic amino 
acid side chains were hand-edited to devise a regular lattice of aromatic-aromatic 
interactions designed to stabilize the walls of the pore, with the aliphatic side 
chains oriented outwards into the lipid medium. Dynamic stability of the pore 
model complexes was evaluated via NAMD36 molecular dynamics simulations 
according to the CHARMM37 force field and electrostatics, but this force field was 
modified to include recently described38 parameters for peptides containing Aib. 
NAMD topology files were created using VMD44 as the basis for force field 
parameter specification, standardization of peptide termini (the N-terminus was 
capped with an acyl group, whereas the C-terminus was converted into an 
amide), and creation of a water saturated box. Water was introduced per default 
density specifications into a periodic unit cell for the simulation chosen to extend 
by 5.0 Angstroms both above and below the pore, but with no buffer within the 
plane of the simulated membrane. Pore stability was ultimately gauged via a 
standard protocol as follows: 1) interatomic interactions within the unit cell were 
relaxed via 1000 steps of temperature-agnostic molecular mechanics refinement, 
2) unit cell dimensions were optimized via a 10000 step molecular dynamics 
simulation implementing the default Langevin piston pumping protocol specified 
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by VMD (standard atmospheric pressure; T = 298K), and finally 3) Constant 
temperature and volume analysis via a 20000 step molecular dynamics 
simulation according to the default production run specifications specified by 
VMD. Uniform decile time-sampling of molecular dynamics simulations of the 
hexapeptide embedded in the periodic endosomal membrane environment was 
performed to characterize the pore geometry and estimate its radius.  For each 
analyzed geometry snapshot, MolAxis45 software was used to quantify the pore 
radius as a function of time and of distance from the center of the channel.  Using 
4.0 Angstrom probe radius and 0.5 Angstrom resolution (all other parameters 
retained at default values), the intelligent sampling encoded within the MolAxis 
program produced radius sampling of between 35-45 points at different locations 
along the pore-perpendicular axis.  From this combined spatial and temporal 
sampling, Dr. Lushington computed mean values for the overall pore radius, the 
bottleneck radius (single smallest radius per timestep). 
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Chapter 4 
 
Toward Tumor Selective Toxicity using Small Molecule-Protein Conjugates 
and Endosome Disruptive Peptides 
 
4.1 Introduction 
 Optimized endosome disruptive peptides developed by the Peterson lab 
provide chemically-defined tools for the delivery of cell-impermeable small 
molecules into the cytosol of living mammalian cells. Structure-activity 
relationships (SAR), experimental data, and molecular modeling provided 
evidence that these peptides form a hexameric pore structure in the lipid bilayers 
of early endosomes with a diameter of ~15 Å. This pore assembly allows the 
efficient release of disulfide-linked small molecules targeted to early endosomes 
by cholesterol-based membrane anchors. 
 During the course of developing improved endosome disruptors, our lab 
also investigated the application of these compounds as a drug delivery system 
for cancer therapeutics.  The preliminary work for this application, performed by 
Dr. Qi Sun and Ning Yang, involved the controlled release of cytotoxins using 
endosome disruptors.  Dr. Sun’s initial work utilized disulfide-linked colchicine,1, 2 
a tubulin-destablilizing cytotoxin, targeted to membranes of early endosomes by 
cholesterylamines and conjugated via a disulfide. Co-treatment with the 
endosome disruptor cholesterylamine-PC-4 (2)3 produced a 5-fold increase in 
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cellular toxicity, providing proof-of-concept that endosome disruption could 
induce cellular toxicity through release of a cytotoxic warhead. 
	  
Figure 4.1. Structures of N-acetyl colchinol methyl ether (90, NACME), the 
membrane anchored disulfide (91) and amide (92) linked CME compounds, and 
endosome disruptor 78. 
	  
 As part of his Master’s thesis, Ning Yang synthesized compounds 91 and 
92 (Figure 4.1) with colchinol methyl ether (CME) as the cytotoxic warhead.4, 5 In 
the absence of endosome disruption, these CME analogues demonstrated less 
cytotoxicity than the previous colchicine analogue, presumably by limiting off-
target toxicity seen with the membrane-anchored colchicine compound.  He also 
found that inclusion of the anionic glutamic acid residue proximal to the disulfide 
enhanced cytotoxicity, presumably by increasing retention of the warhead in the 
cytosol following release from endosomes.   As shown in Figure 4.2, a 50-fold 
increase in cytotoxicity is observed for compound 91 when endosome disruptor 
78 is co-administered in two different cell lines. Compound 92 contains a much 
more stable amide linkage and shows significantly less toxicity in the presence of 
the endosome disruptor. 
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Figure 4.2. Toxicity analysis of compounds 90 – 92 in the presence and absence 
of endosome disruptor 78. Jurkat lymphocytes (A) or PC3 cells (B) were treated 
for 72 h with and without 78 (1 µM). Analysis performed by flow cytometry and fit 
by non-linear regression to provide IC50 values. 
 
	  
 
Table 4.1. IC50 values of compounds 90 – 92 in Jurkat or PC3 cells. Endosome 
disruptor 78 was used to induce release of the cytotoxic CME warhead. MA = 
Membrane Anchor. ED = Endosome Disruptor. 
 
 
This work further demonstrated that endosome disruption can be used to 
release bioactive molecules and produce a physiological effect.  Moreover, 
development of the optimized disulfide-linked colchinol produced a warhead that 
is nearly equipotent to the parent cytotoxin N-acetyl cholchinol methyl ether 
(NACME, 90) in Jurkat cells.  However, the application of this system to cancer 
chemotherapy is hindered by a major limitation; since the cholesterol-based 
Jurkat cells PC3 cells
(IC50, µM) (IC50, µM)
90 (NACME) 0.02 0.01
91 (MA-Disulfide-CME) 2.2 5.0
92 (MA-Amide-CME) 3.7 9.9
91 + 78 (MA-Disulfide-CME + ED) 0.04 0.11
92 + 78 (MA-Amide-CME + ED) 0.63 5.4
78 (ED alone) 3.1 9.5
Compound Added
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membrane anchor is efficiently taken up by nearly all mammalian cell types, 
conjugated cytotoxins such as 91 would not produce selective toxicity to tumor 
cells versus normal cells. 
 To address this limitation, we began to investigate conjugation to 
antibodies as a means to selectively deliver a disulfide-linked cytotoxic warhead 
to tumor cells that overexpress targeted cell surface receptors. These conjugates 
would bind their cell surface antigen and undergo receptor-mediated endocytosis 
to accumulate in endosomes similar to the cholesterol-based membrane 
anchors.6 Release of the warhead could then be induced by co-treatment with 
endosome disruptive peptides to produce tumor-specific toxicity. 
 
4.2 Antibody-Drug Conjugates in Cancer Chemotherapy 
 Antibody-drug conjugates (ADCs) are becoming widely used in cancer 
chemotherapy because of their ability to accumulate and release potent cytotoxic 
agents in tumor cells that overexpress targeted cell surface receptors.7-9  ADCs 
essentially act as prodrugs while in systemic circulation. They can remain in 
circulation for several days by cycling in and out of the vascular endothelium 
through binding to the neonatal Fc receptor (FcRn).10-12 ADCs generally 
comprise an antibody, a cleavable or non-cleavable linker, and a potent 
cytotoxin.13 Examples of three FDA-approved ADCs are shown in Figure 4.3. An 
ideal antibody is targeted to a cell surface receptor that is exclusively or 
abundantly expressed on tumor cells versus normal tissues. This receptor should 
undergo rapid internalization, typically through receptor-mediated endocytosis, as 
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well as appropriate intracellular trafficking to allow for release of the cytotoxic 
payload. Receptors commonly targeted by monoclonal antibodies for cancer 
therapy include the epidermal growth factor receptor (EGFR),14, 15 vascular 
endothelial growth factor (VEGF),16, 17 human epidermal growth factor receptor 2 
(HER2),18, 19 CD-20,20 CD-30,21 and CD-33.22 
Release of the cytotoxin can be achieved though chemical or enzymatic 
means.23-25 Due to the long half-life of ADCs, the stability of the linker is critically 
important. Some ADCs utilize cleavable linkers such as acid-labile hydrazones or 
disulfides. These linkers are typically more labile in systemic circulation, however 
their stability can be increased by addition of steric bulk or modulation of the 
electronic properties near the cleavage site. Non-cleavable linkers typically 
require proteolysis of either a peptide substrate in the linker, such as Adcetris21, 
26, 27 containing a valine-citruline dipeptide linker (Figure 4.3), or degradation of 
the entire antibody in the lysosome. Regardless of the cleavage mechanism, the 
design of the linker must also allow release of an active cytotoxic drug. 
Another important design aspect of ADCs is the method of conjugation 
between the antibody and the linker-drug payload. The most common methods 
are alkylation of reduced cysteine residues, acylation of lysine residues, or 
genetically engineering the antibody for site-specific conjugation. The first two 
methods produce heterogeneous mixtures with several payload molecules linked 
per antibody. Genetically engineered sites allow for specific conjugation of a 
single payload, however each of these methods has demonstrated therapeutic 
efficacy. The stoichiometry of the linked payload is also important. ADCs with 2 – 
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4 drugs per IgG show the greatest efficacy, while more heavily loaded antibodies 
are cleared more rapidly from circulation.28 
	  
Figure 4.3. Structure and composition of current FDA-approved antibody-drug 
conjugates. ADCs contain an antibody targeted to a cell surface receptor, a 
cleavable or non-cleavable linker, and a cytotoxic warhead. 
 
Despite the selectivity of an ADC for tumor cells versus normal tissue, its 
exposure to systemic circulation is far greater than its exposure to the tumor 
environment. As a result, the vast majority of a given dose is cleared in systemic 
circulation and very little of a given dose is localized to tumor cells. Because of 
this, ADCs require highly cytotoxic agents, typically sub-nanomolar potency, to 
produce therapeutic efficacy. Mylotarg utilizes the DNA-cleaving enediyne 
calicheamicin as its cytotoxin along with an acid-labile hydrazone linker.22, 29 
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Although this was the first ADC approved by the FDA, this drug was voluntarily 
withdrawn due to a narrow therapeutic index caused by non-specific cleavage to 
release the highly potent warhead. Subsequent generations of ADCs, 
represented by Adcetris21, 26, 27 and Kadcyla18, 30, 31, utilize potent tubulin-binding 
agents as their cytotoxins and contain more stable linkers that require 
proteolysis. These next-generation ADCs have significantly improved therapeutic 
indices, however the highly potent cytotoxin still causes some dose-limiting 
toxicities. 
 We hypothesized that we could improve the potency of ADCs by inducing 
release of the conjugated cytotoxin through endosome disruption. This method 
could be advantageous for two reasons: 1) inducing cleavage of a disulfide bond 
to release a cytotoxic payload would be more efficient than proteolytic 
mechanisms, and 2) this increase in efficiency would allow the use of cytotoxins 
with lower potency, such as our optimized colchinol methyl ether (CME), and 
thus reduce dose-limiting toxicities caused by systemic exposure. 
 In this chapter, we report the further evaluation of compounds 90 – 92 
using optimized endosome disruptors to induce toxicity. We also report proof-of-
concept experiments to characterize the release of disulfide-linked cargo from 
conjugated antibodies. Furthermore, we describe current and future work 
involving conjugation of endosome disruptive peptides with antibodies to 
generate dual-antibody delivery systems targeting tumor cells that overexpress 
two different cell surface receptors. 
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4.3 Release of Cytotoxic Cargo using Optimized Endosome Disruptors 
 In order to further characterize the release of bioactive molecules, we 
evaluated compounds 90 – 92 in two different cell lines using optimized 
endosome disruptors. Endosome disruptor 80 does not contain the membrane 
anchor, but still demonstrated sub-micromolar endosome disruption activity 
based on release of the fluorescent probe 3 in Jurkat lymphocytes. As shown in 
Table 4.2, co-treatment of 91 with endosome disruptor 80 shows >100-fold 
induction of toxicity versus 91 alone in Jurkat lymphocytes. As a control, the 
colchinol probe 92 shows greatly reduced toxicity when co-treated with 80 due to 
the increased stability of the amide-containing linker. In SKBr3 breast cancer 
cells, co-treatment of 91 with 80 shows significantly less potency, with only a 7-
fold induction of toxicity observed versus 91 alone. Because of this result, we 
evaluated 80 and other endosome disruptors that lack a membrane anchor in 
multiple adherent cell lines. For reasons that are unclear, it was found that the 
endosome disruptive activity of compounds lacking the membrane anchor is 
greatly reduced in most adherent cell lines. This difference may relate to 
differential rates of pinocytosis of the endosome disruptive peptide. 
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Figure 4.4. Toxicity analysis of compounds 90 – 92 in the presence and absence 
of endosome disruptor 80. Jurkat lymphocytes (A) treated for 48 h or SKBr3 cells 
(B) treated for 72 h with and without 80 (1 µM). Analysis performed by flow 
cytometry and fit by non-linear regression to provide IC50 values. C) Structure 
and activity data for endosome disruptor 80. 
 
 
 
Table 4.2. IC50 values of compounds 90 – 92 in Jurkat or SKBr3 cells. Endosome 
disruptor 80 was used to induce release of the cytotoxic CME warhead. MA = 
Membrane Anchor. ED = Endosome Disruptor. 
 
 In contrast to 80, the membrane anchored endosome disruptor 84 
demonstrated robust activity in both the Jurkat and SKBr3 cell lines (Figure 4.5 
Jurkat cells SKBr3 cells
(IC50, µM) (IC50, µM)
90 (NACME) 0.02 0.02
91 (MA-Disulfide-CME) 18 5.1
92 (MA-Amide-CME) >>10 21
91 + 80 (MA-Disulfide-CME + ED) 0.13 0.7
92 + 80 (MA-Amide-CME + ED) 1.5 7.2
80 (ED alone) 23 20
Compound Added
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and Table 4.3). In Jurkat lymphocytes, a 200-fold increase in toxicity was 
observed for 91 when co-treated with 84. In SKBr3 cells, a 100-fold increase in 
toxicity was observed. In both of these cell lines, the combination of 91 and 84 
produced toxicity nearly equipotent to the parent drug NACME (90). Again, the 
more stable amide-linked compound 92 demonstrated greatly reduced toxicity in 
both cell lines. 
 
	  
 
Figure 4.5. Toxicity analysis of compounds 90 – 92 in the presence and absence 
of endosome disruptor 80. Jurkat lymphocytes (A) treated for 48 h or SKBr3 cells 
(B) treated for 72 h with and without 80 (1 µM). Analysis performed by flow 
cytometry and fit by non-linear regression to provide IC50 values.  C) Structure 
and activity data for endosome disruptor 84. 
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Table 4.3. IC50 values of compounds 90 – 92 in Jurkat or SKBr3 cells. Endosome 
disruptor 84 was used to induce release of the cytotoxic CME warhead. MA = 
Membrane Anchor. ED = Endosome Disruptor. 
 
Based on these results, we moved forward to preliminary studies with 
antibody conjugates using membrane anchored endosome disruptors. For 
reasons discussed in the previous chapter, the requirement of the cholesterol-
based membrane anchor was not ideal. However for proof-of-concept 
experiments, these compounds were necessary to produce robust release of 
small molecule cargo in adherent cell lines. Elimination of the membrane anchor 
will be addressed later in this chapter as part of the future directions. 
 
4.4 Release of Disulfide-Linked Cargo from an Antibody Targeted to a 
Cell Surface Receptor 
 For proof-of-concept experiments aimed at releasing small molecule cargo 
from an antibody, we first synthesized compound 93 containing carboxy-
fluorescein linked through a disulfide to an NHS ester. This amine-reactive 
compound can be used to label lysine residues of an antibody and cleavage of 
Jurkat cells SKBr3 cells
(IC50, µM) (IC50, µM)
90 (NACME) 0.02 0.02
91 (MA-Disulfide-CME) 6.3 4.9
92 (MA-Amide-CME) >50 >10
91 + 84 (MA-Disulfide-CME + ED) 0.02 0.08
92 + 84 (MA-Amide-CME + ED) 0.67 7.5
84 (ED alone) 16 11
Compound Added
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the disulfide produces the same fluorescent cargo as compound 3 described in 
the previous chapter. 
 Several unconjugated or ‘naked’ antibodies are FDA-approved and used 
clinically in cancer chemotherapy. For our initial experiments we chose Herceptin 
(Trastuzumab, Genentech), a humanized IgG targeting human epidermal growth 
factor receptor 2 (HER2). This antibody has been used for over a decade to treat 
HER2 positive breast cancer and is also used in several ADCs including Kadcyla 
(Figure 4.3). 
	  
Figure 4.6. Structures of the fluorescein-disulfide NHS ester (93) and the 
conjugated anti-HER2 antibody Herceptin (94). 
 
 Using a standard protein labeling protocol and size-exclusion 
chromatography, Herceptin was conjugated with compound 93 to produce the 
fluorescent protein conjugate 94 (Figure 4.6). We first evaluated the binding and 
trafficking properties of this conjugate by confocal microscopy using HEK-293T 
cells that were transiently transfected with a plasmid expressing HER2 fused to 
cyan fluorescent protein (HER2-CFP, Figure 4.7, Panel B). HEK-293 cells 
express very low levels of HER2 and therefore do not bind Herceptin to a large 
extent. Upon treatment with 94, strong co-localization can be observed between 
the green fluorescent Herceptin conjugate and cells expressing the cyan HER2 
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fusion protein (Figure 4.7, Panel C). To evaluate release of the conjugated 
fluorophore, transfected cells were then co-treated with 94 and endosome 
disruptor 61. Co-treatment produced strong fluorescence in the cytosol and 
nucleus indicative of release of the fluorescent cargo (Figure 4.7, Panel D). 
 
	  
Figure 4.7. Cellular release of carboxyfluorescein from Herceptin in HEK-293 
cells that transiently express HER2-CFP.  A) Schematic representation of 
Herceptin uptake and release of the free fluorophore.  B) Confocal micrographs 
of HEK-293 cells transiently transfected with HER2-CFP for 48 h.  C) Treatment 
of HER2-CFP expressing cells with 94 (1 µM) for 24 h.  D) Co-treatment of 94 (1 
µM) with endosome disruptor 61 (1 µM) for 24 h. 
 
 We performed a similar experiment in SKBr3 cells, which endogenously 
overexpress HER2 on the cell surface. As shown in Figure 4.8, strong 
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fluorescence is observed on the plasma membrane of these cells when treated 
with 94. Upon co-treatment with endosome disruptor 78 (Figure 4.1), 
fluorescence is observed in the cytosol and nucleus (Figure 4.8, Panel C). These 
results demonstrate that an antibody targeted to a cell surface receptor can be 
used in conjunction with endosome disruptors such as 78 to efficiently deliver 
disulfide-linked small molecules. 
 
	  
Figure 4.8. Cellular release of carboxyfluorescein from Herceptin in HER2 
positive SKBr3 cells.  A) Schematic representation of Herceptin uptake and 
release of the free fluorophore.  B) Confocal micrographs of SKBr3 cells treated 
with 94 (1 µM) for 24 h.  C) Co-treatment of 94 (1 µM) with endosome disruptor 
78 (1 µM) for 24 h. 
 
 To expand on the previous results, we designed and synthesized 
compound 95, which allows antibody conjugation of our optimized colchinol 
methyl ether (CME) cytotoxin to antibodies. We labeled Herceptin with this 
compound to produce the antibody-drug conjugate 96 (Figure 4.9). Again using 
HER2-positive SKBr3 cells, we evaluated the toxicity of 96 by flow cytometry in 
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the presence and absence of endosome disruptor 78. Similar to the membrane-
anchored compound 91, we observed a >200-fold increase in toxicity of 96 in the 
presence of the endosome disruptor (Figure 4.8). This result indicates that we 
can significantly improve the toxicity of an ADC using endosome disruptors to 
facilitate the release of a conjugated cytotoxin. 
 
	  
Figure 4.9. Structures of the CME-disulfide NHS ester (95) and the conjugated 
anti-HER2 antibody Herceptin (96). 
 
 
	  
Figure 4.10. Toxicity analysis of CME-conjugated Herceptin (96) in the absence 
and presence of endosome disruptor 78. SKBr3 cells treated for 72 h with and 
without 78 (1 µM). Analysis performed by flow cytometry and fit by non-linear 
regression to provide IC50 values. 
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Table 4.4. IC50 values of compound 96 in the absence and presence of 
endosome disruptor 78 in SKBr3 cells. Endosome disruptor 78 was used to 
induce release of the cytotoxic CME warhead. ED = Endosome Disruptor. 
 
 
4.5 Future Directions: Specific Delivery of Small Molecule Cargo using 
Endosome Disruptor-Antibody Conjugates 
  Disruption of endosomes produces a significant increase in the potency of 
a disulfide-linked antibody-drug conjugate. This induction requires the use of 
membrane-anchored endosome disruptive peptides in adherent cell lines. The 
cholesterol moiety dramatically increases endosomal accumulation and 
consequently increases the potency of the conjugated peptide. However, it also 
significantly limits potential in vivo applications of endosome disruption due to 
poor pharmacokinetics and a lack of selectivity. 
 To address both of these limitations, we are currently focused on the 
development of peptides that can be conjugated to an antibody and produce 
endosome disruption in cells that overexpress a cell surface receptor (Figure 
4.11). Similar to cholesterol conjugation or ADCs, the antibody would provide 
significant accumulation of a linked peptide in endosomes and increase 
SKBr3 cells
(IC50, µM)
90 (NACME) 0.005
96 (Herceptin-S-S-CME) 14
96 + 78 (Herceptin-S-S-CME + ED) 0.05
78 (ED alone) 29
Compound Added
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endosome disruptive activity compared to the peptide alone. The design of the 
linker between the antibody and the peptide is perhaps the most critical aspect of 
this approach. The linker needs to be sufficiently stable to remain intact while in 
systemic circulation, but allow cleavage once a significant amount has 
accumulated in the target cells. Using fluorescence-based screening assays, we 
are currently focused on evaluating several linkers between Erbitux15, 32, 33, an 
FDA-approved antibody targeting the epidermal growth factor receptor (EGFR), 
and the peptide sequence of endosome disruptor 80. 
	  
Figure 4.11. Evaluation of endosome disruptors conjugated to an antibody 
targeted to the epidermal growth factor receptor (EGFR). A) Erbitux (anti-EGFR) 
is conjugated through lysine residues to the peptide sequence of 80 to screen 
various linkers. B) Schematic representation of the fluorescence-based screen 
using 3 to identify linkers that produce robust endosome disruption. 
	  
 Given that several cancer types overexpress multiple cell surface 
receptors14, 34, 35, it would be possible to use two different antibodies as part of 
the same therapy. An endosome disruptive antibody targeting a cell surface 
receptor coupled with a disulfide-linked antibody-drug conjugate targeting a 
second cell surface receptor could provide a chemotherapeutic system 
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potentially with excellent selectivity and minimal side effects (Figure 4.12). Since 
the toxicity of the ADC would be induced by endosome disruption, this dual-
antibody system may require lower doses than current ADCs for inhibition of 
tumor growth. 
	  
Figure 4.12. A novel strategy to produce tumor-specific toxicity based on co-
treatment with two antibodies targeted to cell surface recpetors. Either an 
antibody-drug conjugate or an antibody-endosome disruptor conjugate alone 
would produce no toxicity. The combination in endosomes would induce release 
of the disulfide-linked warhead and result in apoptosis. 
	  
4.6 Conclusions 
 We evaluated a disulfide-linked cytotoxin in two different cell lines using 
optimized endosome disruptors to induce its release and produce cellular toxicity. 
It was found that endosome disruptors that do not contain the cholesterol-based 
membrane anchor were less effective at inducing toxicity in adherent cell lines. 
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The cholesterol-conjugated derivatives, however, were effective at inducing 
toxicity, producing approximately a 100- to 200-fold increase in potency when co-
treated with the disulfide-linked cytotoxin 91. We then evaluated the release of 
small molecule cargo from an antibody targeted to a cell surface receptor. Using 
confocal microscopy, we observed robust release of fluorescent cargo 
conjugated to the anti-HER2 antibody Herceptin. The optimized colchinol cytoxin 
was then conjugated to Herceptin and evaluated for toxicity in HER2-positive 
SKBr3 cells. Similar to the cholesterol-linked system, the CME-Herceptin ADC 
produced a >200-fold increase in toxicity when co-treated with an endosome 
disruptor. This result indicates that the efficacy of an ADC can be enhanced by 
using endosome disruption to induce the release of a cytotoxin, while still 
maintaining selectivity provided by the antibody-receptor interaction. Current 
studies are focused on improving the activity of endosome disruptive peptides 
conjugated to an antibody by investigating the SAR in the linker. We envision 
utilizing this type of antibody conjugate to induce the toxicity of a second ADC to 
produce tumor-specific toxicity. This dual-antibody approach could lead to a 
chemotherapy system with a greatly improved therapeutic index compared to 
current ADC therapies. 
 
4.7 Experimental Section 
4.7.1 General 
Reagents were purchased from Sigma-Aldrich, Fisher Scientific, Acros, 
Aapptec, or EMD Biosciences. Colchicine (97) was purchased from Sigma-
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Aldrich. N-acetyl colchinol methyl ether (90)36, 37, de-acetyl colchinol methyl ether 
(98)36, 37, and Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic acid3 were 
prepared according to previously published methods. All endosome disruptor 
compounds were synthesized by Dr. Chamani Perera and characterization is 
provided in Chapter 3 of this dissertation. The colchinol methyl ether compounds 
91 and 92 were provided by Ning Yang in >95% purity and their corresponding 
syntheses and characterization are described in his Master’s thesis. 1H (400 
MHz) and 13C (101 MHz) NMR spectra were acquired a Bruker Avance 400 
instrument. Chemical shifts are reported in ppm and are referenced to CDCl3 (1H 
7.26 ppm; 13C 77.2 ppm).  Coupling constants JHH are in hertz and are reported 
as follows: chemical shift, multiplicity (app = apparent, s = singlet, d = doublet, t = 
triplet, q = quartet, dd = doublet of doublets), coupling constant, and integration. 
Melting points were acquired using a Thomas Hoover Capillary Melting Point 
Apparatus and are uncorrected. Infrared spectra (IR) were recorded with a 
Perkin-Elmer Spectrum 100 FT-IR spectrophotometer. UV/Vis measurements 
employed an Aligent 8452A diode array spectrophotometer.  High-resolution 
mass spectra were obtained at the Mass Spectrometry Laboratory at the 
University of Kansas. Low-resolution mass spectra were acquired on a Waters 
Micromass ZQ instrument with electrospray ionization (ESI+). Thin layer 
chromatography (TLC) used EMD aluminum-backed silica plates (0.20 mm, 60 
F-254), and flash chromatography used ICN silica gel (200-400 mesh). Plates 
were visualized by UV or staining with phosphomolybdic acid. Preparative HPLC 
was performed with an Agilent 1200 instrument equipped with a Hamilton PRP-1 
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reverse phase column (250 mm length, 21 mm ID, 12-20 µm particle size) with 
detection by absorbance at 215, 254, and 350 nm.  All non-aqueous reactions 
were carried out using flame- or oven-dried glassware under an atmosphere of 
dry argon or nitrogen. Reaction solvents were purified via filtration through two 
columns of activated basic alumina under an atmosphere of Ar using a solvent 
purification system from Glass Contour. Other commercial reagents were used 
as received unless otherwise noted. Yields are reported based on isolated 
material. 
 
4.7.2 Synthetic Procedures and Characterization Data 
 
5-((2-((3-((2,5-dioxopyrrolidin-1-yl)oxy)-3-oxopropyl)disulfanyl)ethyl) 
carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (93). Fmoc-3-
((2-aminoethyl)disulfanyl)propanoic acid3 (28 mg, 0.070 mmol) was dissolved in 
DMF (1 mL) containing 20% piperidine and stirred at 22 °C for 30 min. The 
solvent was removed under vacuum to provide the primary amine. 5-Carboxy 
fluorescein NHS ester (17 mg, 0.035 mmol) was dissolved in dry DMF (2 mL) 
and added to the primary amine along with DIEA (0.2 mL). The reaction was 
stirred at 22 °C for 16 h. Following completion, the solvent was removed under 
vacuum, the residue was re-dissolved in DCM containing 5% methanol, applied 
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to a short silica plug, and eluted with 90/10 DCM/MeOH. The solvent was 
removed to give the crude carboxylic acid product.  This product (~15 mg) was 
dissolved in DMF (2 mL) and EDC (11 mg, 0.06 mmol) and N-
hydroxysuccinimide (NHS, 7 mg, 0.06 mmol) were added. The reaction was 
allowed to stir at 22 °C for 16 h. The solvent was removed under vacuum, and 
the residue was dissolved in DMSO (2 mL) and purified by preperative RP-HPLC 
(Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA (0.1%) over 20 min; 
elution time =  12 min).  Pure fractions were collected, combined, and dried under 
vacuum to give 93 (9 mg, 0.014 mmol, 39% overall yield) as a yellow solid. 1H 
NMR (400 MHz, CD3OD) δ 8.44 (s, 1H), 8.21 (d, J = 9.6 Hz, 1H), 7.31 (d, J = 8.0 
Hz, 1H), 6.71 (d, J = 2.4 Hz, 2H), 6.67 – 6.51 (m, 5H), 3.76 (t, J = 6.6 Hz, 2H), 
3.17 – 2.99 (m, 5H), 2.83 (s, 4H); 13C NMR (101 MHz, CD3OD) δ 174.9, 172.5, 
171.8, 171.6, 168.8, 168.5, 162.3, 154.2, 154.1, 130.4, 130.3, 129.9, 129.2, 
126.3, 125.8, 124.9, 103.6, 40.4, 38.5, 33.4, 31.8, 26.3; IR (film) νmax 3340, 2926, 
2853, 1735, 1618, 1454, 1203, 1115, 1070, 994, 851, 761 cm-1; HRMS (ESI+) 
m/z 659.0740 (M+Na+, C30H24N2O10S2Na requires 659.0765). 
 
 
Figure 4.13. Synthesis of compound 99. Reagents and Conditions: a) succinic 
anhydride, DCM, DIEA, 16 h, 22 °C. 
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4-oxo-4-(((5S)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-dibenzo[a,c][7] 
annulen-5-yl)amino)butanoic acid (99).  Detailed synthetic procedures and 
characterization data of de-acetyl colchinol methyl ether hydrochloride (98) have 
been previously described.36, 37 De-acetyl colchinol methyl ether hydrochloride 
(98, 97 mg, 0.264 mmol) was dissolved in dichloromethane (10 mL) and washed 
with 1 M aq. NaOH (5 mL) to provide the free primary amine.  The organic phase 
was collected, dried over Na2SO4, and concentrated under vacuum.  The primary 
amine was re-dissolved in dry DCM (2 mL) containing diisopropylethylamine 
(DIEA, 0.2 mL).  Succinic anhydride (53 mg, 0.526 mmol, 2 equiv.) was added 
and the reaction was allowed to stir overnight at room temperature.  Upon 
completion, the reaction mixture was loaded directly onto silica and subjected to 
flash chromatography (gradient elution of 99/1 to 9/1 DCM/MeOH) to yield 99 (92 
mg, 0.214 mmol, 81% yield) as an off-white solid. 1H NMR (400 MHz, CDCl3) δ 
7.39 (d, J = 8.4 Hz, 1H), 6.84 (s, 1H), 6.74 (d, J = 7.9 Hz, 1H), 6.56 (s, 1H), 4.72 
(m, 1H), 3.90 (s, 3H), 3.88 (s, 3H), 3.79 (s, 3H), 3.52 (s, 3H), 2.62 – 2.22 (m, 7H), 
1.80 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 176.3, 171.9, 159.0, 152.6, 151.3, 
141.4, 140.6, 134.9, 131.4, 126.8, 125.0, 111.2, 109.2, 107.9, 77.5, 77.2, 76.9, 
61.4, 61.1, 56.3, 55.4, 49.8, 39.4, 30.9, 30.7, 29.7; IR (film) νmax 2934, 1717, 
1651, 1607, 1544, 1484, 1456, 1402, 1292, 1267, 1237, 1194, 1144, 1100, 1003, 
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914, 827, 732, 701 cm-1; HRMS (ESI+) m/z 452.1659 (M+Na+, C23H27NO7Na 
requires 452.1685). 
 
Figure 4.14. Synthesis of compound 95. Reagents and Conditions: a) EDC, 
NHS, DIEA, DMF, 16 h, 22 °C; b) 30% TFA in DCM, 1 h, 22 °C. 
 
 
 
(4R)-5-((2-((3-((2,5-dioxopyrrolidin-1-yl)oxy)-3-oxopropyl)disulfanyl)ethyl) 
amino)-5-oxo-4-(3-(4-oxo-4-(((5R)-3,9,10,11-tetramethoxy-6,7-dihydro-5H-
dibenzo[a,c][7]annulen-5-yl)amino)butanamido)propanamido)pentanoate N-
hydroxysuccinimidyl ester (95).  Solid phase peptide synthesis (SPPS) 
employed a 50 mL peptide synthesis vessel (Quark Glassware) with a wrist 
action shaker and standard Fmoc amino acid methodology. The peptide was 
constructed with 2-chlorotrityl resin (0.89 mmol/g, 112 mg, 0.1 mmol) using 
Fmoc-protected 3-((2-aminoethyl)disulfanyl)propanoic acid3, compound 99, and 
the following Fmoc-protected amino acids: Fmoc-β-Ala-OH, Fmoc-Glu(Ot-Bu)-
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OH. Amino acids were consecutively coupled to the resin by addition of DMF 
solution (2 mL) of amino acid (4.0 eq.), HATU (3.8 eq.) and DIEA (8.0 eq.) with 
shaking at 22 oC for 3 h. Deprotection of Fmoc carbamates on the resin was 
carried out by addition of piperidine (20%) in DMF (1.5 mL for 1 min (4x) with 
bubbling nitrogen for agitation). After completing all the steps of coupling 
reactions, the peptide was cleaved from the resin by treatment with a mixture of 
DCM/TFE/acetic acid (7:2:1) with shaking for 2 h. The resin was removed by 
filtration and washed with DCM (2 mL, 3x). The filtrates were combined and 
concentrated under vacuum.  To ensure complete removal of acetic acid, the 
crude product (100) residue was azeotroped under vacuum from a mixture of 
methanol/toluene (1:3, 3 x 2 mL). 
 
The crude peptide (100, 16 mg) containing a free C-terminal carboxylic acid was 
dissolved in dry DCM (2 mL).  Ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC, 10 mg, 0.052 mmol) was added and allowed to stir at room temperature 
for 15 min.  N-Hydroxysuccinimide (NHS, 7 mg, 0.060 mmol) was then added 
and the reaction was allowed to stir overnight.  Upon completion, the reaction 
mixture was dried under vacuum, re-dissolved in DCM containing 30% TFA and 
allowed to stir for 1 h to remove the tert-butyl ester protecting group.    The 
solvent was removed under vacuum, and the residue was dissolved in DMSO 
(1.5 mL) and purified by preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to 
(0:100) with added TFA (0.1%) over 20 min; elution time =  12 min).  Pure 
fractions were collected, combined, and dried under vacuum to give 95 (5 mg, 
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0.006 mmol, 6% overall yield) as a white solid. HRMS (ESI+) m/z 912.2705 
(M+Na+, C40H51N5O14S2Na requires 912.2772). 
	  
Figure 4.15. Analytical HPLC trace of 95 following purification by preparative 
HPLC. Purity >95% by integration of chromatogram. Monitored by UV 
absorbance at 254 nm. 
	  
	  
	  
	  
	  
4.7.3 Biological Assays and Protocols 
General. Reagents were purchased from Sigma-Aldrich, Fisher Scientific, and 
Acros Organics. Cell culture reagents were from Sigma-Aldrich.  Herceptin 
(trastuzumab) was kindly provided by Prof. Liang Xu (KU Molecular Biosciences). 
UV/Vis absorbance measurements to determine antibody concentration and 
degree of labeling employed a NanoDrop 6000 spectrophotometer. The HER2-
CFP expression plasmid was purchased from AddGene (Plasmid #40268). 
Transfection of plasmids employed the XTremeGene HP reagent (Roche) 
according to the commercial protocol. 
 
Cell culture. Jurkat lymphocytes (human acute leukemia, ATCC #TIB-152) were 
cultivated in Roswell Park Memorial Institute (RPMI) 1640 media. SKBr3 cells 
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(ATCC #HTB-30) were cultivated in DMEM/F12K media. HEK-293T cells were 
cultivated in DMEM media. All media were supplemented with Fetal Bovine 
Serum (FBS, 10%), penicillin (100 units/mL), and streptomycin (100 µg/mL) and 
cell lines were incubated in a humidified 5% CO2 incubator at 37 °C. Media used 
for cell culture and all wash steps contained antibiotics and 10% FBS unless 
otherwise noted. 
 
Microscopy. An inverted Leica TCS SPE confocal laser-scanning microscope 
fitted with a Leica 63X oil-immersion objective was employed for imaging. 
Fluorescent probes were excited with either a 405 nm (CFP) or 488 nm 
(fluorescein) solid-state laser and emitted photons were collected from 410-470 
nm or 495-600 nm, respectively.  HEK-293T or SKBr3 cells were imaged using 8-
well cover glass plates (Ibidi). To allow accurate comparisons of differences in 
cellular fluorescence, laser power and PMT gain settings were identical for all 
samples shown in a given figure. 
 
Analysis by Flow Cytometry of Cytotoxicity from Release of Disulfide-
Linked Colchinol.  Jurkat lymphocytes were suspended at 350,000 cells per mL 
in media and aliquoted into a 48-well plate at 500 µL per well.  SKBr3 cells were 
plated at 50,000 cells per well in 500 µL into 48-well plates. For wells treated with 
endosome disruptor, either 80 or 84 were added at 1 µM (diluted from a 10 mM 
DMSO stock) prior to aliquoting.  N-Acetyl Colchinol methyl ether (NACME, 90), 
the disulfide-linked colchinol probe 91, the amide control 92, or the CME-
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Herceptin conjugate 96 were added at various concentrations from 1 nM to 10 
µM (diluted from a 500x DMSO stock) in duplicate.  The samples were incubated 
at 37 °C for 48 or 72 h as indicated for each graph. For SKBr3 cells, each well 
was treated with 75 µL of 0.05% trypsin and incubated for 8 minutes at 37 °C. 
The trypsin was then neutralized with 150 µL of complete DMEM/F12K media. 
Cells were then analyzed by flow cytometry using an Accuri C6 flow cytometer.  
Forward scatter (FSC) and side scatter (SSC) were used to gate live cells and 
each well was sampled for exactly 10 seconds.  Cell viability was determined 
based on the total live cell count normalized to vehicle controls (as 100%). The 
normalized percent viability was plotted versus concentration and analyzed by 
non-linear regression in GraphPad Prism 5 to provide an IC50 value. 
 
Procedure for Labeling Herceptin with compounds 94 or 96. Lyophilized 
Herceptin was reconstituted in sterile water and the protein concentration was 
determined by absorbance at 280 nm (ε E1% = 13.7 L g-1 cm-1).  To remove 
stabilizing agents and salts, Sephadex G-25 resin (Superfine, Sigma) was 
suspended in PBS (pH 7.0). The resulting slurry (900 µL) was added to a mini-
spin column (USA Scientific) and centrifuged at 16,000 x G to remove the buffer 
and pack the resin. The solution containing Herceptin was loaded onto the 
packed resin of the spin column (50-70 µL per column) and centrifuged at 16,000 
x G for 1 min to separate the protein from the small molecules retained by the 
resin. The absorbance at 280 nm was used to determine the resulting 
concentration. 
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Either the fluorescent disulfide 93 or the CME disulfide 95 were dissolved in 
DMSO to give 10 mM stocks. Aqueous sodium bicarbonate (final concentration = 
50 mM, pH 8) was added to the Herceptin solution, followed by either 93 or 95 
(10 eq. from DMSO stock). Reaction of the NHS ester was allowed to proceed at 
37 °C for 20 min. To purify the conjugate, a Sephadex G-25 resin mini-column 
was used as described above (50 – 70 µL per column). The absorbance at 280 
nm and 495 nm (5-carboxyfluorescein, ε = 70,000 M-1 cm-1)38 of the eluent was 
used to determine the concentration and degree of protein labeling of 94. This 
protocol typically afforded 3-4 molecules of 93 per IgG molecule. It was assumed 
that this procedure also produced 3-4 molecules of 95 per IgG molecule since 
the ADC 96 contains no other distinguishable chromophore. 
 
Analysis by Confocal Microscopy of Release of Fluorophore from 94 by 
Endosome Disruption. HEK-293T or SKBr3 cells were plated at 25,000 cells 
per well in 300 µL into an 8-well cover glass. Cells were allowed to adhere for 24 
h at 37 °C.  
For transfection of HEK-293T cells. The HER2-CFP plasmid was co-treated with 
the XTremeGene HP reagent according to the manufacturers protocol at a ratio 
of 2 µL reagent per 1 µg of plasmid DNA. The transfection was allowed to 
proceed for 48 h at 37 °C. 
Cells were treated with the fluorescent Herceptin conjugate 94 (1 µM) in the 
absence and presence endsome disruptors 61 (1 µM, in HEK cells) or 78 (1 µM, 
in SKBr3 cells). Treatments were allowed to incubate at 37 °C for 24 h. Following 
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treatment, the wells were washed 3x with complete media and analyzed for 
fluorescence localization by confocal microscopy. 
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Chapter 5 
 
Detection of Protein-Protein Interactions by Proximity-Driven SNAr 
Reactions of a Lysine-Linked Fluorophore 
 
5.1 Introduction 
 Protein-protein interactions are involved in virtually every biochemical 
process that occurs in cell biology, from replication and growth signaling to 
apoptosis. Consequently, the identification and analysis of these interactions is of 
critical importance to a variety of scientific disciplines. Numerous methods have 
been developed to detect and characterize protein-protein interactions, from 
classical methods such as affinity blotting and immunoprecipitation to more 
modern techniques such as yeast two-hybrid assays, phage display, quantitative 
mass spectrometry, and NMR spectroscopy.1-5 Several fluorescence-based 
techniques have also been developed, including fluorescence polarization and 
fluorescence resonance energy transfer (FRET).6-8 These experiments typically 
involve a fluorescently labeled protein that undergoes a change in fluorescence 
intensity, wavelength, or polarization upon binding an interacting protein.  
Fluorescence-based methods generally provide a simple way to measure 
protein-protein interactions, however they are also subject to a variety of 
limitations. The protein under investigation typically requires labeling with a single 
fluorophore at a specific residue to produce a proper signal. Extensive labeling 
can dramatically decrease the signal-to-noise for the spectroscopic changes 
	   196 
observed in a protein complex. Moreover, fluorescence methods generally 
require purified and/or engineered protein(s) and can seldom be utilized in 
complex biological systems to identify unknown protein interactions. 
In this chapter, we report a new fluorescence-based method for the 
detection of protein-protein interactions. This method utilizes fluorinated pyronin 
fluorophores that readily react with lysine residues to form stable protein 
conjugates. However, when a labeled protein is in complex with an interacting 
partner, the high effective concentration of proximal lysine residues at the 
protein-protein interface provides a driving force for the reversible exchange of 
these fluorophores. The exchange of this label produces a fluorescent binding 
partner that can be easily detected by gel electrophoresis and/or proteomics 
methods (Figure 5.1). 
	  
Figure 5.1. Proximity-driven transfer of fluorinated pyronin fluorophores between 
lysine residues for detection of protein-protein interactions. 
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Several analogous methods of studying ligand-protein and protein-protein 
interactions have been developed utilizing proximity-driven reactivity of cysteine 
residues,9-11 lysine residues,12-15 label-transfer reagents,16-18 and other 
reactions.19, 20 However, proximity-driven exchange of a fluorophore between 
lysine residues at protein-protein interfaces has not been previously reported. 
 
5.2 Synthesis, Photochemical Properties, and Reactivity of Novel 
Fluorinated Pyronins 
 The Peterson lab recently published the synthesis of fluorinated 
xanthones such as compounds 101 – 103 (Figure 5.2).21 Treatment of these 
xanthones with triflic anhydride followed by tetrabutylammonium bromide 
(TBABr) produces the fluorinated bromopyronins 104 – 106. These compounds 
are stable solids, but react quickly with amine nucleophiles to produce 
aminopyronins such as the ethylamine derivatives 107 – 109. 
	  
Figure 5.2. Synthesis of bromopyronins (104 – 106) and aminopyronins (107 – 
109). Reagents and conditions: a) triflic anhydride, DCM, 5 min, 22 °C; b) TBABr, 
30 min, 22 °C; c) bubbling ethylamine, DCM, 1 min, 22 °C. 
 
The photophysical properties of compounds 104 – 109 are listed in Table 
5.1. The aminopyronins 107 - 109 possess photophysical properties similar to 
other published pyronin molecules.22, 23 The ethyl (107) and iso-propyl (108) 
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substituted molecules are excellent fluorophores (QY ~0.8) with large Stokes 
shifts of ~100 nm (Figure 5.3). The quantum yield of the tert-butyl substituted 109 
is significantly decreased, likely due to steric bulk causing a decrease in 
conjugation of the nitrogen lone pair electrons. To ensure that the fluorescence 
quantum yield of the aminopyronins would not be affected near neutral pH, the 
pKa of compounds 107 – 109 was determined using UV/Vis spectroscopy in 
phosphate-buffered saline (PBS). The absorbance spectra of these compounds 
were unaffected in buffer ranging from pH 4 – 9, however deprotonation was 
observed at higher pH and provided the pKa values listed in Table 5.1. 
 
	  
Figure 5.3. Absorbance and fluorescence emission spectra for bromo- and 
aminopyronins 104 – 109 in PBS (pH 7.0). 
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Table 5.1. Photochemical properties of bromo- and aminopyronins 104 – 109 in 
PBS. pKa measured by change in absorbance at λmax as a function of pH and fit 
to a non-linear regression. Φ = Quantum Yield 
 
To determine whether fluorinated aminopyronins could undergo 
nucleophilic aromatic substitution (SNAr) with amines, we followed the reactivity 
of compounds 107 – 109 in the presence of excess methylamine by low-
resolution mass spectrometry. As shown in Figure 5.4, aminopyronins 107 – 109 
are highly stable under physiological conditions in buffered aqueous solutions. 
Treatment of these compounds with a large excess of methylamine (10 mM) 
resulted in <1% reaction after 96 h. However, under the same conditions in non-
buffered methanol:water (9:1), the addition of methylamine (10 mM) resulted in 
the clean conversion to the substituted aminopyronins 110 – 112 in less than 24 
h. The reaction profiles were fit using pseudo first order kinetics to provide half-
times for the reaction of each compound. The reactivity of the tert-butyl 
substituted 109 was ~2-fold higher than that of 107 and 108. This result 
correlated with the lower quantum yield and decreased pKa of 109 resulting from 
decreased conjugation of the nitrogen lone pair electrons. 
ε (λmax) Abs. Em.
R = (M-1 cm-1) (λmax, nm) (λmax, nm) Φ pKa
104 Et 77,300 530 552 0.72 -
105 i-Pr 76,000 532 554 0.74 -
106 t-Bu 62,100 532 554 0.50 -
107 Et 40,600 410 515 0.78 11.2
108 i-Pr 40,600 414 512 0.83 10.8
109 t-Bu 34,500 414 515 0.45 9.9
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Figure 5.4. SNAr exchange of amine substituent of aminopyronins. (A) Reaction 
scheme of ethylaminopyronins 107 – 109 in buffered aqueous or organic 
solutions. (B) Reaction kinetics of conversion of 107 – 109 (50 µM) to 110 – 112 
by reaction with methylamine (10 mM) at 37 °C. 
 
5.3 SNAr Exchange of Aminopyronins between Lysine Residues at the 
Interface of a Model Protein-Protein Interaction 
 We hypothesized that the unique reactivity of fluorinated aminopyronins 
may be useful for the detection of protein-protein interactions. Using the 
ethylamine-substituted compounds 107 – 109 as model substrates, we found that 
these molecules are highly stable under physiological conditions in a buffered 
aqueous environment. However under more basic conditions, these molecules 
readily react to exchange their amine substituents through SNAr. The high 
effective concentration of proximal lysine residues at the interface of a protein-
protein interaction could provide a driving force for the exchange of these 
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fluorophores from donor to acceptor lysines. As a result, protein partners could 
be revealed by simple SDS-PAGE analysis with fluorescence detection. 
 We chose to evaluate this hypothesis by studying the well-known 
interaction between the constant region (Fc) of human immunoglobulin-G (IgG, 
150 kDa) and Protein A from Staphylococcus aureus (SpA, 42 kDa).24, 25 SpA 
binds the Fc region of IgG with a Kd of approximately 20 – 150 nM.24 We used 
the bromopyronins 104 – 106 to label lysine residues of human IgG to produce 
the aminopyronin conjugates 113 – 115. The reaction mixtures were purified by 
size exclusion chromatography and typically provided IgG conjugates with a 
fluorophore:antibody ratio of 3 – 4. Conjugates 113 – 115 were then added to 
aqueous buffer (pH 7.4) containing both SpA and bovine serum albumin (BSA, 
66 kDa) as a non-binding control. As shown in Figure 5.5, transfer of the 
fluorophore was observed from IgG to SpA, but not to BSA, following analysis by 
SDS-PAGE with fluorescence imaging. Each of the conjugates showed a 
significant amount of transfer after 16 h, but conjugate 114 demonstrated the 
best properties upon quantification of the fluorescent SpA bands. The iso-propyl 
aminopyronin benefits from intermediate reactivity and the highest quantum yield 
compared to the ethyl or tert-butyl substituted molecules. 
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Figure 5.5. Analysis of transfer of pyronins between proteins. Human IgG was 
conjugated to pyronins 104 (A), 105 (B), and 106 (C), added at 5 µM to PBS (pH 
7.4) containing unlabeled SpA (5 µM) or BSA (5 µM), allowed to react at 37 °C, 
and analyzed by SDS-PAGE with fluorescence detection. Quantification of the 
fluorescence of SpA bands is shown on the bottom. 
 
 
 SpA consists of five homologous binding domains that each have high 
binding affinity for the Fc region.26 This protein has also been shown to bind the 
variable Fab fragments of some IgG subclasses.27 To ensure that the Fc region 
of human IgG was responsible for the observed transfer, we labeled the lysine 
residues of purified human Fc region and Fab fragments using the iso-propyl 
bromopyronin 105 to produce conjugates 116 and 117. These conjugates, along 
with the IgG conjugate 114, were added to aqueous buffer containing SpA. The 
labeled Fc conjugate 116 demonstrated robust transfer of the aminopyronin to 
SpA, whereas the Fab conjugate 117 showed little to no transfer (Figure 5.6). 
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Figure 5.6. Analysis of transfer of pyronin from full-length human IgG (A), the 
IgG Fc region (B), and the IgG Fab fragment (C) to SpA. The IgG proteins were 
conjugated to pyronin 105, added at 5 µM to PBS (pH 7.4) containing unlabeled 
SpA (5 µM), allowed to react at 37 °C, and analyzed by SDS-PAGE with 
fluorescence detection. The bands shown are from a single gel where the 
proteins were analyzed in parallel. Quantification of background-subtracted total 
fluorescence of each SpA band is shown on the bottom. 
 
 
A second control experiment was done using human IgG conjugated to 5-
carboxyfluorescein (via an NHS ester, 118) or fluorescein isothiocyanate (FITC, 
119) through much more stable amide or thiourea linkages. These two amine-
reactive fluorophores are commercially available and commonly used to label 
proteins of interest. Using similar conditions, these two conjugates showed no 
transfer of fluorophore to SpA (Figure 5.7), confirming that the unique reactivity of 
fluorinated aminopyronins is critical for the detection of protein-protein 
interactions. 
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Figure 5.7. Examination of the extent of transfer of other fluorophores from IgG 
to SpA. Panels A-C: Comparison of the structures of the fluorophores of IgG 
conjugates. Panel D: Transfer of fluorophores from full-length human IgG to SpA 
as analyzed by SDS-PAGE with fluorescence detection. Human IgG was 
conjugated to pyronin 105, 5-carboxyfluorescein, or FITC. These conjugates 
were purified, added to PBS at 5 µM (pH 7.4) containing unlabeled SpA (5 µM), 
and allowed to react at 37 °C for 16 h. The bands shown in Panel D are from a 
single gel where the proteins were analyzed in parallel. In contrast to the pyronin 
conjugate 114, no transfer of fluorophore was observed with the amide-linked or 
thiourea-linked conjugates 118 or 119. 
 
 
 We further investigated the mechanism of pyronin transfer using 
proteomics methods to identify which lysine residues of SpA were labeled 
following transfer from IgG. Conjugate 114 was incubated with SpA for 18 h at 37 
°C to allow for pyronin transfer. Following incubation, 114 was removed from the 
protein mixture using a large excess of resin-bound SpA and the supernatant 
containing label-transferred SpA was analyzed by trypsin digestion and peptide 
sequencing by mass spectrometry. Remarkably, among the 118 total lysine 
residues of mature SpA, only four homologous residues, Lys-69, Lys-130, Lys-
188, and Lys-246, were found to exchange with the pyronins of IgG (Figure 5.8).  
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Figure 5.8. Analysis of fluorophore transfer from IgG conjugate 114 to SpA by 
trypsin digestion and MS/MS seqeuencing. The amino acid sequence of mature 
SpA (UniProt ID P02976) is shown with Fragments A – E aligned by homology. 
Lysine residues are colored red. Four dominant pyronin-modified tryptic peptides, 
identified with >99% probability, are shown boxed, with arrows illustrating sites of 
lysine modification. The underlined residues in Fragment B represent the 
residues visible in the X-ray crystal structure of IgG Fc-SpA (Figure 5.9). 
 
 
To investigate the molecular basis for this specific reactivity, we examined 
the X-ray crystal structure of the Fc region of human IgG bound to Fragment B of 
SpA (Figure 5.9).28 This structure illustrates that the ε-amino groups of Lys-246 of 
SpA and Lys-288 of IgG reside within 5 – 9 Å of each other and represent the 
most proximal lysine residues in the protein complex. The proximity of these 
residues explains the highly selective reactivity of Lys-246 in Fragment B and the 
homologous residues Lys-69, Lys-130, and Lys-188 in Fragments E, D, and A, 
respectively. 
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Figure 5.9. Panel A: X-ray structure of the Fc region of human IgG (blue) bound 
to Fragment B of SpA (red, PDB ID 1FC2). Carbohydrates of the IgG were 
omitted for clarity. Lysine residues are shown as CPK models. Panel B: 
Mechanism of molecular transfer of pyronin between lysine residues of SpA and 
IgG. 
 
 
5.4 Detection of a Protein-Protein Interaction in a Complex Biological 
System 
 Based on the ability to detect a model protein-protein interaction, we 
hypothesized that this approach could be used to detect protein-protein 
interactions in complex biological systems, such a cell extract. To evaluate this, 
we examined another well-known protein-protein interaction between 
ribonuclease A (Rnase A, 14 kDa) and ribonuclease inhibitor (50 kDa).29, 30 
Rnase inhibitor is a constitutively expressed cytosolic protein comprising 
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approximately 0.1% of total cellular protein. Its abundance provides an excellent 
starting point for validation of this method in a complex biological matrix.31 
Moreover, a crystal structure of the interaction between bovine Rnase A and 
porcine Rnase inhibitor illustrates several lysine residues in close proximity that 
may undergo fluorophore transfer (Figure 5.10, Panel A).30, 32 
	  
Figure 5.10. Panel A: X-ray structure of bovine Rnase A (red) bound to porcine 
Rnase inhibitor (blue, PDB ID 1DFJ) illustrating the proximity of lysine residues 
(CPK models) in the complex. Panels B – C: SDS-PAGE gel imaged by 
fluorescence (B) followed by staining of the same gel with coomassie (C). Lane i: 
protein MW marker; ii: Pyronin-conjugated Rnase A alone; iii: Reaction of 
pyronin-conjugated bovine Rnase A (20 µM) with recombinant human Rnase 
inhibitor (20 µM) for 18 h at 37 °C; iv: Reaction of pyronin-conjugated bovine 
Rnase A (20 µM) with a crude HeLa cell extract for 18 h at 37 °C. The arrows 
show specific proteins identified by comparison with authentic standards. 
 
 
We conjugated bovine Rnase A to bromopyronin 105 using a procedure 
similar to the conjugation of human IgG. The solubility of pyronin-labeled bovine 
Rnase A was significantly reduced, allowing for only 0.3 – 0.6 fluorophores per 
protein molecule. Nevertheless, this conjugate was added to both purified 
recombinant human Rnase inhibitor and a crude protein extract of HeLa cells. 
Following incubation at 37 °C, SDS-PAGE analysis revealed the transfer of 
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fluorophore to both recombinant Rnase inhibitor and endogenous Rnase inhibitor 
in a HeLa extract (Figure 5.10, Panel B). These proteins, along with fluorescent 
Rnase A and its oligomers33, were identified by co-migration with authentic 
standards. Following fluorescence imaging, the gel was then stained using 
coomassie blue to reveal total cellular protein (Figure 5.10, Panel C). A 
comparison of the limited number of fluorescent bands with the abundance of 
total protein present demonstrated the remarkable selectivity of this method for 
detecting interacting proteins. 
 
5.5 Conclusions 
 We demonstrated that fluorinated pyronin fluorophores are unique tools 
for the detection of protein-protein interactions. These molecules form highly 
stable protein conjugates under physiological conditions (pH 7.4), even in the 
presence of high concentrations of other soluble amines. However, the high 
effective concentration of amines between lysine residues at a protein-protein 
interface can produce a proximity-driven SNAr reaction to transfer these 
fluorescent labels and enable detection of interacting partners. Given that lysine 
is one of the most common amino acids on protein surfaces34, and these 
residues are often in close proximity at the interface of a protein complex, this 
method may be useful for the discovery of novel protein-protein interactions 
and/or small molecule inhibitors35, 36 of these interactions. 
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5.6 Experimental Section 
5.6.1 General 
 Reagents were purchased from Sigma Aldrich, Fisher Scientific, Acros, or 
Aapptec. 1H (500 MHz) and 13C (125 MHz) NMR spectra were acquired on 
Bruker DRX-500 or Bruker Avance AV-III 500 instruments. Chemical shifts are 
reported in ppm and are referenced to CD3CN (1.94 ppm for 1H and 118.3 ppm 
for 13C) or CD3OD (3.31 ppm for 1H and 49.0 ppm for 13C). 1H and 13C NMR 
spectra of compounds 7-9 were acquired at 65 °C. Coupling constants JHH are in 
hertz and are reported as follows: chemical shift, multiplicity (app = apparent, s = 
singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets), coupling 
constant, and integration. Melting points were acquired using a Thomas Hoover 
Capillary Melting Point Apparatus and are uncorrected. Infrared spectra (IR) were 
recorded with a Perkin-Elmer Spectrum 100 FT-IR spectrophotometer. UV/Vis 
measurements employed an Aligent 8452A diode array spectrophotometer. 
Fluorescence measurements used a Perkin-Elmer LS55 spectrometer. High-
resolution mass spectra were obtained at the Mass Spectrometry Laboratory at 
the University of Kansas. Low-resolution mass spectra were acquired on a 
Waters Micromass ZQ instrument with electrospray ionization (ESI+). Thin layer 
chromatography (TLC) used EMD aluminum-backed silica plates (0.20 mm, 60 
F-254), and flash chromatography used ICN silica gel (200-400 mesh). Plates 
were visualized by UV or staining with ceric sulfate/molybdic acid. Preparative 
HPLC was performed with an Agilent 1200 instrument equipped with a Hamilton 
PRP-1 reverse phase column (250 mm length, 21 mm ID, 12-20 µm particle size) 
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with detection by absorbance at 215, 254, and 350 nm.  All non-aqueous 
reactions were carried out using flame- or oven-dried glassware under an 
atmosphere of dry argon or nitrogen. Dichloromethane used as reaction solvent 
was purified via filtration through two columns of activated basic alumina under 
an atmosphere of Ar using a solvent purification system from Glass Contour. 
Other commercial reagents were used as received unless otherwise noted. 
Yields are reported based on isolated material. 
 
5.6.2 Synthetic Procedures and Characterization Data 
General procedure A: Synthesis of bromopyronins (104 – 106) from xanthones 
(101 – 103). Xanthones, prepared as previously reported,21 were added to round-
bottom flasks containing dry DCM (2 – 3 mL). Trifluoromethanesulfonic anhydride 
(1 M in DCM, 1.5 eq.) was added dropwise with stirring, and the reaction mixture 
transitioned from pale yellow to bright red. The reaction was stirred at room 
temperature (22 °C) for 5 min. After this period, tetrabutylammonium bromide (3 
eq.) was added, and the reaction was stirred at room temperature for an 
additional 30 min. The reaction mixture was loaded onto silica gel and subjected 
to flash chromatography (eluent: DCM:CH3CN, 20:1 to 3:1). Eluted fractions 
containing pure material were combined and concentrated by rotary evaporation. 
The resulting residue was dissolved in a minimal amount of DCM and 
precipitated with excess diethyl ether. The resulting red solid was filtered, 
washed extensively with diethyl ether, and dried under high vacuum to yield pure 
products as trifluoromethanesulfonate salts. 
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General procedure B. Synthesis of ethylaminopyronins (107 – 109) from 
bromopyronins (104 – 106). The bromopyronin starting material was added to a 
round-bottom flask containing dry CH2Cl2 (1 – 2 mL). Gaseous ethylamine was 
bubbled through the solvent with stirring for 1 min or until the bright red color was 
eliminated and the solution became yellow. The solvent was removed under 
vacuum, the residue was dissolved in DMSO, and the product purified by 
preparative RP-HPLC (Gradient: H2O:CH3CN (9:1) to (0:100) with added TFA 
(0.1%) over 20 min; elution time = 11 – 13 min). Pure fractions were collected, 
combined, and dried under high vacuum. 
 
 
N-(9-bromo-6-(ethylamino)-2,7-difluoro-3H-xanthen-3-ylidene)ethanaminium 
trifluoromethanesulfonate (104). Following general procedure A, 3,6-
bis(ethylamino)-2,7-difluoro-9H-xanthen-9-one (101, 104 mg, 0.327 mmol) 
yielded compound 104 (128 mg, 0.241 mmol, 73%), a red solid, as the 
trifluoromethanesulfonate salt. mp 222-226 °C; 1H NMR (500 MHz, CD3CN) δ 
7.81 (d, J = 11.7 Hz, 2H), 7.15 (s, 2H), 6.87 (d, J = 6.8 Hz, 2H), 3.51 (qd, J = 7.2, 
5.7 Hz, 4H), 1.36 (t, J = 7.2 Hz, 3H); 13C NMR (126 MHz, CD3CN) δ 155.77, 
151.81 (d, J = 251.6 Hz), 149.37 (d, J = 15.6 Hz), 148.10 (t, J = 5.6 Hz), 122.05 
(q, J = 320.8 Hz), 115.24 (d, J = 9.5 Hz), 113.73 (d, J = 23.4 Hz), 96.33 (d, J = 
4.2 Hz), 39.39, 13.72;  IR (film) nmax 3272, 2978, 1621, 1582, 1524, 1480, 1321, 
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1253, 1139, 1032, 856 cm-1; HRMS (ESI) m/z 381.0419 (M+, C17H16BrF2N2O+ 
requires 381.0409).  
 
 
N-(9-bromo-6-(isopropylamino)-2,7-difluoro-3H-xanthen-3-ylidene)propan-2-
aminium trifluoromethanesulfonate (105). Following general procedure A, 2,7-
difluoro-3,6-bis(isopropylamino)-9H-xanthen-9-one (102, 90 mg, 0.268 mmol) 
yielded compound 105 (95 mg, 0.170 mmol, 63%), a red solid, as the 
trifluoromethanesulfonate salt.  mp 214-218 °C; 1H NMR (500 MHz, CD3CN) δ 
7.78 (d, J = 11.7 Hz, 2H), 6.93 (s, 2H), 6.89 (d, J = 6.8 Hz, 2H), 4.01 (dq, J = 
13.0, 6.5 Hz, 2H), 1.36 (d, J = 6.4 Hz, 12H); 13C NMR (126 MHz, CD3CN) δ 
155.82, 151.78 (d, J = 251.8 Hz), 148.53 (d, J = 15.6 Hz), 147.91 (t, J = 5.6 Hz), 
122.05 (q, J = 320.9 Hz), 115.18 (d, J = 9.5 Hz), 113.83 (d, J = 23.6 Hz), 96.58 
(d, J = 4.1 Hz), 46.92, 21.83; IR (film) nmax 3255, 2980, 1655, 1624, 1580, 1537, 
1523, 1487, 1426, 1360, 1324, 1271, 1203, 1151, 1034, 871 cm-1; HRMS (ESI) 
m/z 409.0714 (M+, C19H20BrF2N2O+ requires 409.0722). 
 
 
N-(9-bromo-6-(ethylamino)-2,7-difluoro-3H-xanthen-3-ylidene)-2-
methylpropan-2-aminium trifluoromethanesulfonate (106). Following general 
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procedure A, 3,6-bis(tert-butylamino)-2,7-difluoro-9H-xanthen-9-one (103, 84 mg, 
0.231 mmol) yielded compound 106 (82 mg, 0.139 mmol, 60%), a red solid, as 
the trifluoromethanesulfonate salt. mp 194-199 °C; 1H NMR (500 MHz, CD3CN) δ 
7.84 (d, J = 12.0 Hz, 2H), 7.12 (d, J = 6.9 Hz, 2H), 6.58 (s, 2H), 1.56 (s, 18H); 13C 
NMR (126 MHz, CD3CN) δ 155.27, 152.33 (d, J = 251.9 Hz), 148.70 (t, J = 5.6 
Hz), 147.94 (d, J = 14.2 Hz), 122.07 (q, J = 320.9 Hz), 115.40 (d, J = 9.8 Hz), 
113.46 (d, J = 24.6 Hz), 98.16 (d, J = 3.3 Hz), 54.92, 28.71; IR (film) nmax 2964, 
2877, 1620, 1520, 1471, 1344, 1260, 1147, 1030, 868 cm-1; HRMS (ESI) m/z 
437.1019 (M+, C21H24BrF2N2O+ requires 437.1035). 
 
 
N-(6,9-bis(ethylamino)-2,7-difluoro-3H-xanthen-3-ylidene)ethanaminium 
2,2,2-trifluoroacetate (107). Following general procedure B, compound 104 (53 
mg, 0.100 mmol) yielded compound 107 (40 mg, 0.087 mmol, 87%), a yellow 
solid, as the TFA salt. mp 136-140 °C; 1H NMR (500 MHz, CD3OD) δ 7.86 (d, J = 
13.3 Hz, 2H), 6.68 (d, J = 7.4 Hz, 2H), 4.00 (q, J = 7.2 Hz, 2H), 3.35 (q, J = 7.2 
Hz, 4H), 1.52 (t, J = 7.2 Hz, 3H), 1.33 (t, J = 7.2 Hz, 6H); 13C NMR (126 MHz, 
CD3OD) δ 162.93 (q, J = 34.5 Hz), 155.94, 155.45, 150.01 (d, J = 243.0 Hz), 
146.36 (d, J = 14.8 Hz), 118.41 (q, J = 293.8 Hz), 110.19, 101.60, 97.64 (d, J = 
4.5 Hz), 44.17, 38.68, 14.83, 13.98; IR (film) nmax 3441, 3264, 2985, 1686, 1650, 
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1624, 1512, 1471, 1314, 1197, 1174, 1124, 797, 718 cm-1; HRMS (ESI) m/z 
346.1698 (M+, C19H22F2N3O+ requires 346.1725). 
 
 
N-(9-(ethylamino)-2,7-difluoro-6-(isopropylamino)-3H-xanthen-3-
ylidene)propan-2-aminium 2,2,2-trifluoroacetate (108). Following general 
procedure B, compound 105 (34 mg, 0.061 mmol) yielded compound 108 (24 
mg, 0.050 mmol, 82%), a yellow solid, as the TFA salt. mp 174-178 °C; 1H NMR 
(500 MHz, CD3OD) δ 7.90 (d, J = 13.2 Hz, 2H), 6.77 (d, J = 7.4 Hz, 2H), 4.03 (q, 
J = 7.2 Hz, 2H), 3.85 (hept, J = 6.4 Hz, 2H), 1.52 (t, J = 7.2 Hz, 3H), 1.34 (d, J = 
6.4 Hz, 12H); 13C NMR (126 MHz, CD3OD) δ 162.94 (q, J = 25.4 Hz), 156.11, 
155.58, 150.02 (d, J = 243.1 Hz), 145.62 (d, J = 14.6 Hz), 118.46 (q, J = 306.2 
Hz), 110.37, 101.68, 98.15 (d, J = 4.3 Hz), 45.80, 44.16, 22.14, 14.81; IR (film) 
nmax 3265, 2923, 2852, 1650, 1623, 1589, 1518, 1479, 1324, 1168, 1142, 875, 
816, 760 cm-1; HRMS (ESI) m/z 374.2060 (M+, C21H26F2N3O+ requires 
374.2038). 
 
N-(6-(tert-butylamino)-9-(ethylamino)-2,7-difluoro-3H-xanthen-3-ylidene)-2-
methylpropan-2-aminium 2,2,2-trifluoroacetate (109). Following general 
procedure B, compound 106 (46 mg, 0.078 mmol) yielded compound 109 (32 
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mg, 0.061 mmol, 79%), a yellow solid, as the TFA salt. mp 166-170 °C; 1H NMR 
(500 MHz, CD3OD) δ 7.95 (d, J = 13.5 Hz, 2H), 7.04 (d, J = 7.6 Hz, 2H), 4.05 (q, 
J = 7.2 Hz, 2H), 1.54 – 1-50 (m, 21H); 13C NMR (126 MHz, CD3OD) δ 162.98 (q, 
J = 31.4 Hz), 156.34, 154.89, 150.53 (d, J = 242.8 Hz), 144.76 (d, J = 13.4 Hz), 
118.74 (d, J = 294.3 Hz), 110.16, 101.88, 100.18 (d, J = 3.5 Hz), 53.26, 44.16, 
29.13, 14.75; IR (film) nmax 3435, 3260, 2922, 2851, 1677, 1648, 1622, 1514, 
1470, 1320, 1199, 1170, 1132, 827, 798, 718 cm-1; HRMS (ESI) m/z 402.2336 
(M+, C23H30F2N3O+ requires 402.2351). 
 
Measurement of extinction coefficients (ε). Beer’s Law plots of absorbance 
versus concentration were measured in aqueous PBS (pH 7.0) with increasing 
concentrations of sample (Figure 5.11). Values for absorbance λmax were 
determined for all samples. Linear least squares fitting of the data (including a 
zero intercept) was used to determine the slope, which corresponds to the 
extinction coefficient. Molar absorptivity (M-1 cm-1) was calculated using the 
following equation (b = path length = 1 cm): Absorbance = [ε] [b] [concentration 
(M)] 
 
Measurement of quantum yields (Φ). Samples were excited at absorbance 
λmax and the integrated fluorescence emission was quantified (a 1 cm path length 
quartz cuvette was used). Fluorescein (Φ = 0.92 in 0.1 M NaOH) and 
carboxyfluorescein (Φ = 0.925 in 0.1 M NaOH) provided standards. The 
integrated fluorescence emission at a given concentration was plotted against 
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the maximum absorbance of the sample at that concentration determined by 
extrapolation based on absorbance measurements at higher concentrations 
(Figure 5.12). Linear least squares fitting of the data (including a zero intercept) 
was used to calculate the slope, which is proportional to the quantum yield. 
Quantum yields were calculated with the following equation using the average of 
the values measured for fluorescein and carboxyfluorescein as standards: Φx = 
Φst(Gradx/Gradst), where Φst represents the quantum yield of the standard, Φx 
represents the quantum yield of the unknown, and Grad is the slope of the best 
linear fit. 
 
Measurement of pKa values. Absorbance spectra for pyronins 107 – 109 (10 
µM in PBS) were obtained between pH 4 – 12. Samples were analyzed 
immediately upon adjustment to final pH values with aqueous HCl or NaOH to 
avoid potential hydrolysis. The absence of hydrolysis under these conditions was 
confirmed by analysis of absorbance spectra upon re-acidification of aliquots 
subjected to basic pH. The absorbance spectra of 107 – 109 did not change 
appreciably in the range of pH 4 – 9 (data not shown), but substantial changes in 
absorbance were observed at more basic pH values (Figure 5.13). Values for 
pKa were calculated using non-linear regression of pH-dependent changes in 
absorbance at 415 nm. 
 
Analysis of the kinetics of reaction of pyronins 107 – 109 with methylamine. 
To ethylaminopyronins 107 – 109 (50 µM) at 37 °C in either MeOH/H2O (9:1), or 
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H2O, was added aqueous methylamine (final [MeNH2]=10 mM). The pH of the 
reaction in pure H2O was adjusted to 7.4 by addition of conc. aq. HCl. Low-
resolution mass spectra were collected from three independent reactions of each 
pyronin over time. The integrated peak intensities of the ethyl-substituted starting 
materials and methyl-substituted products were summed and normalized to 
100% to quantify changes in starting material and product over time. The 
resulting curves, corresponding to pseudo first order kinetic profiles, were 
analyzed with an exponential one-phase association model (Prism 6 software) to 
calculate half-time values. 
 
	  
Figure 5.11. Determination of extinction coefficients (ε) in PBS (pH 7.0). 
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Figure 5.12. Determination of quantum yields (Φ) for pyronins 104 - 109. 
Fluorescein and 5-carboxyfluorescein in aqueous NaOH (0.1 M, Φ = 0.92) 
provided standards. Values for 104 – 109 were obtained in PBS (pH 7.0). 
	  
Figure 5.13. Determination of pKa values of aminopyronins 107 - 109. 
Absorbance at 415 nm was plotted as a function of pH and analyzed by non-
linear regression (Prism 6 software). Samples were analyzed immediately upon 
adjustment to final pH values with aqueous HCl or NaOH to avoid any potential 
hydrolysis. 
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Figure 5.14. 1H NMR (500 MHz) of 104 in CD3CN. 
 
 
	  
	  
Figure 5.15. 13C NMR (125 MHz) of 104 in CD3CN. 
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Figure 5.16. 1H NMR (500 MHz) of 105 in CD3CN. 
 
	  
Figure 5.17. 13C NMR (125 MHz) of 105 in CD3CN. 
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Figure 5.18. 1H NMR (500 MHz) of 106 in CD3CN. 
 
	  
Figure 5.19. 13C NMR (125 MHz) of 106 in CD3CN. 
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Figure 5.20. 1H NMR (500 MHz) of 107 in CD3OD at 65 °C. 
 
	  
Figure 5.21. 13C NMR (125 MHz) of 107 in CD3OD at 65 °C. 
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Figure 5.22. 1H NMR (500 MHz) of 108 in CD3OD at 65 °C. 
 
	  
Figure 5.23. 13C NMR (125 MHz) of 108 in CD3OD at 65 °C. 
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Figure 5.24. 1H NMR (500 MHz) of 109 in CD3OD at 65 °C. 
 
	  
Figure 5.25. 13C NMR (125 MHz) of 109 in CD3OD at 65 °C. 
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5.6.3 Biological assays and Protocols 
 
General. Reagents were purchased from Sigma-Aldrich, Fisher Scientific, and 
Acros Organics. Cell culture reagents were from Sigma-Aldrich. Staphylococcyl 
Protein A (SpA, recombinant) was obtained from GenScript. Human 
immunoglobulin-G and bovine ribonuclease A (from bovine pancreas) were from 
Sigma-Aldrich. Human IgG Fc region and human IgG Fab fragment were 
purchased from Athens Research and Technology.  Ribonuclease inhibitor 
(recombinant, human placental) was from New England BioLabs. Absorbance 
data for protein quantification were collected on a Thermo Scientific NanoDrop 
1000 spectrophotometer. Analysis by SDS-PAGE employed an XCell II module 
with Bis-Tris 4-12% polyacrylamide gradient gels (1.5 mm, Life Technologies) 
and MOPS-SDS running buffer (Life Technologies). An Alpha Imager MultiImage 
II Light Cabinet (DE-500) with UV excitation (365 nm) and a 560 ± 40 nm 
emission filter was used for fluorescence imaging of gels. Sequencing of tryptic 
peptides by mass spectrometry was performed by the KU Analytical Proteomics 
Laboratory (APL) with a Thermo Finnigan LTQ-FTICR hybrid mass spectrometer. 
 
Cell Culture. HeLa cells (ATCC #CCL-2) were cultivated in DMEM containing 
fetal bovine serum (FBS, 10%), penicillin (100 units/mL), and streptomycin (100 
µg/mL). Cells were grown in a humidified incubator (5% CO2) at 37 °C. 
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Procedure for labeling of human IgG with pyronins. Lyophilized human IgG 
was reconstituted in sterile water and the protein concentration was determined 
by absorbance at 280 nm (ε E1% = 13.7 L g-1 cm-1).37 The corresponding 
bromopyronin (104 – 106) was dissolved in ethanol at 10 mM. Aqueous sodium 
bicarbonate (final concentration = 50 mM, pH 8) was added to the protein 
solution, followed by the bromopyronin (10 equiv.) in ethanol. This reaction was 
allowed to proceed at 37 °C for 20 min. To purify the conjugate, Sephadex G-25 
resin (Superfine, Sigma) was suspended in PBS (pH 7.0). The resulting slurry 
(900 µL) was added to a mini-spin column (USA Scientific) and centrifuged at 
16,000 x G to remove the buffer and pack the resin. After the 20 min conjugation 
reaction, the solution containing the bromopyronin and IgG was loaded onto the 
packed resin of the spin column (50 – 70 µL per column) and centrifuged at 
16,000 x G for 1 min to separate the labeled protein from the small molecule 
retained by the resin. The absorbance at 280 nm and 425 nm of the eluent was 
determined to quantify the degree of protein labeling. This protocol typically 
afforded 3 – 4 molecules of pyronin per IgG molecule. 
 
Procedure for labeling of human IgG with commercial amine-reactive 
fluorophores. Lyophilized human IgG was reconstituted in sterile water and the 
protein concentration was determined by absorbance at 280 nm (ε E1% = 13.7 L 
g-1 cm-1).37 Aqueous sodium bicarbonate (final concentration = 50 mM, pH 8) was 
added to the protein solution.  The commercially available fluorophores 5-
carboxyfluorescein NHS-ester (10 equiv. from 10 mM DMSO stock solution) or 
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fluorescein isothiocyanate (G-isomer, 10 equiv. from 10 mM DMSO stock 
solution) were added and the reaction was incubated at 37 °C for 20 min.  
Purification of the conjugate protein was performed using Sephadex G-25 loaded 
spin columns as described above.  Typical labeling was 5 molecules of 5-
carboxyfluorescein per molecule protein and 4 molecules FITC per molecule 
protein. 
 
Procedure for labeling of human Fc and Fab regions with pyronins. Human 
Fc and Fab regions were obtained as aqueous solutions ([Fc] = 1.5 mg/mL, [Fab] 
= 5 mg/mL).  Aqueous sodium bicarbonate (final concentration = 50 mM, pH 8) 
was added to this protein solution, followed by bromopyronin 105 in ethanol (10 
equiv., from a 10 mM stock solution). The reaction was allowed to proceed for 20 
min at room temperature (21-23 °C), and the labeled protein was purified using 
Sephadex G-25 and the spin column protocol described for purification of full-
length human IgG conjugates. The final protein concentration was determined by 
absorbance at 280 nm (ε E1% = 13.5 L g-1 cm-1 used for both proteins; provided 
by product data sheet). Both the Fc and Fab regions were typically labeled at 1.5 
to 2 molecules of pyronin per molecule of protein. 
 
Procedure for labeling of ribonuclease A with pyronin. Bovine ribonuclease 
A was reconstituted in sterile water and the protein concentration determined 
from absorbance at 280 nm (ε = 8,640 M-1 cm-1, calculated with the peptide 
property calculator: http://www.basic.northwestern.edu/biotools/proteincalc.html 
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based on the sequence for bovine ribonuclease A (UniProt: P61823). Aqueous 
sodium bicarbonate (final concentration = 50 mM, pH 8) was added to this 
protein solution, followed by bromopyronin 105 in ethanol (2 equiv., from a 10 
mM stock solution). NOTE: Unlike the more soluble IgG, extensive labeling of 
ribonuclease A was found to cause this protein to precipitate from solution, 
greatly reducing the yield. The reaction was allowed to proceed for 20 min at 
room temperature (21 – 23 °C), and the labeled protein was subsequently 
separated from excess fluorophore using the spin column protocol described for 
purification of human IgG conjugates. Ribonuclease A was typically labeled at 
0.3 – 0.6 molecules of pyronin per molecule of ribonuclease A. 
 
Analysis of transfer of pyronin from human IgG to SpA. Human IgG was 
labeled with bromopyronins 104 – 106 as previously described. These IgGs were 
combined with bovine serum albumin (BSA) and Staphylococcal protein A (at a 
final concentration of 5 µM for each protein) in phosphate-buffered saline (PBS) 
at pH 7.4. These protein mixtures were incubated at 37 °C for 0 – 16 h and 
analyzed by SDS-PAGE with fluorescence imaging.  Quantitative analysis of SpA 
fluorescence was performed using Adobe Photoshop (CS6).  Fluorescence 
intensity was measured using average pixel density of a fixed region of interest 
(ROI) encompassing each SpA band.  Background fluorescence was adjusted for 
by measuring fluorescence intensity at t = 0 and subtracting this value from 
subsequent time points. 
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Analysis of transfer of pyronin from human Fc and Fab regions to SpA. The 
full-length human IgG, Fc region, and Fab fragment were labeled with 
bromopyronin 105 as previously described. These proteins were combined with 
Staphylococcal protein A (at a final concentration of 5 µM for each protein) in 
phosphate-buffered saline (PBS) at pH 7.4. These protein mixtures were 
incubated at 37 °C for 0-16 h and analyzed by SDS-PAGE with fluorescence 
imaging.  Quantitative analysis of SpA fluorescence was performed as described 
above for pyronin transfer between human IgG and SpA. 
 
Analysis of transfer of commercially available fluorophores from human 
IgG to SpA. Human IgG was labeled with bromopyronin 105, 5-
carboxyfluorescein NHS-ester, or FITC as previously described. These IgGs 
were combined with Staphylococcal protein A (at a final concentration of 5 µM for 
each protein) in phosphate-buffered saline (PBS) at pH 7.4. These protein 
mixtures were incubated at 37 °C for 16 h and analyzed by SDS-PAGE with 
fluorescence imaging. 
 
 
Analysis of lysine residues on SpA that accept pyronins from IgG. Human 
IgG was conjugated with bromopyronin 105 as previously described. This labeled 
IgG (25 µM) was allowed to react with SpA (10 µM) in PBS (pH 7.4) at 37 °C for 
18 h. Following this incubation period, excess Protein A agarose (Pierce 
Biotechnology) was added to immobilize the IgG. The resulting slurry was 
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centrifuged at 2,000 rpm for 5 min, and the supernatant containing enriched SpA 
was removed for analysis by sequencing of tryptic peptides. Protein samples 
were diluted with ammonium bicarbonate (0.2 M), and treated with DTT (10 mM) 
at 37 °C for 30 min. Iodoacetamide was added (final concentration = 20 mM) and 
samples were further incubated at room temperature for 30 minutes to alkylate 
cysteine residues. Following this incubation period, sequencing-grade Trypsin 
(0.5 µg, Promega) was added and the samples incubated at 37 °C overnight. 
Trifluoroacetic acid (0.1% final concentration) was added to neutralize the 
trypsin, and samples were stored at 4 °C prior to analysis by MS/MS sequencing. 
Tandem mass spectra were extracted using Xcalibur version 2.1. All MS/MS 
samples were analyzed using Mascot software (Matrix Science, London, UK; 
version 2.3.02). Mascot was used to search the uniprot_sprot database (538010 
entries) assuming digestion by trypsin. Mascot was searched with a fragment ion 
mass tolerance of 0.50 Da and a parent ion tolerance of 20 PPM. 
Carbamidomethyl cysteine was specified in Mascot as a fixed modification. 
Modification of lysine by the pyronin was specified in Mascot as a variable 
modification. Scaffold (version 4.0.4, Proteome Software Inc., Portland, OR) was 
used to validate MS/MS based peptide and protein identifications. Peptide 
identifications were accepted if they could be established at greater than 95.0% 
probability by the Peptide Prophet algorithm with Scaffold delta-mass 
correction.38, 39 Protein identifications were accepted if they could be established 
at greater than 99.0% probability and contained at least 2 identified peptides.  
Protein probabilities were assigned by the Protein Prophet algorithm.38, 39 
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Proteins that contained similar peptides and could not be differentiated based on 
MS/MS analysis alone were grouped to satisfy the principles of parsimony. 
 
Transfer of pyronin from ribonuclease A to endogenous ribonuclease 
inhibitor present in a lysate of HeLa cells. Ribonuclease A was labeled with 
bromopyronin 105 as previously described. HeLa cells (~107) in a T75 culture 
flask were trypsinized, centrifuged at 2,000 rpm for 2 min, and washed with PBS 
(pH 7.4). The cell pellet was re-suspended in PBS (200 µL) containing 10 mM 
DTT, 1 mM EDTA, and 1 mM PMSF. The cell suspension was cooled to 4 °C and 
homogenizied by brief ultrasonication (one 3 sec. pulse). The resulting lysate 
was centrifuged (18,000 x G, 10 min, 4 °C). The supernatant containing the 
cytosolic fraction was removed and the total protein concentration was 
determined with a Pierce BCA Protein Assay Kit. An aliquot containing 50 µg of 
total protein was added to PBS (pH 7.4) containing pyronin-labeled ribonuclease 
A (20 µM) and incubated at 37 °C for 18 h. As a positive control, labeled 
ribonuclease A (20 µM) was co-incubated with purified human recombinant 
ribonuclease inhibitor (200 units) at 37 °C for 18 h. Following incubation, the 
protein mixtures were subjected to SDS-PAGE with fluorescence imaging. The 
gel was subsequently stained using Coomassie blue to reveal all proteins and 
allow examination of the specificity of fluorophore transfer. 
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APPENDIX A 
List of cell lines used in the research 
 
  
Cell Line Media Growth Organism Tissue Type Source Notes
BxPc-3 DMEM + 10% FBS + 
Pen/Strep
Adherent Human Pancreas Liang Xu_KU 
(via ATCC)
ATCC #CRL-1687
CHO-K1 F12K + 10% FBS + 
Pen/Strep
Adherent Chinese 
Hamster
Ovary ATCC ATCC #CCL-61
CHO-ldlA DMEM/F12K Mix + 10% 
FBS + Pen/Strep
Adherent Chinese 
Hamster
Ovary Monty Krieger 
MIT
Stable knockdown of LDLR
CHO-
ldlA_mSR-B1
DMEM/F12K Mix + 10% 
FBS + Pen/Strep + 200 
µg/mL G418
Adherent Chinese 
Hamster
Ovary Monty Krieger 
MIT
Stable knockdown of LDLR 
+ Stable expression of 
mouse SR-B1
HEK-293T DMEM + 10% FBS + 
Pen/Strep
Adherent Human Kidney ATCC ATCC #CRL-11268
HeLa DMEM + 10% FBS + 
Pen/Strep
Adherent Human Cervical ATCC ATCC #CCL-2
HeLa_GFP
DMEM + 10% FBS + 
Pen/Strep + 200 µg/mL 
G418
Adherent Human Cervical
Matt Levy 
Einstein 
University
Stable expression of GFP
HeLa_pGE-
NEG
DMEM + 10% FBS + 
Pen/Strep + 200 µg/mL 
G418
Adherent Human Cervical Peterson Lab 
(dh)
Stable expression of empty 
vector
HeLa_pGE-
POS
DMEM + 10% FBS + 
Pen/Strep + 200 µg/mL 
G418
Adherent Human Cervical Peterson Lab 
(dh)
Stable expression of shRNA 
against human Rnase 
inhibitor
Jurkat RPMI-1640 + 10% FBS 
+ Pen/Strep
Suspension Human T-cell 
Lymphocyte
ATCC ATCC #TIB-152
KBM-7 Iscove's MEM + 10% 
FBS + Pen/Strep
Suspension Human T-cell 
Lymphocyte
Haplogen Haploid for all 
chromosomes except chr8
NPC1 (-/-) 
Fibroblast
Earle's MEM + 15% FBS 
+ Pen/Strep
Adherent Human Fibroblast Coriell Cell 
Repository
Non-functional NPC1        
GM-03123
NPC2 (-/-) 
Fibroblast
Earle's MEM + 15% FBS 
+ Pen/Strep
Adherent Human Fibroblast Coriell Cell 
Repository
Non-functional NPC2      
GM-18455
SKBr-3 DMEM/F12K Mix + 10% 
FBS + Pen/Strep
Adherent Human Breast ATCC ATCC #HTB-30
THP-1
RPMI-1640 + 10% FBS 
+ Pen/Strep + 50 µM 2-
ME
Suspension Human Macrophage ATCC ATCC #TIB-202
wt Fibroblast Earle's MEM + 10% FBS 
+ Pen/Strep
Adherent Human Skin ATCC ATCC #CRL-2076               
Control line for NPC1/2(-/-)
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List of plasmids 
 
Name Gene Product
Gene 
Species Vector Type Source Notes
pCMV-XL5_NPC2 NPC2 Human pCMV6-XL5
Mammalian 
Expression Vector Origene
Origene Cat.# 
SC116115
pcDNA3_NPC2 NPC2 Human pcDNA3
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
pcDNA3_NPC2_F85A NPC2 Mutant Human pcDNA3
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
Expresses NPC2 with 
diminished activity
pcDNA3_NPC2_V115F NPC2 Mutant Human pcDNA3
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
Expresses NPC2 with 
diminished activity
pcDNA3_NPC2_W128A NPC2 Mutant Human pcDNA3
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
Expresses NPC2 with 
diminished activity
pcDNA3_NPC2_W128F NPC2 Mutant Human pcDNA3
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
Expresses NPC2 with 
diminished activity
pcDNA3_NPC2_W128V NPC2 Mutant Human pcDNA3
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
Expresses NPC2 with 
diminished activity
NPC2_mCherry
NPC2-mCherry 
fusion Human pCMV6-XL5
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
C-terminal mCherry 
fusion
NPC2_shRNA_pSil 6-1
shRNA targeting 
NPC2 Human pSilencer
Mammalian 
Expression Vector
F. Moatamed 
(UCLA)
NPC2_shRNA_pSil 3-3
shRNA targeting 
NPC2 Human pSilencer
Mammalian 
Expression Vector
F. Moatamed 
(UCLA)
pSil_ΔshRNA Empty Vector Human pSilencer
Mammalian 
Expression Vector
F. Moatamed 
(UCLA)
N-term HA tag_NPC2 NPC2-HA fusion Human pCMV6-XL5
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
N-terminal 
hemagglutinin tag
C-term HA tag_NPC2 NPC2-HA fusion Human pCMV6-XL5
Mammalian 
Expression Vector
P. Gao (KU 
PPG)
C-terminal 
hemagglutinin tag
Myc-DDK-TSPAN2 Tetraspanin 2 Human pCMV6
Mammalian 
Expression Vector Origene
Origene Cat.# 
RC204809
HSH000133-1-mU6
shRNA targeting 
TSPAN2 Human n/a shRNA Genecopoeia
Product ID# 
HSH000133
HSH000133-2-mU6
shRNA targeting 
TSPAN2 Human n/a shRNA Genecopoeia
Product ID# 
HSH000134
HSH000133-3-mU6
shRNA targeting 
TSPAN2 Human n/a shRNA Genecopoeia
Product ID# 
HSH000135
HSH000133-4-mU6
shRNA targeting 
TSPAN2 Human n/a shRNA Genecopoeia
Product ID# 
HSH000136
CSHCTR001-mU6 Scrambled shRNA n/a n/a Scrambled shRNA Genecopoeia
pGFP-UV GFP-UV n/a
Bacterial Expression 
Vector Clonetech
pEGFP-C1 EGFP n/a
Mammalian 
Expression Vector Clonetech
pmCherry-N1 mCherry n/a
Mammalian 
Expression Vector Clonetech
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Name Gene Product
Gene 
Species Vector Type Source Notes
pGE-NEG Empty Vector n/a pGE-1
Mammalian 
Expression Vector
K. Dickson 
(Lawrence U.)
pGE-POS
shRNA targeting 
Rnase Inhibitor Human pGE-1
Mammalian 
Expression Vector
K. Dickson 
(Lawrence U.)
EGFR-wt EGFR Human pBABE puro
Mammalian 
Expression Vector Addgene
Addgene Plasmid 
#11011
HER2-wt HER2 Human pcDNA3
Mammalian 
Expression Vector Addgene
Addgene Plasmid 
#16257
pErbB1-Citrine EGFR-YFP fusion Human pEYFP-N1
Mammalian 
Expression Vector Addgene
Addgene Plasmid 
#40266
pErbB2-CFP HER2-CFP fusion Human pcDNA3
Mammalian 
Expression Vector Addgene
Addgene Plasmid 
#40268
pcDNA3 Empty Vector n/a pcDNA3
Mammalian 
Expression Vector
D. Sahoo 
(Med. Coll. of 
Wisc.)
pClaI SR-B1 Human pcDNA3
Mammalian 
Expression Vector
D. Sahoo 
(Med. Coll. of 
Wisc.)
pClaI_S112F SR-B1 Mutant Human pcDNA3
Mammalian 
Expression Vector
D. Sahoo 
(Med. Coll. of 
Wisc.)
Expresses SR-B1 with 
diminished activity
pClaI_T175A SR-B1 Mutant Human pcDNA3
Mammalian 
Expression Vector
D. Sahoo 
(Med. Coll. of 
Wisc.)
Expresses SR-B1 with 
diminished activity
pCS2+_DISP wt_5myc
Dispatched 1_C-
term 5 myc tag Mouse pCS2+
Vertebrate 
Expression Vector
A. Salic 
(Harvard Univ)
pCS2+_DISP delta 
loop1_5myc
Dispatched 1_C-
term 5 myc tag
Mouse pCS2+ Vertebrate 
Expression Vector
A. Salic 
(Harvard Univ)
pCS2+_DISP 
wt_mCherry
Dispatched 
1_mCherry fusion
Mouse pCS2+ Vertebrate 
Expression Vector
A. Salic 
(Harvard Univ)
pCS2+_DISP delta 
loop1_mCherry
Dispatched 
1_mCherry fusion Mouse pCS2+
Vertebrate 
Expression Vector
A. Salic 
(Harvard Univ)
